

(19) World Intellectual Property  
Organization  
International Bureau




(43) International Publication Date  
25 March 2004 (25.03.2004)

PCT

(10) International Publication Number  
**WO 2004/024161 A1**

- (51) International Patent Classification<sup>7</sup>: **A61K 31/517**. (74) Agent: **SCHUCK, Alexander**; Isenbruck-Bösl-Hörschler-Wichmann-Huhn, Patentanwälte, Theodor-Heuss-Anlage 12, 68165 Mannheim (DE).  
C07D 403/04, A61P 3/06
- (21) International Application Number:  
PCT/EP2003/010036
- (22) International Filing Date:  
10 September 2003 (10.09.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
02 020 255.2 10 September 2002 (10.09.2002) EP
- (71) Applicant (for all designated States except US): **PHENEX PHARMACEUTICALS AG** [DE/DE]; Im Neuenheimer Feld 515, 69120 Heidelberg (DE).
- (72) Inventors; and  
(75) Inventors/Applicants (for US only): **DEUSCHLE, Ulrich** [DE/DE]; Wundtstrasse 9/20, 69123 Heidelberg (DE). **KÖGL, Manfred** [AT/DE]; Hauptstrasse 131/4, 69214 Lippelheim (DE). **BLUME, Beatrix** [DE/DE]; Heinrich-Heine-Strasse 20, 69221 Dossenheim (DE). **ALBERS, Michael** [DE/DE]; Obere Schulstrasse 3, 69221 Dossenheim (DE). **KOBER, Ingo** [DE/DE]; Am Grossen Wald 30, 69251 Gaiberg (DE).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SI, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SI, SZ, TZ, UG, ZM, ZW). Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM). European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR). OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NI, SN, TD, TG).
- Published:  
— with international search report  
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **NOVEL 2-AMINO-4-OXOQUINAZOLONES AS LXR NUCLEAR RECEPTOR BINDING COMPOUNDS WITH PARTIAL AGONISTIC PROPERTIES**



(57) Abstract: The present invention relates to compounds according to the general formula (I) which bind to the Liver X receptors (LXR) receptors. LXRalpha/NR1H3 and LXRbeta/NR1H2) and act as selective agonists of the LXR receptors. The invention further relates to the treatment of diseases and/or conditions through binding of said nuclear receptors and selective agonistic effects by said compounds and the production of medicaments using said compounds. In particular the compounds are useful in the treatment of hypercholesterolemia, obesity or other diseases associated with elevated lipoprotein (LDL) levels.

NOVEL 2-AMINO-4-OXOQUINAZOLONES AS LXR NUCLEAR RECEPTOR BINDING COMPOUNDS  
WITH PARTIAL AGONISTIC PROPERTIES

Liver X Receptor (LXR) is a prototypical type 2 nuclear receptor which activates  
10 genes upon binding to promoter region of target genes in a prototypical heterodimeric  
fashion with Retinoid X Receptor (hereinafter RXR, Forman et al., Cell, 81, 687-93,  
1995). The term LXR includes all subtypes of this receptor. Specifically LXR includes  
LXR $\alpha$  (also known as LXR $\alpha$ , RLD-1 and NR1H3) and LXR $\beta$  (also known as  
LXR $\beta$ , NER, NER1, UR, OR-1, R1P15 and NH1H2) and ligands of LXR should be  
15 understood to include ligands of LXR $\alpha$  or LXR $\beta$ . The relevant physiological ligands  
of LXR seem to be oxidized derivatives of cholesterol, including 22-  
hydroxycholesterol and 24,25(S)-epoxycholesterol (Lehmann, et al., Biol. Chem.  
272(6), 3137-40, 1997). The oxysterol ligands bound to LXR were found to regulate  
the expression of several genes that participate in cholesterol metabolism (Janowski,  
20 et al., Nature, 383, 728-31, 1996).

LXR is proposed to be a hepatic oxysterol sensor. Upon activation (e.g. binding of  
oxysterols) it influences the conversion of dietary cholesterol into bile acids by  
upregulating the transcription of key genes which are involved in bile acid synthesis  
25 such as CYP7A1. Hence, activation of LXR in the liver could result in an increased  
synthesis of bile acids from cholesterol which could lead to decreased levels of  
hepatic cholesterol. This proposed LXR function in hepatic cholesterol metabolism  
was experimentally confirmed using knockout mice. Mice lacking the receptor LXR $\alpha$   
lost their ability to respond normally to an increase in dietary cholesterol and did not  
30 induce transcription of the gene encoding CYP7A1. This resulted in accumulation of  
large quantities of cholesterol in the livers and impaired hepatic function (Peet, et al.,  
Cell, 93, 693-704, 1998).

Besides its important function in liver, LXR plays an important role in the regulation of  
35 cholesterol homeostasis in macrophages and intestinal mucosa cells where it  
upregulates cholesterol transporters from the ABC (=ATP binding cassette) family of  
membrane proteins (Repa, et al., J Biol Chem. 2002 May 24;277(21):18793-800).

5 These transporters are believed to be crucially involved in the uptake of cholesterol from the diet since mutations in their genes leads to diseases such as sitosterolemia (Berge, et al., Science (2000);290(5497):1771-5.).

Other members of the ABC transporter family seem to be responsible for the efflux of  
10 cholesterol from loaded macrophages, a process which is thought to prevent the generation of atherosclerotic lesions. Stimulation of LXR by synthetic ligands might result in an increased cholesterol efflux from macrophages and a decreased building up of cholesterol loaded atherosclerotic plaques (Venkateswaran, et al., PNAS (2000) 24;97(22):12097-102; Sparrow, et al., J Biol Chem (2002) 277(12):10021-7; Joseph, et al., PNAS (2002);99(11):7604-9). Direct evidence that synthetic LXR  
15 ligands inhibit the development of atherosclerosis has been provided in two animal models of atherosclerosis: A significant reduction in the formation of atherosclerotic plaques were shown in two studies in animal models using full LXR agonists Joseph et al. PNAS (2002) 99:7604-9 and Terasaka et al. (2003) Terasaka et al. FEBS Lett. (2003) 536:6-11. In addition, two recent reports have highlighted the potential use of LXR agonists in diabetes (Cao et al., (2003) J Biol Chem. 278:1131-6 and inflammatory disorders (Joseph et al., (2003) Nat Med. 9:213-9).

However, in animal studies it was observed that activation of LXR in the liver by full  
25 agonists like T0901317 does not only increase bile acid synthesis but also stimulates the de novo synthesis of fatty acids and triglycerids through the upregulation of key enzymes such as Fatty Acid Synthase (FAS) or Stearyl-CoA Desaturase (SCD-1) (Schultz, et al., Genes Dev (2000) 14(22):2831-8). Elevation of serum triglyceride levels is an independent risk factor for atherosclerosis (for review see Miller (1999 )  
30 Hosp Pract (Off Ed) 34: 67-73.).

Thus, LXR activity needs to be selectively modulated for therapeutic benefit. In particular, compounds need to be found that stimulate reverse cholesterol transport, but do not significantly increase triglyceride levels. This might be particularly relevant  
35 for the usage of such compounds in diabetic patients since an even more severe lipogenic effect was reported for the full agonist T0901317 in db/db mice which serve as an animal model for diabetes (Chisholm et al. (2003) J.Lipid Res (epub August 16)).

5

Therefore, an ideal synthetic LXR binding compound should have properties that retain the agonistic activity on hepatic bile acid formation and ABC-transporter - mediated decrease in cholesterol uptake from the diet and increased cholesterol efflux from macrophages. In parallel such a compound should lack the hyperlipidemic potential which is exerted through increased fatty acid and triglyceride synthesis.

10

To date only few compounds have been described which bind the LXR receptor and thus show utility for treating diseases or conditions which are due to or influenced by said nuclear receptor (Collins, et al., J Med Chem. (2002) 45(10):1963-6; Schultz, et al., Genes Dev (2000) 14(22):2831-8; Sparrow, et al., J Biol Chem (2002) 277(12):10021-7). No non-steroidal compounds have so far been described which show selectivity regarding the induction of ABC transporter genes without simultaneous induction of lipogenic genes like FAS and SREBP-1c (Kaneko et al. (2003) J Biol Chem (epub July 7).

20

It is thus an object of the invention to provide for compounds which by means of binding the LXR receptor act as partial agonists of said receptor with a selective property regarding the upregulation of genes like the ABC transporters in macrophages and/or other cell types and a strongly reduced liability to increase the expression of genes involved in triglyceride synthetic pathways (like FAS and SREBP-1c). These compounds should show utility for treating diseases or conditions which are due to or influenced by said nuclear receptor.

25

It is further an object of the invention to provide for compounds that may be used for the manufacture of a medicament for the treatment of cholesterol associated conditions or diseases. It is still a further object of the invention to provide for compounds that lower serum cholesterol and/or increase High Density Lipoproteins (HDL) and/or decrease Low Density Lipoproteins (LDL). It is also an object of the invention to provide for compounds that may be used for the treatment of lipid disorders including hypercholesterolemia, atherosclerosis, Alzheimer's disease, skin disorders, inflammation, obesity and diabetes.


30

35

5 The present invention provides, *inter alia*, novel LXR nuclear receptor protein binding compounds according to the general formula (I) shown below. Said compounds are also binders of mammalian homologues of said receptor. Further the object of the invention was solved by providing for amongst the LXR nuclear receptor protein binding compounds according to the general formula (I) such compounds which act  
10 as partial agonists or mixed agonists / antagonists of the human LXR receptor or a mammalian homologue thereof. Further the object of the invention was solved by providing for amongst the LXR receptor protein binding compounds according to the general formula (I) such compounds which act as partial agonists of the human LXR receptor resulting therefore in the induction of ABC transporter proteins such as  
15 ABCA1 or ABCG1 in cell types such as macrophages but lacking a strong potential to induce genes involved in triglyceride synthetic pathways such as fatty acid synthase (FAS) or SREBP1c.

The invention provides for LXR agonists that may be used for the manufacture of a  
20 medicament for the treatment of cholesterol associated conditions or diseases. In a preferred embodiment compounds are provided that lower serum cholesterol and/or increase High Density lipoproteins (HDL) and/or decrease Low Density Lipoproteins (LDL). Also compounds are provided that may be used for the treatment of lipid disorders including hypercholesterolemia, atherosclerosis, Alzheimer's disease, skin  
25 disorders, inflammation, obesity and diabetes.

The invention provides for a compound of the formula (I), or pharmaceutical acceptable salts or solvates thereof, hereinafter also referred to as the "compounds according to the invention" including particular and preferred embodiments thereof.



5

(I)

The compounds of the invention can also exist as solvates and hydrates. Thus, these compounds may crystallize with, for example, waters of hydration, or one, a number  
 10 of, or any fraction thereof of molecules of the mother liquor solvent. The solvates and hydrates of such compounds are included within the scope of this invention.

In one embodiment of the invention in formula (I) above, R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, -  
 independent from each other - H, halogen, hydroxy, protected hydroxy, cyano, nitro,  
 15 C<sub>1</sub> to C<sub>6</sub> alkyl, C<sub>1</sub> to C<sub>6</sub> substituted alkyl, C<sub>1</sub> to C<sub>7</sub> alkoxy, C<sub>1</sub> to C<sub>7</sub> substituted alkoxy,  
 C<sub>1</sub> to C<sub>7</sub> acyl, C<sub>1</sub> to C<sub>7</sub> substituted acyl, C<sub>1</sub> to C<sub>7</sub> acyloxy, carboxy, protected carboxy,  
 carboxymethyl, protected carboxymethyl, hydroxymethyl, protected hydroxymethyl,  
 amino, protected amino, (monosubstituted)amino, protected (monosubstituted)amino,  
 (disubstituted)amino, carboxamide, protected carboxamide, N-(C<sub>1</sub> to C<sub>6</sub>  
 20 alkyl)carboxamide, protected N-(C<sub>1</sub> to C<sub>6</sub> alkyl)carboxamide, N, N-di(C<sub>1</sub> to C<sub>6</sub>  
 alkyl)carboxamide, trifluoromethyl, N-((C<sub>1</sub> to C<sub>6</sub> alkyl)sulfonyl)amino, N-  
 (phenylsulfonyl)amino or phenyl,

and R<sub>5</sub> is H, C<sub>1</sub> to C<sub>8</sub> alkyl, C<sub>1</sub> to C<sub>8</sub> substituted alkyl, C<sub>7</sub> to C<sub>12</sub> alkylphenyl or C<sub>7</sub> to  
 25 C<sub>12</sub> substituted phenylalkyl.

In an other embodiment of the invention in formula (I) above R<sub>1</sub>, R<sub>3</sub> and R<sub>4</sub> are H, R<sub>2</sub>  
 is halogen, hydroxy, protected hydroxy, cyano, nitro, C<sub>1</sub> to C<sub>6</sub> alkyl, C<sub>1</sub> to C<sub>6</sub>  
 substituted alkyl, C<sub>1</sub> to C<sub>7</sub> alkoxy, C<sub>1</sub> to C<sub>7</sub> substituted alkoxy, C<sub>1</sub> to C<sub>7</sub> acyl, C<sub>1</sub> to C<sub>7</sub>  
 30 substituted acyl, C<sub>1</sub> to C<sub>7</sub> acyloxy, carboxy, protected carboxy, carboxymethyl,  
 protected carboxymethyl, hydroxymethyl, protected hydroxymethyl, amino, protected  
 amino, (monosubstituted)amino, protected (monosubstituted)amino,  
 (disubstituted)amino, carboxamide, protected carboxamide, N-(C<sub>1</sub> to C<sub>6</sub>  
 alkyl)carboxamide, protected N-(C<sub>1</sub> to C<sub>6</sub> alkyl)carboxamide, N, N-di(C<sub>1</sub> to C<sub>6</sub>  
 35 alkyl)carboxamide, trifluoromethyl, N-((C<sub>1</sub> to C<sub>6</sub> alkyl)sulfonyl)amino, N-  
 (phenylsulfonyl)amino or phenyl,

and R<sub>5</sub> is H, C<sub>1</sub> to C<sub>8</sub> alkyl, C<sub>1</sub> to C<sub>8</sub> substituted alkyl.

5

The symbol "H" denotes a hydrogen atom.

The term "C<sub>1</sub> to C<sub>7</sub> acyl" encompasses groups such as formyl, acetyl, propionyl, butyryl, pentanoyl, pivaloyl, hexanoyl, heptanoyl, benzoyl and the like. Preferred acyl groups are acetyl and benzoyl.

The term "C<sub>1</sub> to C<sub>7</sub> substituted acyl" denotes the acyl group substituted by one or more, and preferably one or two, halogen, hydroxy, protected hydroxy, oxo, protected oxo, cyclohexyl, naphthyl, amino, protected amino, (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted)amino, guanidino, heterocyclic ring, substituted heterocyclic ring, imidazolyl, indolyl, pyrrolidinyl, C<sub>1</sub> to C<sub>7</sub> alkoxy, C<sub>1</sub> to C<sub>7</sub> acyl, C<sub>1</sub> to C<sub>7</sub> acyloxy, nitro, C<sub>1</sub> to C<sub>6</sub> alkyl ester, carboxy, protected carboxy, carbamoyl, carboxamide, protected carboxamide, N-(C<sub>1</sub> to C<sub>6</sub> alkyl)carboxamide, protected N-(C<sub>1</sub> to C<sub>6</sub> alkyl)carboxamide, N,N-di(C<sub>1</sub> to C<sub>6</sub> alkyl)carboxamide, cyano, methylsulfonylamino, thiol, C<sub>1</sub> to C<sub>4</sub> alkylthio or C<sub>1</sub> to C<sub>4</sub> alkylsulfonyl groups. The substituted acyl groups may be substituted once or more, and preferably once or twice, with the same or with different substituents.

The term "substituted phenyl" specifies a phenyl group substituted with one or more, and preferably one or two, moieties chosen from the groups consisting of halogen, hydroxy, protected hydroxy, cyano, nitro, C<sub>1</sub> to C<sub>6</sub> alkyl, C<sub>1</sub> to C<sub>6</sub> substituted alkyl, C<sub>1</sub> to C<sub>7</sub> alkoxy, C<sub>1</sub> to C<sub>7</sub> substituted alkoxy, C<sub>1</sub> to C<sub>7</sub> acyl, C<sub>1</sub> to C<sub>7</sub> substituted acyl, C<sub>1</sub> to C<sub>7</sub> acyloxy, carboxy, protected carboxy, carboxymethyl, protected carboxymethyl, hydroxymethyl, protected hydroxymethyl, amino, protected amino, (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted)amino, carboxamide, protected carboxamide, N-(C<sub>1</sub> to C<sub>6</sub> alkyl)carboxamide, protected N-(C<sub>1</sub> to C<sub>6</sub> alkyl)carboxamide, N, N-di(C<sub>1</sub> to C<sub>6</sub> alkyl)carboxamide, trifluoromethyl, N-((C<sub>1</sub> to C<sub>6</sub> alkyl)sulfonyl)amino, N-(phenylsulfonyl)amino or phenyl, wherein the phenyl is substituted or unsubstituted, such that, for example, a biphenyl results.

Examples of the term "substituted phenyl" includes a mono- or di(halo)phenyl group such as 2, 3 or 4-chlorophenyl, 2,6-dichlorophenyl, 2,5-dichlorophenyl, 3,4-dichlorophenyl, 2, 3 or 4-bromophenyl, 3,4-dibromophenyl, 3-chloro-4-fluorophenyl,

2, 3 or 4-fluorophenyl and the like; a mono or di(hydroxy)phenyl group such as 2, 3 or 4-hydroxyphenyl, 2,4-dihydroxyphenyl, the protected-hydroxy derivatives thereof and the like; a nitrophenyl group such as 2, 3 or 4-nitrophenyl; a cyanophenyl group, for example, 2, 3 or 4-cyanophenyl; a mono- or di(alkyl)phenyl group such as 2, 3 or 4-methylphenyl, 2,4-dimethylphenyl, 2, 3 or 4-(iso-propyl)phenyl, 2, 3 or 4-ethylphenyl, 2, 3 or 4-(n-propyl)phenyl and the like; a mono or di(alkoxy)phenyl group, for example, 2,6-dimethoxyphenyl, 2, 3 or 4-methoxyphenyl, 2, 3 or 4-ethoxyphenyl, 2, 3 or 4-(isopropoxy)phenyl, 2, 3 or 4-(t-butoxy)phenyl, 3-ethoxy-4-methoxyphenyl and the like; 2, 3 or 4-trifluoromethylphenyl; a mono- or dicarboxyphenyl or (protected carboxy)phenyl group such as 2, 3 or 4-carboxyphenyl or 2,4-di(protected carboxy)phenyl; a mono-or di(hydroxymethyl)phenyl or (protected hydroxymethyl)phenyl such as 2, 3, or 4-(protected hydroxymethyl)phenyl or 3,4-di(hydroxymethyl)phenyl; a mono- or di(aminomethyl)phenyl or (protected aminomethyl)phenyl such as 2, 3 or 4-(aminomethyl)phenyl or 2,4-(protected aminomethyl)phenyl; or a mono- or di(N-(methylsulfonylamino))phenyl such as 2, 3 or 4-(N-(methylsulfonylamino))phenyl. Also, the term "substituted phenyl" represents disubstituted phenyl groups wherein the substituents are different, for example, 3-methyl-4-hydroxyphenyl, 3-chloro-4-hydroxyphenyl, 2-methoxy-4-bromophenyl, 4-ethyl-2-hydroxyphenyl, 3-hydroxy-4-nitrophenyl, 2-hydroxy 4-chlorophenyl and the like.

The term "heteroaryl" means a heterocyclic aromatic derivative which is a five-membered or six-membered ring system having from 1 to 4 heteroatoms, such as oxygen, sulfur and/or nitrogen, in particular nitrogen, either alone or in conjunction with sulfur or oxygen ring atoms. Examples of heteroaryls include pyridinyl, pyrimidinyl, and pyrazinyl, pyridazinyl, pyrrolo, furano, thiopheno, oxazolo, isoxazolo, phthalimido, thiazolo and the like.

The term "substituted heteroaryl" means the above-described heteroaryl is substituted with, for example, one or more, and preferably one or two, substituents which are the same or different which substituents can be halogen, hydroxy, protected hydroxy, cyano, nitro, C<sub>1</sub> to C<sub>6</sub> alkyl, C<sub>1</sub> to C<sub>7</sub> alkoxy, C<sub>1</sub> to C<sub>7</sub> substituted alkoxy, C<sub>1</sub> to C<sub>7</sub> acyl, C<sub>1</sub> to C<sub>7</sub> substituted acyl, C<sub>1</sub> to C<sub>7</sub> acyloxy, carboxy, protected carboxy, carboxymethyl, protected carboxymethyl, hydroxymethyl, protected



5 hydroxymethyl, amino, protected amino, (monosubstituted)amino, protected  
 (monosubstituted)amino, (disubstituted)amino, carboxamide, protected carboxamide,  
 N-(C<sub>1</sub> to C<sub>6</sub> alkyl)carboxamide, protected N-(C<sub>1</sub> to C<sub>6</sub> alkyl)carboxamide, N, N-di(C<sub>1</sub>  
 to C<sub>6</sub> alkyl)carboxamide, trifluoromethyl, N-((C<sub>1</sub> to C<sub>6</sub> alkyl)sulfonyl)amino or N-  
 (phenylsulfonyl)amino groups.

10

The term "substituted naphthyl" specifies a naphthyl group substituted with one or  
 more, and preferably one or two, moieties either on the same ring or on different  
 rings chosen from the groups consisting of halogen, hydroxy, protected hydroxy,  
 cyano, nitro, C<sub>1</sub> to C<sub>6</sub> alkyl, C<sub>1</sub> to C<sub>7</sub> alkoxy, C<sub>1</sub> to C<sub>7</sub> acyl, C<sub>1</sub> to C<sub>7</sub> acyloxy, carboxy,  
 15 protected carboxy, carboxymethyl, protected carboxymethyl, hydroxymethyl,  
 protected hydroxymethyl, amino, protected amino, (monosubstituted)amino,  
 protected (monosubstituted)amino, (disubstituted)amino, carboxamide, protected  
 carboxamide, N-(C<sub>1</sub> to C<sub>6</sub> alkyl)carboxamide, protected N-(C<sub>1</sub> to C<sub>6</sub>  
 alkyl)carboxamide, N, N-di(C<sub>1</sub> to C<sub>6</sub> alkyl)carboxamide, trifluoromethyl, N-((C<sub>1</sub> to C<sub>6</sub>  
 20 alkyl)sulfonyl)amino or N-(phenylsulfonyl)amino.

Examples of the term "substituted naphthyl" includes a mono or di(halo)naphthyl  
 group such as 1, 2, 3, 4, 5, 6, 7 or 8-chloronaphthyl, 2, 6-dichloronaphthyl, 2, 5-  
 dichloronaphthyl, 3, 4-dichloronaphthyl, 1, 2, 3, 4, 5, 6, 7 or 8-bromonaphthyl, 3, 4-  
 25 dibromonaphthyl, 3-chloro-4-fluoronaphthyl, 1, 2, 3, 4, 5, 6, 7 or 8-fluoronaphthyl and  
 the like; a mono or di(hydroxy)naphthyl group such as 1, 2, 3, 4, 5, 6, 7 or 8-  
 hydroxynaphthyl, 2, 4-dihydroxynaphthyl, the protected-hydroxy derivatives thereof  
 and the like; a nitronaphthyl group such as 3- or 4-nitronaphthyl; a cyanonaphthyl  
 group, for example, 1, 2, 3, 4, 5, 6, 7 or 8-cyanonaphthyl; a mono- or  
 30 di(alkyl)naphthyl group such as 2, 3, 4, 5, 6, 7 or 8-methylnaphthyl, 1, 2,  
 4-dimethylnaphthyl, 1, 2, 3, 4, 5, 6, 7 or 8-(isopropyl)naphthyl, 1, 2, 3, 4, 5, 6, 7 or  
 8-ethylnaphthyl, 1, 2, 3, 4, 5, 6, 7 or 8-(n-propyl)naphthyl and the like; a mono or  
 di(alkoxy)naphthyl group, for example, 2, 6-dimethoxynaphthyl, 1, 2, 3, 4, 5, 6, 7 or  
 8-methoxynaphthyl, 1, 2, 3, 4, 5, 6, 7 or 8-ethoxynaphthyl, 1, 2, 3, 4, 5, 6, 7 or  
 35 8-(isopropoxy)naphthyl, 1, 2, 3, 4, 5, 6, 7 or 8-(t-butoxy)naphthyl, 3-ethoxy-4-  
 methoxynaphthyl and the like; 1, 2, 3, 4, 5, 6, 7 or 8-trifluoromethylnaphthyl; a mono-  
 or dicarboxynaphthyl or (protected carboxy)naphthyl group such as 1, 2, 3, 4, 5, 6, 7  
 or 8-carboxynaphthyl or 2, 4-di-(protected carboxy)naphthyl; a mono-or

- 5 di(hydroxymethyl)naphthyl or (protected hydroxymethyl)naphthyl such as 1, 2, 3, 4, 5, 6, 7 or 8-(protected hydroxymethyl)naphthyl or 3, 4-di(hydroxymethyl)naphthyl; a mono- or di(amino)naphthyl or (protected amino)naphthyl such as 1, 2, 3, 4, 5, 6, 7 or 8-(amino)naphthyl or 2, 4-(protected amino)-naphthyl, a mono- or di(aminomethyl)naphthyl or (protected aminomethyl)naphthyl such as 2, 3, or 10 4-(aminomethyl)naphthyl or 2, 4-(protected aminomethyl)-naphthyl; or a mono- or di-(N-methylsulfonylamino) naphthyl such as 1, 2, 3, 4, 5, 6, 7 or 8-(N-methylsulfonylamino)naphthyl. Also, the term "substituted naphthyl" represents disubstituted naphthyl groups wherein the substituents are different, for example, 3-methyl-4-hydroxynaphth-1-yl, 3-chloro-4-hydroxynaphth-2-yl, 2-methoxy-4-bromonaphth-1-yl, 4-ethyl-2-hydroxynaphth-1-yl, 3-hydroxy-4-nitronaphth-2-yl, 2-hydroxy-4-chloronaphth-1-yl, 2-methoxy-7-bromonaphth-1-yl, 4-ethyl-5-hydroxynaphth-2-yl, 3-hydroxy-8-nitronaphth-2-yl, 2-hydroxy-5-chloronaphth-1-yl and the like.
- 20 The term "C<sub>1</sub> to C<sub>8</sub> alkyl" denotes such radicals as methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, amyl, tert-amyl, hexyl, n-heptyl, 2-heptyl, 3-heptyl, 4-heptyl, 2-methyl-1hexyl, 2-methyl-2hexyl, 2-methyl-3-hexyl, n-octyl and the like.
- 25 The term "C<sub>2</sub> to C<sub>6</sub> alkenyl" denotes such radicals as propenyl or butenyl.

Examples of the above substituted alkyl groups include the 2-oxo-prop-1-yl, 3-oxo-but-1-yl, cyanomethyl, nitromethyl, chloromethyl, hydroxymethyl, tetrahydropyran-2-yl, trityloxymethyl, propionyloxymethyl, amino, 30 methylamino, aminomethyl, dimethylamino, carboxymethyl, allyloxycarbonylmethyl, allyloxycarbonylamino, methoxymethyl, ethoxymethyl, t-butoxymethyl, acetoxymethyl, chloromethyl, bromomethyl, iodomethyl, trifluoromethyl, 6-hydroxyhexyl, 2,4-dichloro(n-butyl), 2-aminopropyl, 1-chloroethyl, 2-chloroethyl, 1-bromoethyl, 2-chloroethyl, 1-fluoroethyl, 2-fluoroethyl, 1-iodoethyl, 2-iodoethyl, 1-chloropropyl, 2-chloropropyl, 3-chloropropyl, 1-bromopropyl, 2-bromopropyl, 3-bromopropyl, 1-fluoropropyl, 2-fluoropropyl, 3-fluoropropyl, 1-iodopropyl, 2-iodopropyl, 3-iodopropyl, 2-aminoethyl, 1-aminoethyl, N-benzoyl-2-aminoethyl, N-acetyl-2-aminoethyl, N-benzoyl-1-aminoethyl, N-acetyl-1-aminoethyl and the like.

5

The term "C<sub>1</sub> to C<sub>8</sub> substituted alkyl" denotes that the above C<sub>1</sub> to C<sub>8</sub> alkyl groups are substituted by one or more, and preferably one or two, halogen, hydroxy, protected hydroxy, oxo, protected oxo, C<sub>3</sub> to C<sub>7</sub> cycloalkyl, naphthyl, amino, protected amino, (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted)amino, 10 guanidino, protected guanidino, heterocyclic ring, substituted heterocyclic ring, imidazolyl, indolyl, pyrrolidinyl, C<sub>1</sub> to C<sub>7</sub> alkoxy, C<sub>1</sub> to C<sub>7</sub> acyl, C<sub>1</sub> to C<sub>7</sub> acyloxy, nitro, carboxy, protected carboxy, carbamoyl, carboxamide, protected carboxamide, N-(C<sub>1</sub> to C<sub>6</sub> alkyl)carboxamide, protected N-(C<sub>1</sub> to C<sub>6</sub> alkyl)carboxamide, N,N-di(C<sub>1</sub> to C<sub>6</sub> alkyl)carboxamide, cyano, methylsulfonylamino, thiol, C<sub>1</sub> to C<sub>4</sub> alkylthio or C<sub>1</sub> to C<sub>4</sub> 15 alkylsulfonyl groups. The substituted alkyl groups may be substituted once or more, and preferably once or twice, with the same or with different substituents.

The term "C<sub>7</sub> to C<sub>12</sub> phenylalkyl" denotes a C<sub>1</sub> to C<sub>6</sub> alkyl group substituted at any position by a phenyl, substituted phenyl, heteroaryl or substituted heteroaryl.

20 Examples of such a group include benzyl, 2-phenylethyl, 3-phenyl(n-propyl), 4-phenylhexyl, 3-phenyl(n-amyl), 3-phenyl(sec-butyl) and the like. Preferred C<sub>7</sub> to C<sub>12</sub> phenylalkyl groups are the benzyl and the phenylethyl groups.

The term "C<sub>7</sub> to C<sub>12</sub> substituted phenylalkyl" denotes a C<sub>7</sub> to C<sub>12</sub> phenylalkyl group substituted on the C<sub>1</sub> to C<sub>6</sub> alkyl portion with one or more, and preferably one or two, 25 groups chosen from halogen, hydroxy, protected hydroxy, oxo, protected oxo, amino, protected amino, (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted)amino, guanidino, protected guanidino, heterocyclic ring, substituted heterocyclic ring, C<sub>1</sub> to C<sub>6</sub> alkyl, C<sub>1</sub> to C<sub>6</sub> substituted alkyl, C<sub>1</sub> to C<sub>7</sub> alkoxy, C<sub>1</sub> to C<sub>7</sub> substituted alkoxy, C<sub>1</sub> to C<sub>7</sub> acyl, C<sub>1</sub> to C<sub>7</sub> substituted acyl, C<sub>1</sub> to C<sub>7</sub> acyloxy, nitro, 30 carboxy, protected carboxy, carbamoyl, carboxamide, protected carboxamide, N-(C<sub>1</sub> to C<sub>6</sub> alkyl)carboxamide, protected N-(C<sub>1</sub> to C<sub>6</sub> alkyl)carboxamide, N, N-(C<sub>1</sub> to C<sub>6</sub> dialkyl)carboxamide, cyano, N-(C<sub>1</sub> to C<sub>6</sub> alkylsulfonyl)amino, thiol, C<sub>1</sub> to C<sub>4</sub> alkylthio, C<sub>1</sub> to C<sub>4</sub> alkylsulfonyl groups; and/or the phenyl group may be substituted with one or more, and preferably one or two, substituents chosen from halogen, hydroxy, 35 protected hydroxy, cyano, nitro, C<sub>1</sub> to C<sub>6</sub> alkyl, C<sub>1</sub> to C<sub>6</sub> substituted alkyl, C<sub>1</sub> to C<sub>7</sub> alkoxy, C<sub>1</sub> to C<sub>7</sub> substituted alkoxy, C<sub>1</sub> to C<sub>7</sub> acyl, C<sub>1</sub> to C<sub>7</sub> substituted acyl, C<sub>1</sub> to C<sub>7</sub> acyloxy, carboxy, protected carboxy, carboxymethyl, protected carboxymethyl, hydroxymethyl, protected hydroxymethyl, amino, protected amino,

5 (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted)amino, carboxamide, protected carboxamide, N-(C<sub>1</sub> to C<sub>6</sub> alkyl) carboxamide, protected N-(C<sub>1</sub> to C<sub>6</sub> alkyl) carboxamide, N, N-di(C<sub>1</sub> to C<sub>6</sub> alkyl)carboxamide, trifluoromethyl, N-((C<sub>1</sub> to C<sub>6</sub> alkyl)sulfonyl)amino, N-(phenylsulfonyl)amino, cyclic C<sub>2</sub> to C<sub>7</sub> alkylene or a phenyl group, substituted or unsubstituted, for a resulting biphenyl group. The  
10 substituted alkyl or phenyl groups may be substituted with one or more, and preferably one or two, substituents which can be the same or different.

Examples of the term "C<sub>7</sub> to C<sub>12</sub> substituted phenylalkyl" include groups such as 2-phenyl-1-chloroethyl, 2-(4-methoxyphenyl)ethyl, 4-(2,6-dihydroxy phenyl)n-hexyl, 2-  
15 (5-cyano-3-methoxyphenyl)n-pentyl, 3-(2,6-dimethylphenyl)n-propyl, 4-chloro-3-aminobenzyl, 6-(4-methoxyphenyl)-3-carboxy(n-hexyl), 5-(4-aminomethylphenyl)-3-(aminomethyl)n-pentyl, 5-phenyl-3-oxo-n-pent-1-yl and the like.

20 The term "heterocycle" or "heterocyclic ring" denotes optionally substituted five-membered to eight-membered rings that have 1 to 4 heteroatoms, such as oxygen, sulfur and/or nitrogen, in particular nitrogen, either alone or in conjunction with sulfur  
25 or oxygen ring atoms. These five-membered to eight-membered rings may be saturated, fully unsaturated or partially unsaturated, with fully saturated rings being preferred. Preferred heterocyclic rings include morpholino, piperidinyl, piperazinyl, 2-amino-imidazolyl, tetrahydrofurano, pyrrolo, tetrahydrothiophen-yl, hexylmethyleneimino and heptylmethyleneimino.

30 The term "substituted heterocycle" or "substituted heterocyclic ring" means the above-described heterocyclic ring is substituted with, for example, one or more, and preferably one or two, substituents which are the same or different which substituents can be halogen, hydroxy, protected hydroxy, cyano, nitro, C<sub>1</sub> to C<sub>12</sub> alkyl, C<sub>1</sub> to C<sub>12</sub>  
35 alkoxy, C<sub>1</sub> to C<sub>12</sub> substituted alkoxy, C<sub>1</sub> to C<sub>12</sub> acyl, C<sub>1</sub> to C<sub>12</sub> acyloxy, carboxy, protected carboxy, carboxymethyl, protected carboxymethyl, hydroxymethyl, protected hydroxymethyl, amino, protected amino, (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted)amino carboxamide, protected

5 carboxamide, N-(C<sub>1</sub> to C<sub>12</sub> alkyl)carboxamide, protected N-(C<sub>1</sub> to C<sub>12</sub>  
alkyl)carboxamide, N, N-di(C<sub>1</sub> to C<sub>12</sub> alkyl)carboxamide, trifluoromethyl, N-((C<sub>1</sub> to C<sub>12</sub>  
alkyl)sulfonyl)amino, N-(phenylsulfonyl)amino, heterocycle or substituted heterocycle  
groups.

10

The term "C<sub>1</sub> to C<sub>8</sub> alkoxy" as used herein denotes groups such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, t-butoxy and like groups. A preferred alkoxy is methoxy. The term "C<sub>1</sub> to C<sub>8</sub> substituted alkoxy" means the alkyl portion of the alkoxy can be substituted in the same manner as in relation to C<sub>1</sub> to C<sub>8</sub> substituted alkyl.

15

The term "C<sub>1</sub> to C<sub>8</sub> aminoacyl" encompasses groups such as formyl, acetyl, propionyl, butyryl, pentanoyl, pivaloyl, hexanoyl, heptanoyl, octanoyl, benzoyl and the like.

20 The term "C<sub>1</sub> to C<sub>8</sub> substituted aminoacyl" denotes the acyl group substituted by one or more, and preferably one or two, halogen, hydroxy, protected hydroxy, oxo, protected oxo, cyclohexyl, naphthyl, amino, protected amino, (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted)amino, guanidino, heterocyclic ring, substituted heterocyclic ring, imidazolyl, indolyl,  
25 pyrrolidinyl, C<sub>1</sub> to C<sub>12</sub> alkoxy, C<sub>1</sub> to C<sub>12</sub> acyl, C<sub>1</sub> to C<sub>12</sub> acyloxy, nitro, C<sub>1</sub> to C<sub>12</sub> alkyl ester, carboxy, protected carboxy, carbamoyl, carboxamide, protected carboxamide, N-(C<sub>1</sub> to C<sub>12</sub> alkyl)carboxamide, protected N-(C<sub>1</sub> to C<sub>12</sub> alkyl)carboxamide, N,N-di(C<sub>1</sub> to C<sub>12</sub> alkyl)carboxamide, cyano, methylsulfonylamino, thiol, C<sub>1</sub> to C<sub>10</sub> alkylthio or C<sub>1</sub> to C<sub>10</sub> alkylsulfonyl groups. The substituted acyl groups may be substituted once or  
30 more, and preferably once or twice, with the same or with different substituents.

Examples of C<sub>1</sub> to C<sub>8</sub> substituted acyl groups include 4-phenylbutyryl, 3-phenylbutyryl, 3-phenylpropanoyl, 2-cyclohexanylacetyl, cyclohexanecarbonyl, 2-furanoyl and 3-dimethylaminobenzoyl.

35

This invention also provides a pharmaceutical composition comprising an effective amount of a compound according to the invention. Such pharmaceutical compositions can be administered by various routes, for example oral,

5 subcutaneous, intramuscular, intravenous or intracerebral. The preferred route of  
administration would be oral at daily doses of the compound for adult human  
treatment of about 0.01-5000 mg, preferably 1-1500 mg per day. The appropriate  
dose may be administered in a single dose or as divided doses presented at  
appropriate intervals for example as two, three four or more subdoses per day.

10

For preparing pharmaceutical compositions containing compounds of the invention,  
inert, pharmaceutically acceptable carriers are used. The pharmaceutical carrier can  
be either solid or liquid. Solid form preparations include, for example, powders,  
tablets, dispersible granules, capsules, cachets, and suppositories.

15

A solid carrier can be one or more substances which can also act as diluents,  
flavoring agents, solubilizers, lubricants, suspending agents, binders, or tablet  
disintegrating agents; it can also be an encapsulating material.

20 In powders, the carrier is generally a finely divided solid which is in a mixture with the  
finely divided active component. In tablets, the active compound is mixed with the  
carrier having the necessary binding properties in suitable proportions and  
compacted in the shape and size desired.

25 For preparing pharmaceutical composition in the form of suppositories, a low-melting  
wax such as a mixture of fatty acid glycerides and cocoa butter is first melted and the  
active ingredient is dispersed therein by, for example, stirring. The molten  
homogeneous mixture is then poured into convenient-sized molds and allowed to  
cool and solidify.

30

Powders and tablets preferably contain between about 5% to about 70% by weight of  
the active ingredient, preferably comprising (especially consisting of) one or more of  
the compounds according to this invention. Suitable carriers include, for example,  
magnesium carbonate, magnesium stearate, talc, lactose, sugar, pectin, dextrin,  
35 starch, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, a low-melting  
wax, cocoa butter and the like.


5 The pharmaceutical compositions can include the formulation of the active compound  
with encapsulating material as a carrier providing a capsule in which the active  
component (with or without other carriers) is surrounded by a carrier, which is thus in  
association with it. In a similar manner, cachets are also included. Tablets, powders,  
cachets, and capsules can be used as solid dosage forms suitable for oral  
10 administration.

Liquid pharmaceutical compositions include, for example, solutions suitable for oral  
or parenteral administration, or suspensions, and emulsions suitable for oral  
administration. Sterile water solutions of the active component or sterile solutions of  
15 the active component in solvents comprising water, ethanol, or propylene glycol are  
examples of liquid compositions suitable for parenteral administration.

Sterile solutions can be prepared by dissolving the active component in the desired  
solvent system, and then passing the resulting solution through a membrane filter to  
20 sterilize it or, alternatively, by dissolving the sterile compound in a previously  
sterilized solvent under sterile conditions.


In a preferred embodiment of the invention in the compounds claimed, or the  
pharmaceutical acceptable salts or solvates thereof,  $R_1$ ,  $R_3$  and  $R_4$  are H,  $R_2$  is  
25 halogen and preferably iodine over bromine and chlorine and  $R_5$  is H,  $C_1$  to  $C_8$  alkyl  
or  $C_1$  to  $C_8$  substituted alkyl.

A particularly preferred compound which may act as a partial agonist of LXR is  
shown in formula (II) below (MOLNAME TR1040001892). It has been demonstrated  
30 that this compound has a low effective concentration at LXR with an  $EC_{50}$  of 2  $\mu$ M in  
a FRET assay wherein the  $EC_{50}$  reflects the half-maximal effective concentration,  
and which is higher than the  $EC_{50}$  of 0.015  $\mu$ M for the published LXR agonist  
TO901317 (J. Schultz et al., Genes Dev. 14, 2831-2838, 2000). Compound  
according to formula (II) does show selective upregulation of ABCA1 and ABCG1 in  
35 THP-1 macrophages but does not significantly upregulate FAS and much reduced  
SREBP-1c in HepG2 cells (see EXAMPLE 5 further down).



(II)


It has also been found that the compound according to formula (III) (Molname TR1040011382) to be active as partial agonist of the LXR human nuclear receptors with a selective upregulation of the target genes ABCA1 and ABCG1 in THP-1 cells compared to FAS and SREBP-1c in HepG2 cells.




(III)

It has also been found that the compounds according to formulas (IV) (Molname TR1040002211) and (V) (Molname TR1040002212) to be active as partial agonist of the LXR human nuclear receptors however with a reduced selectivity regarding the upregulation of the target genes ABCA1 and ABCG1 in THP-1 cells versus FAS and SREBP-1c in HepG2 cells compared to compounds of formula (II) and (III) (see EXAMPLE 5 further down)





(IV)



(V)

In particular the invention relates to a compound as described above wherein said compounds is capable of binding the LXR receptor protein or a portion thereof encoded by a nucleic acid according to SEQ ID NO:1 or NO:2 (Fig. 3 ) or a mammalian homologue thereof. This compound can bind to the LXR receptor protein or a portion thereof in a mixture comprising 10-200 ng of LXR receptor protein, a fusion protein containing LXR or a portion thereof, preferably the ligand binding domain, fused to a Tag, 5-100 mM Tris/HCl at pH 6,8-8,3; 60-1000 mM KCl; 0-20 mM MgCl<sub>2</sub>; 100-1000ng/μl BSA in a total volume of preferably about 25 μl[see also EXAMPLE 1 and Fig.2).

A mammalian receptor protein homologue of the protein encoded by a nucleic acid according to SEQ ID NO:1 or 2, as used herein is a protein that performs substantially the same task as LXR does in humans and shares at least 40% sequence identity at the amino acid level, preferably over 50 % sequence identity at the amino acid level more preferably over 65 % sequence identity at the amino acid

- 5 level, even more preferably over 75 % sequence identity at the amino acid level and  
most preferably over 85 % sequence identity at the amino acid level.

The invention in particular concerns a method for prevention or treatment of a LXR  
receptor protein or LXR receptor protein homologue mediated disease or condition in  
10 a mammal comprising administration of a therapeutically effective amount of a  
compound according to the invention wherein the prevention or treatment is directly  
or indirectly accomplished through the binding of a compound according to the  
invention to the LXR receptor protein or to the LXR receptor protein homologue.

- 15 The term mediated herein means that the physiological pathway in which the LXR  
receptor protein acts is either directly or indirectly involved in the disease or condition  
to be treated or prevented. In the case where it is indirectly involved it could be that,  
e.g. modulating the activity of LXR by a compound according to the invention  
influences a parameter which has a beneficial effect on a disease or a condition. One  
20 such example is that modulation of LXR activity leads to decreased levels of serum  
cholesterol or certain lipoproteins which in turn have a beneficial effect on the  
prevention and treatment of atherosclerosis. Herein a condition is a physiological or  
phenotypic state which is desirably altered. One such example would be obesity  
which is not necessarily medically harmful but nonetheless a non desirable  
25 phenotypic condition. In a preferred embodiment of the invention the method for  
prevention or treatment of a LXR receptor protein mediated disease or condition is  
applied to a human. This may be male or female.

- Pharmaceutical compositions generally are administered in an amount effective for  
30 treatment or prophylaxis of a specific condition or conditions. Initial dosing in human  
is accompanied by clinical monitoring of symptoms, such symptoms for the selected  
condition. In general, the compositions are administered in an amount of active agent  
of at least about 100 µg/kg body weight. In most cases they will be administered in  
one or more doses in an amount not in excess of about 20 mg/kg body weight per  
35 day. Preferably, in most cases, doses is from about 100 µg/kg to about 5 mg/kg body  
weight, daily.

- 5 For administration particularly to mammals, and particularly humans, it is expected that the daily dosage level of active agent will be 0,1 mg/kg to 10 mg/kg and typically around 1 mg/kg.

10 By "therapeutically effective amount" is meant a symptom-alleviating or symptom-reducing amount, a cholesterol-reducing amount, a cholesterol absorption blocking amount, a protein and/or carbohydrate digestion-blocking amount and/or a de novo cholesterol biosynthesis-blocking amount of a compound according to the invention.

- 15 Likewise the invention concerns a method of treating in mammal a disease which is correlated with abnormal cholesterol, triglyceride, or bile acid levels or deposits comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound according to the invention.

- 20 Accordingly, the compounds according to the invention may also be used in a method of prevention or treatment of mammalian atherosclerosis, gallstone disease, lipid disorders, Alzheimer's disease, skin disorders, inflammation, obesity or cardiovascular disorders such as coronary heart disease or stroke.

- 25 The invention further concerns a method of blocking in a mammal the cholesterol absorption in the intestine in need of such blocking comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound according to the invention. The invention may also be used to treat obesity in humans.

30

- The Liver X Receptor alpha is a prototypical type 2 nuclear receptor meaning that it activates genes upon binding to the promoter region of target genes in a heterodimeric fashion with Retinoid X Receptor. The relevant physiological ligands of LXR are oxysterols. The compounds have been demonstrated to have a high binding efficacy (binding coefficients measured as EC50 in the range of 1-5  $\mu$ M) as well as agonistic and/or partial agonistic properties. Consequently they may be applied to regulate genes that participate in bile acid, cholesterol and fatty acid homeostasis as well as other downstream regulated genes. Examples of such genes are but are not
- 35

5 limited to lipid absorption, cholesterol biosynthesis, cholesterol transport or binding,  
bile acid transport or binding, proteolysis, amino acid metabolism, glucose  
biosynthesis, protein translation, electron transport, and hepatic fatty acid  
metabolism. LXR often functions in vivo as a heterodimer with the Retinoid X  
Receptor. Published non-steroidal LXR agonists such as the "Tularik" compound  
10 "TO901317" (see figure 5) are known to influence the regulation of various liver  
genes. Genes found to be regulated by TO901317 can be found in figure 6. Thus, the  
invention also concerns a method of modulating a gene whose expression is  
regulated by the LXR receptor in a mammal comprising administration of a  
therapeutically effective amount of a compound according to the invention to said  
15 mammal.

A number of direct and indirect LXR target genes have been described whose  
regulated expression contribute to cholesterol homeostasis and lipogenesis. In this  
respect the direct regulation of Cyp7A, which was shown to be a direct target gene of  
20 LXR at least in the rodent lineage is an important aspect of cholesterol removal by  
increased metabolism of bile acids (Lehmann et al., J Biol.Chem. 272 (6) 3137-3140;  
1007). Gupta et al. (Biochem. Biophys Res.Com, 293; 338-343, 2002) showed that  
LXR  $\alpha$  regulation of Cyp7A is dominant over FXR inhibitory effects on Cyp7A  
transcription.

25 A key transcription factor that was also shown to be a direct target gene for the LXR  
receptor is SREBP-1C (Repa et al., Genes and Development, 14:2819-2830; 2000;  
Yoshikawa et al.; Mol.Cell.Biol.21 (9) 2991-3000, 2001). SREBP-1C itself activates  
transcription of genes involved in cholesterol and fatty acid synthesis in liver but also  
30 other mammalian tissues. Some of the SREBP1c target genes involved in  
lipogenesis like FAS and SCD have shown to be additionally direct targets of the  
LXR receptors (Joseph et al.; J Biol Chem. 2002 Mar 29;277(13):11019-25; Liang et  
al., J Biol Chem. 2002 Mar 15;277(11):9520-8.).

35 A primary limitation for the applicability of LXR agonists as e.g. anti-atherosclerotic  
drugs comes from the observation that compounds with full agonistic activity, e.g.  
TO901317, not only elevate HDL cholesterol levels but do also increase plasma  
triglyceride levels in mice (Schultz et al., 2000 Genes Dev. 14:2831-8.).  
Concomitantly, not only genes that are involved in cholesterol efflux such as the

cholesterol transporter ABCA1 (Venkateswaran et al., 2000 PNAS. 97:12097-102.), ABCG1 as well as the lipid binding protein Apolipoprotein E (Laffite et al. 2001 PNAS 98:507-512) are induced by full LXR agonists, but also genes involved in lipogenesis, including the fatty acid synthase FAS (Joseph et al 2002 J Biol Chem. 277:11019-11025), and SREB P-1c (Yoshikawa et al., 2001 Mol Cell Biol. 21:2991-3000). Elevation of serum triglyceride levels is an independent risk factor for atherosclerosis (for review see Miller (1999) Hosp Pract (Off Ed) 34: 67-73.). Thus, LXR activity needs to be selectively modulated for therapeutic benefit. In particular, compounds need to be found that stimulate reverse cholesterol transport, but do not significantly increase triglyceride levels.

Another gene that has been shown to be directly regulated by LXRs is the LPL gene, that codes for a key enzyme that is responsible for the hydrolysis of triglycerides in circulating lipoprotein, releasing free fatty acids to peripheral tissues. (Zhang et al. J Biol Chem. 2001 Nov 16;276(46):43018-24.) This enzyme is believed to promote uptake of HDL cholesterol in liver, thereby promoting reverse cholesterol transport. A similar functional involvement in HDL clearance is described for the CETP gene product that facilitated the transfer of HDL cholesterol esters from plasma to the liver. LXR response elements were found in the CETP promoter and direct activation of this gene by LXR was demonstrated (Luo and Tall; J Clin Invest. 2000 Feb;105(4):513-20.).

The regulated transport of cholesterol through biological membranes is an important mechanism in order to maintain cholesterol homeostasis. A pivotal role in these processes in multiple tissues like e.g. macrophages and intestinal mucosa cells is maintained by the ATP-binding cassette transporter proteins (ABC). ABCA1 and ABCG1 were identified as direct LXR target genes (Costet et al.; J Biol Chem. 2000 Sep 8;275(36):28240-5) that mediate cholesterol efflux and prevent thereby e.g. generation of atherogenic plaques in macrophages (Singaraja et al. J Clin Invest. 2002 Jul;110(1):35-42). Other ABC transporters like ABCG5 and ABCG8, primarily expressed in hepatocytes and enterocytes have also been reported to be directly responsive to LXR agonists (Repa et al., J Biol Chem. 2002 May 24;277(21):18793-800. Kennedy et al., J Biol Chem. 2001 Oct 19;276(42):39438-47) and mediate the secretion of sterols from the liver and efflux of dietary sterols from the gut.

5 Apolipoproteins E, C-I, C-II, and C-IV, that fulfill important roles in lipoprotein/lipid  
homeostasis have also been shown to be direct targets of the LXR receptor ( Laffitte  
et al., Proc Natl Acad Sci U S A. 2001 Jan 16;98(2):507-12; Mak et al.; J Biol Chem.  
2002 May 24 [epub ahead of print]). These proteins have been found to be crucial  
10 components of chylomicrons, VLDL, IDL, and HDL and are among other things  
associated with hypertriglyceridemia and arteriosclerosis.

Recently the LXR $\alpha$  itself was shown to be regulated by both LXR receptors in human  
cell types including macrophages suggesting an autoregulatory amplification event in  
the response to LXR ligands which could e.g. lead to an enhanced stimulation of LXR  
15 target genes like e.g. ABCA1 (Bolten et al.; Mol Endocrinol. 2002 Mar;16(3):506-14.;  
Laffitte et al., Mol Cell Biol. 2001 Nov;21(22):7558-68; Whitney et al.; J Biol Chem.  
2001 Nov 23;276(47):43509-15).

Besides the important function of LXR receptors in tissues like liver and  
20 macrophages it has recently been reported that that stimulation of epidermal  
differentiation is mediated by Liver X receptors in murine epidermis. Differentiation  
marker genes like involucrin, loricin and profilaggrin have been shown to be  
upregulated upon LXR ligand treatment (Kömüves et al.; J Invest Dermatol. 2002  
Jan;118(1):25-34.).

25 Another recent report describes the regulation of cholesterol homeostasis (primarily  
the regulation of ABCA1, ABCG1 and SREBP-1C) by the LXR receptors in the  
central nervous system suggesting that LXRs may prove beneficial in the treatment of  
CNS diseases such as Alzheimer's and Niemann-Pick disease that are known to be  
30 accompanied by dysregulation of cholesterol balance (Whitney et al.; Mol Endocrinol.  
2002 Jun;16(6):1378-85).

Activation of LXR by an agonist improves glucose tolerance in a murine model of  
diet-induced obesity and insulin resistance. Gene expression analysis in LXR  
35 agonist-treated mice reveals coordinate regulation of genes involved in glucose  
metabolism in liver and adipose tissue, e.g. the down-regulation of peroxisome  
proliferator-activated receptor gamma coactivator-1 alpha (PGC-1),  
phosphoenolpyruvate carboxykinase (PEPCK), and glucose-6-phosphatase

5 expression and induction of glucokinase in liver. In adipose tissue, activation of LXR led to the transcriptional induction of the insulin-sensitive glucose transporter, GLUT4. LXR agonist may limit hepatic glucose output and improve peripheral glucose uptake (Laffitte et al. (2003) PNAS 100:5419-24).

10 Therefore one other important embodiment of the invention concerns methods that enhances or suppresses amongst other today yet unknown LXR target genes the above mentioned genes and the associated biological processes and pathways through LXR compounds that are subject of this invention.

15 The compounds according to the invention may be used as medicaments, in particular for the manufacture of a medicament for the prevention or treatment of a LXR receptor protein or LXR receptor protein homologue mediated disease or condition in a mammal wherein the prevention or treatment is directly or indirectly accomplished through the binding of the compound according to the invention to the LXR receptor protein or LXR receptor protein homologue. These pharmaceutical  
20 compositions contain 0,1 % to 99,5 % of the compound according to the invention, more particularly 0,5 % to 90 % of the compound according to the invention in combination with a pharmaceutically acceptable carrier.

25 The invention concerns also the use of a compound according to the invention for the manufacture of a medicament for the prevention or treatment of a LXR receptor protein mediated disease or condition wherein the mammal described above is a human. The medicament may be used for regulating the cholesterol transport system, for regulating levels of cholesterol, triglyceride, and/or bile acid in a mammal preferentially a human by activating the LXR receptor. The medicament may be used  
30 for the treatment of atherosclerosis, gallstone disease, lipid disorders, Alzheimer's disease, skin disorders, obesity or a cardiovascular disorder.

The invention further concerns the use of a compound according to the invention for the manufacture of a medicament capable for blocking in a mammal, preferentially in  
35 a human the cholesterol absorption in the intestine. Further the claimed compound may be used for the manufacture of a medicament for treating obesity in humans and

- 5 for modulating a gene whose expression is regulated by the LXR receptor (see details above and figures).



## EXAMPLES

### EXAMPLE 1

In vitro screening for compounds which influence LXR binding to coactivators.

For screening purposes a GST and 6 x His fusion of the LBD (from amino acids 155 of hLXRalpha to 447) of human LXRalpha is constructed by first cloning a Gateway cassette (Invitrogen) in frame into the Sma I site of the pAGGHLT Polylinker (Pharmingen). Then a PCR fragment specifically amplified from human liver cDNA is cloned into the resulting pACGHLT-GW following the manufacturers instructions for Gateway cloning (Invitrogen) to yield pACGHLT-GW-hLXRalphaLBD.

Primers used for Amplification are:

GGGGACAAGTTTGTACAAAAAAGCAGGCTCGCTTCGCAAATGCCGTCAG and  
GGGGACCACTTTGTACAAGAAAGCTGGGTCCCCTTCTCAGTCTGTTCCACTT .

100 % sequence integrity of all recombinant products is verified by sequencing.

Recombinant Baculovirus is constructed from pACGHLT-GW-hLXRalphaLBD using the Pharmingen Baculovirus Expression vector system according to instructions of the manufacturer. Monolayer cultures of SF9 cells are infected by the virus as recommended by Pharmingen or 200ml cultures of  $1 \times 10^6$  cells/ml grown in 2 liter Erlenmeyer flasks on an orbital shaker at 30 rpm are infected by 10ml of same virus stock. In both cases cells are harvested 3 days after infection. All cell growth is performed in Gibco SF900 II with Glutamine (Invitrogen) medium without serum supplementation at 28°C. Since SF9 cells contain significant amounts of endogenous GST, purification is performed via His and not via GST affinity chromatography. To this end instructions of Pharmingen for purification of recombinant His tagged proteins from SF9 cells are followed with the following modifications: All detergents are omitted from the buffers and cells were lysed on ice by 5 subsequent sonication pulses using a sonicator needle at maximum power.

All eluates are dialyzed against 20 mM Tris/HCl pH 6,8, 300 mM KCl; 5 mM MgCl<sub>2</sub>; 1 mM DTT; 0,2 mM PMSF; 10% Glycerol. A typical dialyzed eluate fraction contains the fusion protein at a purity of more than 80%. Total protein concentration is 0,1-0,3 mg/ml.

For E. coli expression of a NR coactivator, pDest17-hTif2BD expressing a NR interaction domain from amino acids 548-878 of human Tif2 (Acc. No: XM\_011633 RefSeq) tagged by 6 N-terminal His residues is constructed. Therefore, a PCR fragment specifically amplified from human liver cDNA is subcloned into pDest 17 (Invitrogen) following the manufacturers instructions for Gateway cloning (Invitrogen). Primers used for Amplification are:

GGGGACAAGTTTGTACAAAAAAGCAGGCTCGTTAGGGTCATCGTTGGCTTCACC  
and  
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAAAGTTGCCCTGGTTCGTGGGT  
TA

For E. coli expression plasmid DNA is transformed into chemically competent E. coli BL21 (Invitrogen, USA) and cells are grown to an OD600 of 0.4-0.7 before expression was induced by addition of 0,5 mM IPTG according instructions of the manufacturer (Invitrogen). After induction for 8 hours at 30°C cells are harvested by centrifugation for 10 minutes at 5000 x g. Fusion proteins are affinity purified using Ni-NTA Agarose (QIAGEN) according to the instructions of the manufacturer. Recombinant Tif2 construct is dialyzed against 20 mM Tris/HCL pH 7.9; 60 mM KCl; 5 mM MgCl<sub>2</sub>; 1 mM DTT, 0,2 mM PMSF; 10% glycerol. A typical dialyzed eluate fraction contains the fusion protein at a purity of more than 80%. Total protein concentration is 0,1-0,3 mg/ml.

The TIF2 fragment is subsequently biotinylated by addition of 5-40µl/ml Tif2 fraction of a Biotinamidocaproate N-Hydroxysuccinimide-ester (Sigma) solution (20 mg/ml in DMSO). Overhead rotating samples are incubated for 2 hours at room temperature. Unincorporated label is then separated using G25 Gel filtration chromatography (Pharmacia Biotech, Sweden). Protein containing fractions from the column are pooled and tested for activity in the assay as described below.

For screening of compound libraries as provided for by the methods shown below in the examples for substances which influence the LXR/Tif 2 interaction, the Perkin Elmer LANCE technology is applied. This method relies on the binding dependent energy transfer from a donor to an acceptor fluorophore attached to the binding partners of interest. For ease of handling and reduction of background from compound fluorescence LANCE technology makes use of generic fluorophore labels and time resolved detection (for detailed description see Hemmilä I, Blomberg K and

Hurskainen P, Time-resolved resonance energy transfer (TR-FRET) principle in LANCE, Abstract of Papers Presented at the 3<sup>rd</sup> Annual Conference of the Society for Biomolecular Screening, Sep., California (1997) )

For screening, 20-200 ng of biotinylated Tif 2 fragment and 10-200 ng of GST-LXR fragment are combined with 0.5-2 nM LANCE Eu-(W1024) labelled anti-GST antibody (Perkin Elmer) and 0,1-0,5µg of highly fluorescent APC-labelled streptavidin (Perkin Elmer, AD0059) in the presence of 50µM of individual compounds to be screened in a total volume of 25 µl of 20 mM Tris /HCl pH 6,8; 300 mM KCl; 5 mM MgCl<sub>2</sub>; 100-1000 ng/µl/ BSA DMSO content of the samples is kept below 4%. Samples are incubated for a minimum of 60 minutes in the dark at room temperature in FIA-Plates black 384well med. binding (Greiner).

The LANCE signal is detected by a Perkin Elmer VICTOR2V™ Multilabel Counter applying the detection parameters listed in Fig. 2. The results are visualized by plotting the ratio between the emitted light at 665 nm and at 615 nm. For every batch of recombinant proteins amount of proteins, including BSA and labeling reagents giving the most sensitive detection of hits is determined individually by analysis of dose response curves for 22R Hydroxycholesterol and TO 901317

## EXAMPLE 2

Experimental procedure for the preparation of the compounds according to the invention.

### *o*-AZIDOBENZOIC ACID SYNTHESIS (2)

The anthranilic acid (1, 1 eq., 0.5-1 M) is suspended in 6 M HCl, containing enough AcOH (0-20% dependent upon the anthranilic acid) to facilitate dissolution of the anthranilic acid and/or the intermediate diazonium salt, and cooled to 0 °C. NaNO<sub>2</sub> (1.1 eq., 1.3-2.5 M) dissolved in H<sub>2</sub>O is added to the anthranilic acid solution at a rate such that the temperature of the reaction solution remains below 5 °C. The resulting homogeneous solution of the diazonium salt is slowly filtered through a sintered glass funnel into a solution of NaN<sub>3</sub> (1.1 eq., 0.7-1.1 M) and NaOAc (12 eq.) in H<sub>2</sub>O. The

reaction mixture is stirred/shaken for 30-60 min following cessation of vigorous N<sub>2</sub> evolution. Following acidification of the reaction mixture to pH 1 with concentrated HCl, the mixture was cooled to 0 °C to encourage complete precipitation of the *o*-azidobenzoic acid. The precipitate is collected by filtration and washed with 6 M HCl (2x) and H<sub>2</sub>O (2x). The *o*-azidobenzoic acid product (2) is dried *in vacuo* (500 mtorr, 30 °C).

#### ACYLATION OF HYDROXYMETHYL RESIN (4)

To hydroxymethyl resin (1.0 eq., 1.3 mmol/g) and the *o*-azidobenzoic acid (1, 2.5 eq.) is added DMF (to give 400 mM *o*-azidobenzoic acid, 1), CsCO<sub>3</sub> (2.0 eq.) and KI (2.0 eq.). Following agitation of the reaction mixture for 36-48 h, the resin-bound *o*-azidobenzoic acid (4) is washed with MeOH (2 cycles), CH<sub>2</sub>Cl<sub>2</sub> (3 cycles), MeOH (3 cycles), DMF (3 cycles), MeOH (3 cycles) and CH<sub>2</sub>Cl<sub>2</sub> (3 cycles), and dried *in vacuo*.

#### AZA-WITTIG FORMATION (5)

To the resin-bound *o*-azidobenzoic acid (4, 1.0 eq.) is added a solution of PPh<sub>3</sub> (THF, 500 mM, 5.0 eq.). After 6 h, the resin is washed with 3 cycles of the following: THF (3 cycles), toluene (3 cycles), CH<sub>2</sub>Cl<sub>2</sub> (3 cycles) and hexanes (3 cycles). Followed by drying *in vacuo* to afford resin bound iminophosphorane (5)

#### CARBODIIMIDE FORMATION (6)

To the resin-bound iminophosphorane (5, 1 eq.) is added isocyanate (9, 5 eq., 450 mM) dissolved in ClCH<sub>2</sub>CH<sub>2</sub>Cl. The compounds are shaken at ambient temperature for 16 h, washed with 3 cycles of the following: THF (3 cycles), toluene (3 cycles), CH<sub>2</sub>Cl<sub>2</sub> (3 cycles) and hexanes (3 cycles), and dried *in vacuo* to afford carbodiimide (6).

#### GUANIDINE FORMATION / CYCLIZATION

To the carbodiimide functionalized resin (6) is added secondary amine (10, 0.6 eq., 500 mM) dissolved in  $\text{ClCH}_2\text{CH}_2\text{Cl}$ . The reaction mixture is heated to 50 °C in an incubator for 12-72 h to afford 2-aminoquinazoline (8).

All of the final products are analyzed using an Evaporative Light Scattering Detector (ELSD) detection to determine purity.

### EXAMPLE 3

This example illustrates that compounds according to the invention (experiments shown were done with MOLSTRUCTURE TR1040001892, TR1040011382, TR1040002211 and TR1040002212 (see formulas (II) to (V) for structural formulas)) activate luciferase reporter gene expression in a dose dependent manner mediated through GAL4-LXR $\alpha$ -LBD or GAL4-LXR $\beta$ -LBD constructs in HEK293 cells. TR1040001892 and TR1040011382 do activate LXR beta LBD tract mediated luciferase activity much stronger than with LXR alpha construct which is in contrast to the similar activation of both LXR alpha and LXR beta LBD containing constructs by TR1040002211 and TO901317.

HEK293 cells are grown in 96 well plates and co-transfected with pFR-luc (Stratagene) and pCMV-BD-LXR $\alpha$ -LBD or pCMV-BD-LXR $\beta$ -LBD (each 100 ng of plasmid DNA per well). Transfection is carried using Lipfectamine 2000 (Gibco-BRL) according to the manufacturers protocol. The ligand binding domains (LBD) of LXR $\alpha$  and LXR $\beta$  are cloned into the pCMV-BD-GW (the Gateway Reading Frame Cassette B is cloned as an EcoRV fragment into SmaI site of pCMV-BD) applying the manufacturer protocols for the Gateway<sup>TM</sup> system (Invitrogen).

Luciferase reporter activity is measured in triplicates from extracts of cells after incubating cells in culture medium (DMEM [Gibco-BRL] + 10% FCS [PAA laboratories]) for 16 hours (5%  $\text{CO}_2$ , 37°C) containing 0,5% DMSO (control) or 0,5% DMSO with increasing concentrations of TR1040001892, TR1040002211 or TO901317 (Sigma T 2320, see figure 5 for structural formula). The type of assay used here is a mammalian one hybrid (M1H) assay that is known to those skilled in the art.

Dose-dependent luciferase activities originating from pFR-luc demonstrate the relative activities of the compounds with the LXRA or LXRb LBDs in this mammalian one hybrid type approach.

#### EXAMPLE 4

This example shows that described compounds can increase the abundance of mRNA of LXR target genes like ABCA1 and ABCG1 in THP-1 cells which are treated with TPA or FAS and SREBP-1c in HepG2 cells as shown in Fig 8A-D.

THP-1 cells are seeded in 24 well plates at  $3 \times 10^5$  cells per well in RPMI 1640 medium containing 10 % FCS and 100 nM TPA for 24 h. HepG2 cells are seeded in poly-L-Lysine coated 24well plates at  $1 \times 10^6$  cells per well in EMEM medium containing 10 % FCS until they are appr. 60% confluent.

Before treatment with LXR compounds, the growth medium is changed to medium containing 10% charcoal/dextran-stripped FCS for 12 h. Treatment is done for 12h (THP-1 cells) and 24h (HepG2 cells), respectively, in medium containing 10% charcoal/dextran-stripped FCS (and 100 nM PMA in the case of THP-1 cells).

LXR compounds are dissolved in DMSO, with the final solvent concentration never exceeding 0.125% . All treatments are done in triplicates and experiments repeated twice. Total RNA is extracted using the Qiagen Rneasy Mini Kit and treated with DNase (DNAfree kit, Ambion). RNA is reverse transcribed with Oligo(dT) primer and real-time reverse transcription PCR (TaqMan) is performed using the ABI Prism 7900HT Sequence Detection System and reagents supplied by Applied Biosystems. mRNA steady state levels are normalised to H3 histone (H3F3A ) expression levels.

The sequences of forward primers, reverse primers and TaqMan probes are as follows :

FAS : CTGAGACGGAGGCCATATGCT, GCTGCCACACGCTCCTCTAG, FAM-CAGCAGTTCACGGACATGGAGCACAA-TAMRA  
ABCA1 :TCCTGTGGTGTCTTCTGGATGAAC, CTTGACAACACTTAGGGCACAATTC, FAM- ACCACAGGCATGGATCCCAAAGCC-TAMRA

## EXAMPLE 5

All compounds T0901317, TR1040002211, TR1040002212, TR1040001892, TR1040011382, LN0000006662 and LN0000006674 cause a marked increase in cholesterol export in differentiated THP-1 macrophages (see Figure 9 A).

Strikingly, the compound T0901317 causes a marked increase in triacylglyceride mass in HepG2 liver cells, while compounds like TR1040001892 and TR1040011382 do not cause a significant increase in triacylglyceride mass. Compounds TR1040002211 and TR1040002212 cause a slight increase in triacylglyceride mass.

This behavior is similar to the selective transcriptional effect of compounds like TR1040001892 and TR1040011382 on the LXR target genes in HepG2 versus THP-1 cells.

Methods: Cultures of the monocyte-macrophage cell line and the hepatocytes HepG2 are obtained from the American Type tissue Culture Collection, Rockville, MD and were grown in RPMI 1640 medium supplemented with 10% fetal bovine serum, 10 mM HEPES, 2 mM Pyruvate, 50  $\mu$ M  $\beta$ -Mercaptoethanol (THP-1) and Minimum essential medium (Eagle) with 2 mM L-glutamine and Earle's BSS supplemented with 10% fetal bovine serum, 2 mM glutamine, 0.1 mM non-essential amino acids, 1 mM sodium pyruvate (HepG2), respectively, at 37°C in 5% CO<sub>2</sub>.

THP-1 cells are differentiated into macrophages by addition of 100 nM Phorbol 12-Myristate 13-Acetate (PMA; Sigma P8139) and PMA included in the medium of all subsequent experiments to maintain differentiation.

For cholesterol efflux measurements and triacylglyceride analysis cells are seeded in 6well plates at  $1.8 \times 10^6$  cells (THP-1) and  $1 \times 10^6$  cells (HepG2) per well, respectively.

## CHOLESTEROL EFFLUX

THP-1 cells are seeded in 6well plates at  $1 \times 10^6$  cells per well in RPMI 1640 medium containing 10 % FCS and 100 nM TPA for 72 h. After washing with PBS cells are incubated 24 h with fresh in RPMI 1640 medium containing 10 % FCS and 100 nM TPA. Cells are washed twice with PBS and RPMI 1640 medium containing 0.15% BSA and 100 nM TPA is added for further 24 h. Treatment with LXR compounds is done for 24 h in RPMI 1640 medium containing 0.15% BSA, 100 nM TPA and 40

µg/ml ApoA1 (Calbiochem # 178452). Medium is collected, centrifuged to remove cell debris and assayed for cholesterol using a commercial fluorometric kit (Molecular Probes A-12216). The remaining cellular proteins are lysed with 0.3 N NaOH and protein content measured with the Biorad Bradford reagent.

#### TRIGLYCERIDE ASSAY

HepG2 cells are seeded in poly-L-Lysine coated 6well plates at  $1 \times 10^6$  cells per well in EMEM medium containing 10 % FCS until they were appr. 60% confluent. Before treatment with LXR compounds growth medium is changed to medium containing 10% charcoal/dextran-stripped FCS for 12 h. Treatment is done for 24h in medium containing 10% charcoal/dextran-stripped FCS. Cells are washed twice with ice-cold PBS/0.2% BSA and twice with cold PBS and all liquid carefully removed. Triglyceride are extracted with 1.5 ml hexane/ isopropanol = 3:2 per well with gentle shaking for 2-3 h at RT according to Pan et al. (2002) JBC 277, 4413-4421 and Goti et al. (1998) Biochem J, 332, 57-65. The extraction solution is collected, dried under vacuum and redissolved in isopropanol/ 1.5% triton. The remaining cellular proteins are lysed with 0.3 N NaOH and protein content measured with the Biorad Bradford reagent.

Triglyceride levels are measured as esterified glycerol using a commercial enzymatic colorimetric kit (Sigma 343-25P). In a preliminary assay it is checked by omitting the lipase enzyme that contribution of free glycerol is negligible.

#### FIGURE CAPTIONS

##### FIG. 1

Fig. 1 shows the synthesis of the compounds according to the invention as also described in EXAMPLE 2.



**FIG. 2**

Fig. 2 shows the measurement parameters employed by the Wallace VICTOR2V™ Multilabel Counter which was used for measuring the EC<sub>50</sub> values (see also EXAMPLE 1)

**FIG. 3**

Shows a table with the accession numbers for the key genes

**FIG. 4**

Fig. 4 shows the internal molecular name used by the applicant (MOLNAME) as well as the corresponding structures of preferred compounds according to the invention. The figure further shows their respective EC<sub>50</sub> values (EC50 AVG) as established according to the Example 1 in multiple experiments (see above), as well as their respective average efficacy (% activity relative to TO901317 control agonist).

**FIG. 5**

Figure 5 shows various known LXR ligands. The compound TO901317 is used as a reference compound here. It is apparent from their structures that the inventors have identified novel compounds which are structurally not related to these known ligands.

**FIG. 6**

Figure 6 shows various genes that have been found to be regulated through binding of an LXR agonist to the LXR protein.

**FIG. 7**

Fig 7A and Fig 7B show dose dependence of indicated compounds with LXR alpha LBD (7A) or LXR beta (7B) LBD containing constructs in mammalian one hybrid (M1H) type assays. The respective  $\mu$ M concentrations of the compounds TO901317,

TR1040002211, TR1040002212. TR1040001892 and TR1040011382 are given on the x-axis and the relative light units (RLU) are depicted on the y-axis.

**Fig. 8**

Analysis of mRNA content of the indicated genes (ABCA1, ABCG1, FAS and SREBP-1c) in total RNA isolated from THP-1 cells (8A and 8B) or HepG2 cells (8C and 8D) treated for 12 or 24 hours with indicated concentrations ( $\mu\text{M}$  on x-axis) of T0901317, TR1040011382, TR1040001892 and TR1040002211. The relative fold induction is depicted on the y-axis.


**Fig. 9**

Analysis of relative fold increase in total cholesterol from supernatants of cultivated THP-1 cells (indicated on the y-axis) incubated with ApoA1 and with or without  $10\mu\text{M}$  of the compounds T0901317, TR1040002211, TR1040002212. TR1040001892, TR1040011382, LN0000006662 and LN0000006674 as indicated on the X-axis of Fig 9A.

Analysis of relative levels of total triglyceride (TG) content in HepG2 cells (indicated on the y-axis) treated with  $25\mu\text{M}$  of the indicated compounds T0901317, TR1040002211, TR1040002212. TR1040001892, TR1040011382, LN0000006662 and LN0000006674 (indicated on the x-axis).

**Claims:**

1. A compound of the formula (I), or pharmaceutically acceptable salts or solvates thereof,




wherein substituents and indices have the following meanings:

R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, - independent from each other - is H, halogen, hydroxy, protected hydroxy, cyano, nitro, C<sub>1</sub> to C<sub>6</sub> alkyl, C<sub>1</sub> to C<sub>6</sub> substituted alkyl, C<sub>1</sub> to C<sub>7</sub> alkoxy, C<sub>1</sub> to C<sub>7</sub> substituted alkoxy, C<sub>1</sub> to C<sub>7</sub> acyl, C<sub>1</sub> to C<sub>7</sub> substituted acyl, C<sub>1</sub> to C<sub>7</sub> acyloxy, carboxy, protected carboxy, carboxymethyl, protected carboxymethyl, hydroxymethyl, protected hydroxymethyl, amino, protected amino, (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted)amino, carboxamide, protected carboxamide, N-(C<sub>1</sub> to C<sub>6</sub> alkyl)carboxamide, protected N-(C<sub>1</sub> to C<sub>6</sub> alkyl)carboxamide, N, N-di(C<sub>1</sub> to C<sub>6</sub> alkyl)carboxamide, trifluoromethyl, N-((C<sub>1</sub> to C<sub>6</sub> alkyl)sulfonyl)amino, N-(phenylsulfonyl)amino or phenyl,

R<sub>5</sub> is H, C<sub>1</sub> to C<sub>8</sub> alkyl, C<sub>2</sub> to C<sub>6</sub> alkenyl, C<sub>1</sub> to C<sub>8</sub> substituted alkyl, C<sub>7</sub> to C<sub>12</sub> alkylphenyl or C<sub>7</sub> to C<sub>12</sub> substituted phenylalkyl.


2. A compound of the formula (I), or pharmaceutically acceptable salts or solvates thereof,




wherein the substituents and indices have the following meanings:

R<sub>1</sub>, R<sub>3</sub> and R<sub>4</sub> are H, R<sub>2</sub> is halogen, hydroxy, protected hydroxy, cyano, nitro, C<sub>1</sub> to C<sub>6</sub> alkyl, C<sub>1</sub> to C<sub>6</sub> substituted alkyl, C<sub>1</sub> to C<sub>7</sub> alkoxy, C<sub>1</sub> to C<sub>7</sub> substituted alkoxy, C<sub>1</sub> to C<sub>7</sub> acyl, C<sub>1</sub> to C<sub>7</sub> substituted acyl, C<sub>1</sub> to C<sub>7</sub> acyloxy, carboxy, protected carboxy, carboxymethyl, protected carboxymethyl, hydroxymethyl, protected hydroxymethyl, amino, protected amino, (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted)amino, carboxamide, protected carboxamide, N-(C<sub>1</sub> to C<sub>6</sub> alkyl)carboxamide, protected N-(C<sub>1</sub> to C<sub>6</sub> alkyl)carboxamide, N, N-di(C<sub>1</sub> to C<sub>6</sub> alkyl)carboxamide, trifluoromethyl, N-((C<sub>1</sub> to C<sub>6</sub> alkyl)sulfonyl)amino, N- (phenylsulfonyl)amino or phenyl, and R<sub>5</sub> is H, C<sub>1</sub> to C<sub>8</sub> alkyl, C<sub>2</sub> to C<sub>6</sub> alkenyl, C<sub>1</sub> to C<sub>8</sub> substituted alkyl.


3. A compound according to claim 1 or 2 with: R<sub>1</sub>, R<sub>3</sub> and R<sub>4</sub> being H, R<sub>2</sub> being halogen and preferably iodine over bromine and chlorine and R<sub>5</sub> being H, C<sub>1</sub> to C<sub>6</sub> alkyl, C<sub>3</sub> to C<sub>5</sub> alkenyl, C<sub>1</sub> to C<sub>6</sub> substituted alkyl.
4. A compound according to any of claims 1 to 3 being




5. A compound according to any of claims 1 to 3 being



6. A compound according to claim 1 being




7. A compound according to claim 1 being




(V)

8. A compound according to any of claims 1 to 3 being



(VI)

9. A compound according to claim 1 or 2 being



(VII)

10. A compound of according to any of claims 1 to 9 wherein said compound is capable of binding the NR1H3 receptor protein encoded by a nucleic acid comprising SEQ ID NO:2 or a portion thereof or a mammalian homologue thereof .
11. A compound of according to any of claims 1 to 9 wherein said compound is capable of binding the NR1H2 receptor protein encoded by a nucleic acid comprising SEQ ID NO:1 or a portion thereof or a mammalian homologue thereof.
12. A compound according to any of claims 1 to 9 for use as a medicament.
13. A method for prevention or treatment of a NR1H3 and/or NR1H2 receptor protein mediated disease or NR1H3 and/or NR1H2 receptor protein homologue mediated disease or condition in a mammal comprising administration of a therapeutically effective amount of a compound according to claims 1 to 9 wherein the prevention or treatment is directly or indirectly accomplished through the binding of the compound according claims 1 to 9 to the NR1H3 and/or NR1H2 receptor proteins or to the NR1H3 and/or NR1H2 receptor protein homologues.
14. A method for regulating the cholesterol synthesis or transport in a mammal which comprises activating the NR1H3 and/or NR1H2 receptors with a therapeutically effective amount of a compound according to claims 1 to 9.
15. A method of treating in mammal a disease which is affected by cholesterol, triglyceride, bile acid, glucose or glucocorticoid levels comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound according to claims 1 to 9.
16. A method of treating in a mammal Atherosclerosis, Alzheimers disease, Type II diabetes, lipid disorders, obesity, an inflammatory or a cardiovascular

disorder comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound according to claims 1 to 9.


17. A method according to any of claims 13 to 16 wherein the expression of one or more of the genes out of the group comprising ABCA1, ABCG1, ABCG5, ABCG8, apolipoprotein-CI, -CII, -CIV, -E, LPL (lipoprotein lipase), CETP (cholesteryl ester transfer protein) or other genes that positively regulate cholesterol homeostasis is increased upon compound administration.
18. A method according to any of claims 13 to 16 wherein the expression of one or more of the genes out of the group comprising 11- $\beta$ -HSD (11- $\beta$  hydroxysteroid dehydrogenase), PEPCCK (phosphoenolpyruvat carboxykinase), G-6-P (glucose-6-phosphatase) is reduced upon compound administration.
19. A method according to any of claims 13 to 16 wherein the expression of one or more of the genes out of the group comprising FAS (Fatty Acid Synthase), SREBP-1c (Sterol-response element binding protein), SCD-1 (Stearoyl-CoA Desaturase), Angiopoietin like protein 3 (Angptl3) or other genes which are relevant for controlling serum triglyceride or glucose levels are not or more weakly increased in liver and or other organs compared to administration of a full agonist like TO901317.
20. A method of blocking in a mammal the cholesterol or fatty acid absorption in the intestine of a mammal in need of such blocking comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound according to claims 1 to 9.
21. A method for treating obesity in a mammal comprising administering a therapeutically effective amount of a compound according to any of claims 1 to 9.
22. A method of modulating a gene whose expression is regulated by the NR1H3 and/or NR1H2 receptor in a mammal comprising administering a therapeutically effective amount of a compound according to claims 1 to 9.



23. A method according to any of claims 13 to 19 wherein the expression of ABCA1 and/or ABCG1 and/or ABCG5 and/or ABCG8 are increased.
24. Use of a compound according to any of claims 1 to 9 in a method according to claims 13 to 23 wherein the mammal is a human
25. Use of a compound according to any of claims 1 to 9 for the manufacture of a medicament for the prevention or treatment of a NR1H3 and/or NR1H2 receptor protein or NR1H3 and/or NR1H2 receptor protein homologue mediated disease or condition in a mammal wherein the prevention or treatment is directly or indirectly accomplished through the binding of the compound to the NR1H3 and/or NR1H2 receptor protein or NR1H3 and/or NR1H2 receptor protein homologue.
26. Use of a compound according to any of claims 1 to 9 for the manufacture of a medicament for prevention or treatment of a NR1H3 and/or NR1H2 receptor protein mediated disease or condition wherein the mammal is a human.
27. Use of a compound according to any of claims 1 to 9 for the manufacture of a medicament for regulating the cholesterol transport system in a mammal by activating the NR1H3 and/or NR1H2 receptor.
28. Use of a compound according to any of claims 1 to 9 for the manufacture of a medicament for regulating levels of cholesterol, triglyceride, and/or bile acid.
29. Use of a compound according to any of claims 1 to 9 for the manufacture of a medicament for treating in a mammal atherosclerosis, alzheimer disease, gallstone disease, lipid disorders, inflammatory disorder, type II diabetes, obesity or a cardiovascular disorder.
30. Use of a compound according to any of claims 1 to 9 for the manufacture of a medicament capable for blocking in a mammal the cholesterol and/or fatty acid absorption in the intestine.

31. Use of a compound according to any of claims 1 to 9 for the manufacture of a medicament for treating obesity in a mammal.
32. Use of a compound according to any of claims 1 to 9 for the manufacture of a medicament for modulating a gene whose expression is regulated by the NR1H3 and/or NR1H2 receptor.
33. Use of a compound according to any of claims 1 to 9 in a mammal for the selective up-regulation of one or more genes selected from the group comprising ABCA1, ABCG1, ABCG5, ABCG8, apolipoprotein-CI, -CII, -CIV, -E, LPL (lipoprotein lipase), CETP (cholesteryl ester transfer protein) or other genes that positively regulate cholesterol homeostasis are increased and a weaker regulation of one or more of the genes selected from the group comprising FAS and SREBP-1c or other genes that positively regulate lipogenesis, said compound showing a larger difference in regulation of the two groups of genes when compared with the regulatory behaviour of a full agonist like T0901317 on both groups of genes.
34. Use of a compound according any of claims 1 to 9 in a use according to claims 25 to 33 wherein the mammal is human.

Fig.1




**Fig. 2**





Number of repeats .....	1
plate: GREINER FIA-Plate black 384 well med. binding	
Measurement height .....	3.50 mm
Label technology .....	TR-F Lance
Emission filter name .....	D615
Emission filter slot .....	A1
Emission aperture .....	Normal
Excitation filter .....	D340
Delay .....	50 $\mu$ s
Window time .....	400 $\mu$ s
Cycle .....	1000 $\mu$ s
Light integrator capacitors .....	1
Light integrator ref. level .....	95
Flash energy area .....	High
Flash energy level .....	223
Flash absorbance measurement .....	No
Beam .....	Normal
Label technology .....	TR-F Lance
Emission filter name .....	D665
Emission filter slot .....	A8
Emission aperture .....	Normal
Excitation filter .....	D340
Delay .....	50 $\mu$ s
Window time .....	400 $\mu$ s
Cycle .....	1000 $\mu$ s
Light integrator capacitors .....	1
Light integrator ref. level .....	95
Flash energy area .....	High
Flash energy level .....	223
Flash absorbance measurement .....	No
Beam .....	Normal

**Fig. 3**

<b>Gene definition</b>	<b>NCBI Accession number of gene</b>	<b>Corresponding SEQ ID Number</b>
Liver X receptor beta NR1H2	NM_007121	1
Liver X receptor alpha NR1H3	NM_005693	2
Steroid receptor coactivator 1	U90661	3

Fig. 4 A

MOLNAME	MOLECULE STRUCTURE	EC50 AVG	EFF
		[μM]	AV
TO901317	 TO901317	0,1	10

MOLNAME	MOLECULE STRUCTURE	EC50 AVG ( $\mu$ M)	%EF AV
TR1040002211		1,5	50
TR1040002212		4	75
TR1040011382		12	80
TR1040001892		4	50






LN0000006662		4	60
LN0000006674		5	20
LN0000007460		5	50




Fig. 5




TO901317




TO314407




Hypocholamide



24(S),25-Epoxycholesterol



7a-Hydroxycholesterol



GW3965

**Fig. 6**

<b>Protein / Gene Name</b>	<b>NCBI Acccesion number of gene</b>	<b>Corresponding SEQ ID number</b>
Liver X receptor beta, LXR $\beta$	NM_007121	1
Liver X receptor alpha, LXR $\alpha$	NM_005693	2
Cholesterol 7 $\alpha$ hydroxylase, Cyp7A1	NM_000780	3
Fatty Acid Synthase FAS	NM_004104	4
Stearyl CoA desaturase, SCD	XM_030447	5
Sterol Response Element Binding Protein 1C, SREBP-1C	NM_004176	6
ATP binding cassette transporter A1; ABCA1	NM_005502	7
ATP binding cassette transporter G1; ABCG1	XM_032950	8
ATP binding cassette transporter G5; ABCG5	NM_022436	9
ATP binding cassette transporter G8; ABCG8	AF324494	10
Apolipoprotein E, apoE	NM_000041	11
Apolipoprotein C-I, apoC-I	NM_001645	12
Apolipoprotein C-II apoC-II	NM_000483	13
Apolipoprotein C-IV, apoC-IV	U32576	14
Lipoprotein Lipase, LPL	M15856	15
Cholesteryl Ester Transfer Protein, CETP	NM_000078	16
Phosphoenolpyruvate carboxykinase 1 (PEPCK)	NM_002591	17
Glucose-6-phosphatase (G6P)	NM_000151	18
Insulin-responsive glucose transporter (GLUT4)	M20747	19
Angiopietin-like 3, ANGPTL3	NM_01445	20
11-beta Hydroxysteroid dehydrogenase HSD11B1 variant 2	NM_181755	21
11-beta Hydroxysteroid dehydrogenase HSD11B1 variant 1	NM_005525	22

Fig. 7A




Fig. 7B




Fig. 8A




Fig. 8B




Fig. 8C




Fig. 8D




Fig. 9 A





Fig. 9 B



## SEQUENCE LISTING

<110> Phenex Pharmaceuticals AG

<120> Novel selective LXR Nuclear Receptor Binding Compounds with partial agonistic properties

<130> PX62420PC

<160> 23

<170> PatentIn version 3.1

<210> 1

<211> 2010

<212> DNA

<213> Homo sapiens

<400> 1  
caagaagtgg cgaagttacc tttagaggta tttagtagc ggcggtgtgt caggggctaa 60  
agaggaggac gaagaaaagc agagcaaggg aaccaggggc aacaggagta gttcactccg 120  
cgagaggccg tccacgagac cccgcgcgcg aggcattgagc cccgcccccc acgcattgagc 180  
cccgcccccc gctgttgctt ggagaggggc gggacctgga gagaggctgc tccgtgaccc 240  
caccatgtcc tctcctacca cgagttccct ggatacccc ctccttgga atggcccccc 300  
tcagcctggc gccccttctt cttcacccac tgtaaaggag gagggtccgg agccgtggcc 360  
cgggggtccg gacctgatg tcccaggcac tgatgaggcc agctcagcct gcagcacaga 420  
ctgggtcatc ccagatcccg aagaggaacc agagcgcaag cgaaagaagg gccagcccc 480  
gaagatgctg ggccacgagc tttagccgtg ctgtggggac aaggcctccg gcttccacta 540  
caacgtgctc agctgcgaag gctgcaaggc cttcttccgg cgagtggtgg tccgtggtgg 600  
ggccaggcgc tatgcctgcc ggggtggcgg aacctgccag atggacgctt tcatgcggcg 660  
caagtgccag cagtgccggc tgcgcaagtg caaggaggca gggatgaggg agcagtgcgt 720  
cctttctgaa gaacagatcc ggaagaagaa gattcggaag cagcagcagc aggagtcaca 780  
gtcacagtgc cagtcacctg tggggccgca gggcagcagc agctcagcct ctgggcctgg 840  
ggcttcccct ggtggatctg aggcaggcag ccagggtccc ggggaaggcg aggggtgtcca 900  
gctaacagcg gctcaagaac taatgatcca gcagttggtg gcggcccaac tgcagtgcaa 960



```

caaacgctcc ttctccgacc agcccaaagt cacgccctgg cccctgggcg cagaccccca 1020
gtcccagat gcccgccagc aacgctttgc ccacttcacg gagctggcca tcatctcagt 1080
ccaggagatc gtggacttcg ctaagcaagt gcctggtttc ctgcagctgg gccgggagga 1140
ccagatcgcc ctctgaagg catccactat cgagatcatg ctgctagaga cagccaggcg 1200
ctacaaccac gagacagagt gtatcacctt cttgaaggac ttcacctaca gcaaggacga 1260
cttccaccgt gcaggcctgc aggtggagtt catcaacccc atcttcgagt tctcgcgggc 1320
catgcggcgg ctgggcctgg acgacgctga gtacgccctg ctcatcgcca tcaacatctt 1380
ctcggccgac cggcccaacg tgcaggagcc gggccgcgtg gaggcgttgc agcagcccta 1440
cgtggaggcg ctgctgtcct acacgcgcac caagaggccg caggaccagc tgcgcttccc 1500
gcgcatgctc atgaagctgg tgagcctgcg cacgctgagc tctgtgact cggagcaggt 1560
cttcgccttg cggctccagg acaagaagct gccgcctctg ctgtcggaga tctgggacgt 1620
ccacgagtga ggggctggcc acccagcccc acagccttgc ctgaccaccc tccagcagat 1680
agacgccggc accccttcct cttcctaggg tggaaggggc cctgggagag cctgtagacc 1740
tatcggctct catcccttgg gataagcccc agtccaggtc caggaggtc cctccctgcc 1800
cagcgagtct tccagaaggg gtgaaagggg tgcagggtccc gaccactgac ctttcccggc 1860
tgccctccct cccagctta cacctcaagc ccagcacgca gcgtacctg aacagagggg 1920
ggggaggacc catggctctc cccccctagc cggggagacc aggggccttc ctcttcctct 1980
gcttttattt aataaaaata aaaacagaaa 2010

```

&lt;210&gt; 2

&lt;211&gt; 1528

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 2

```

cagtgccttg gtaatgacca gggctccaga aagagatgtc cttgtggctg ggggcccctg 60
tgctgacat tcctcctgac tctgcggtgg agctgtggaa gccaggcgca caggatgcaa 120
gcagccaggc ccagggaggc agcagctgca tcctcagaga ggaagccagg atgccccact 180
ctgctggggg tactgcaggg gtggggctgg aggtgcaga gcccacagcc ctgctcacca 240
gggcagagcc cccttcagaa cccacagaga tccgtccaca aaagcggaaa aaggggccag 300
ccccaaaat gctggggaac gagctatgca gcgtgtgtgg ggacaaggcc tcgggcttcc 360
actacaatgt tctgagctgc gagggctgca agggattctt ccgccgcagc gtcacaaagg 420
gagcgacta catctgccac agtggcggcc actgccccat ggacacctac atgcgtcgca 480
agtgccagga gtgtcggtt cgcaaatgcc gtcaggctgg catgcgggag gagtgtgtcc 540
tgtcagaaga acagatccgc ctgaagaaac tgaagcggca agaggaggaa caggctcatg 600

```

ccacatcctt gccccccagg cgttcctcac ccccccaaat cctgccccag ctcagcccgg 660  
 aacaactggg catgatcgag aagctcgtcg ctgcccagca acagtgtaac cggcgctcct 720  
 tttctgaccg gcttcgagtc acgccttggc ccatggcacc agatccccat agccgggagg 780  
 cccgtcagca gcgctttgcc cacttcactg agctggccat cgtctctgtg caggagatag 840  
 ttgactttgc taaacagcta cccggcttcc tgcagctcag ccgggaggac cagattgccc 900  
 tgctgaagac ctctgcgatc gaggtgatgc ttctggagac atctcggagg tacaaccctg 960  
 ggagtgaag tatcaccttc ctcaaggatt tcagttataa ccgggaagac tttgccaaag 1020  
 cagggtgca agtggaattc atcaaccca tcttcgagtt ctccagggcc atgaatgagc 1080  
 tgcaactcaa tgatgccgag tttgccttgc tcattgctat cagcatcttc tctgcagacc 1140  
 ggccaacgt gcaggaccag ctccagggtg agaggctgca gcacacatat gtggaagccc 1200  
 tgcattgccta cgtctccatc caccatcccc atgaccgact gatgttccca cggatgctaa 1260  
 tgaaactggt gagcctccgg accctgagca gcgtccactc agagcaagtg tttgcaactg 1320  
 gtctgcagga caaaaagctc ccaccgctgc tctctgagat ctgggatgtg cacgaatgac 1380  
 tgttctgtcc ccatattttc tgttttcttg gccggatggc tgaggcctgg tggctgcctc 1440  
 ctagaagtgg aacagactga gaagggcaaa cattcctggg agctgggcaa ggagatcctc 1500  
 ccgtggcatt aaaagagagt caaagggt 1528

<210> 3

<211> 2877

<212> DNA

<213> Homo sapiens

<400> 3

gtggcatcct tccctttcta atcagagatt ttcttcctca gagattttgg cctagatttg 60  
 caaaatgatg accacatcct tgatttgggg gattgctata gcagcatgct gttgtctatg 120  
 gcttattcctt ggaattagga gaaggcaaac ggggtgaacca cctctagaga atggattaat 180  
 tccatacctg ggctgtgctc tgcaatttgg tgccaatcct cttgagttcc tcagagcaaa 240  
 tcaaaggaaa catggtcatg tttttacctg caaactaatg ggaaaatatg tccatttcat 300  
 caaaaatccc ttgtcatacc ataagggtgt gtgccacgga aaatattttg attggaaaaa 360  
 atttcacttt gctacttctg cgaaggcatt tgggcacaga agcattgacc cgatggatgg 420  
 aaataccact gaaaacataa acgacacttt catcaaaacc ctgcagggcc atgccttgaa 480  
 tttccctcacg gaaagcatga tggaaaacct ccaacgtatc atgagacctc cagtctcctc 540  
 taactcaaag accgctgcct gggtgacaga agggatgtat tctttctgct accgagtgat 600  
 gtttgaagct gggtatTTaa ctatctttgg cagagatcct acaaggcggg acacacagaa 660  
 agcacatatt ctaaacaatc ttgacaactt caagcaattc gacaaagtct ttccagccct 720

ggtagcaggc ctccccattc acatgttcag gactgcgac aatgcccggg agaaactggc	780
agagagcttg aggcacgaga acctccaaaa gagggaaagc atctcagaac tgatcagcct	840
gcgcattgtt ctcaatgaca ctttgtccac ctttgatgat ctggagaagg ccaagacaca	900
cctcgtggtc ctctgggcat cgcaagcaaa caccattcca gcgactttct ggagtttatt	960
tcaaattgatt aggaacccag aagcaatgaa agcagctact gaagaagtga aaagaacatt	1020
agagaatgct ggtcaaaaag tcagcttgga aggcaatcct atttgtttga gtcaagcaga	1080
actgaatgac ctgccagtat taaatagtat aatcaaggaa tcgctgaggc tttccagtgc	1140
ctccctcaac atccggacag ctaaggagga tttcactttg caccttgagg acggttccta	1200
caacatccga aaagatagca tcatagctct ttaccacag ttaatgcact tagatccaga	1260
aatctacca gaccctttga cttttaaata tgataggtat cttgatgaaa acgggaagac	1320
aaagactacc ttctatttga atggactcaa gttaaagtat tactacatgc ctttggatc	1380
gggagctaca atatgtcctg gaagattgtt cgctatccac gaaatcaagc aatttttgat	1440
tctgatgctt tcttattttg aattggagct tatagagggc caagctaaat gtccaccttt	1500
ggaccagtcc cgggcaggct tgggcatttt gccgccattg aatgatattg aatttaaata	1560
taaattcaag ctttgtgaa tacatggctg gaataagagg aactagatg atattacagg	1620
actgcagaac accctcacca cacagtcctt ttggacaaat gcatttagtg gtggtagaaa	1680
tgattcacca ggtccaatgt tgttcaccag tgcttgcttg tgaatcttaa ctttttggtg	1740
acagtttcca gatgctatca cagactctgc tagtgaaaag aactagtctc taggagcaca	1800
ataatttgtt ttcatttga taagtccatg aatgttcata tagccagggg ttgaagttaa	1860
ttattttcaa aggaaaacac ctttatttta ttttttttca aaatgaagat acacattaca	1920
gccagggtg gtagcaggca cctgtagtct tagctactcg agaggccaaa gaaggaggat	1980
ggcttgagcc caggagtcca agaccagcct ggacagctta gtgagatccc gtctccgaag	2040
aaaagatatg tattctaatt ggcagattgt tttttcctaa ggaaactgct ttatttttat	2100
aaaactgcct gacaattatg aaaaaatgtt caaatcacg ttctagtga actgcattat	2160
ttgttgacta gatgggtggg ttcttcgggt gtgatcatat atcataaagg atatttcaaa	2220
tgattatgat tagttatgtc ttttaataaa aaggaaatat ttttcaactt cttctatata	2280
caaaattcag ggctttaaac atgattatct tgatttcca aaaacactaa aggtgggttt	2340
attttccctt catgttttaa cttattgttg ctgaaaactc tatgtccggc tttaactatc	2400
ttctctatat ttttatttca ttcacattaa tgagaagagt tttctcagag attaaaaaag	2460
gtagtttttc tgtcattgtt aaatacacat tatcactgaa aaaatgtagc ttttatgatg	2520
tatgttttaa agttaaaact ggatggaaat agccatttgg aagctttggt tatgaaacat	2580
gtggagtgta ttaagtgcag cttgacatta tgttttattt aaatgccttt tatcgctaaa	2640
tgacttgacg atgaaaaaaa ctaagggtgac tcgagtgttt aaatgcctgt gtacaacaat	2700
gctttgataa aatattttta ggtatgagtt atcagctcta tgtcaattga tatttctgtg	2760

tagtatttat atttaaatta tatttacctt ttgcttatt ttacaaatat taagaaaata 2820  
 ttctaacatt tgataatttt gaaatgattc atctttcaga aataaaagta tgaatct 2877

<210> 4

<211> 8461

<212> DNA

<213> Homo sapiens

<400> 4

gagggagcca gagagacggc agcggccccc gcctccctct ccgccgcgct tcagcctccc 60  
 gctccgccgc gctccagcct cgctctccgc cgcgcgcacc gccgccgcgc cctcaccag 120  
 agcagccatg gaggaggtgg tgattgccgg catgtccggg aagctgccag agtcggagaa 180  
 cttgcaggag ttctgggaca acctcatcgg cgggtgtggac atggtcacgg acgatgaccg 240  
 tcgctggaag gcggggctct acggcctgcc cgggcggtcc ggcaagctga aggacctgtc 300  
 taggtttgat gcctccttct tcggagtcca cccaagcag gcacacacga tggaccctca 360  
 gctgcggctg ctgctggaag tcacctatga agccatcgtg gacggaggca tcaaccaga 420  
 ttactccga ggaacacaca ctggcgtctg ggtgggcgtg agcggctctg agacctcga 480  
 ggccctgagc cgagaccccg agacactcgt gggctacagc atgggtgggt gccagcgagc 540  
 gatgatggcc aaccggctct cttcttctt cgacttcaga gggcccagca tcgcactgga 600  
 cacagctgc tcctccagcc tgatggccct gcagaacgcc taccaggcca tccacagcgg 660  
 gcagtgccct gccgccatcg tggggggcat caatgtcctg ctgaagccca acacctccgt 720  
 gcagtctctg aggctgggga tgctcagccc cgagggcacc tgcaaggcct tcgacacagc 780  
 ggggaatggg tactgccgct cggaggggtg ggtggccgtc ctgctgacca agaagtcct 840  
 ggcccgccgc gtgtacgcca ccattctgaa cgccggcacc aatacagatg gcttcaagga 900  
 gcaaggcgtg accttcccc caggggatat ccaggagcag ctcatccgt cgttgtagca 960  
 gtcggccgga gtggcccctg agtcatttga atacatcgaa gccacggca caggcaccaa 1020  
 ggtgggcgac cccagggagc tgaatggcat caccgagcc ctgtgcgcca cccgccagga 1080  
 gccgtgctc atcggctcca ccaagtccaa catggggcac ccggagccag cctcggggct 1140  
 ggcagccctg gccaaggctg tgctgtccct ggagcacggg ctctgggccc ccaacctgca 1200  
 cttccatagc cccaaccctg agatcccagc gctgttgat gggcggctgc aggtggtgga 1260  
 ccagcccctg ccgctccgtg gcggcaacgt gggcatcaac tcctttggct tcgggggctc 1320  
 caacgtgcac atcatcctga ggcccaacac gcagccgccc cccgcacccg ccccatgac 1380  
 caccctgccc cgtctgtgc gggccagcgg acgcacccct gaggcgtgc agaagctgct 1440  
 ggagcagggc ctccggcaca gccaggacct ggctttcctg agcatgctga acgacatgc 1500  
 ggctgtcccc gccaccgcca tgcccttccg tggtacgct gtgctgggtg gtgagcgcg 1560

tggcccagag gtgcagcagg tgcccgcctgg cgagcgcccc ctctggttca tctgctctgg 1620  
 gatgggcaca cagtggcgcg ggatggggct gagcctcatg cgcttgacc gcttccgaga 1680  
 ttccatccta cgctccgatg aggctgtgaa gccattcggc ctgaagggtg cacagctgct 1740  
 gctgagcaca gacgagagca cttttgatga catcgtccat tcgtttgtga gcctgactgc 1800  
 catccagata ggcctcatag acctgctgag ctgcatgggg ctgaggccag atggcatcgt 1860  
 cgccactcc ctgggggagg tggcctgtgg ctacgccgac ggctgcctgt cccaggagga 1920  
 ggccgtcctc gctgcctact ggaggggaca gtgcatcaaa gaagccatc tcccgcggg 1980  
 cgccatggca gccgtgggct tgtcctggga ggagtgtaaa cagcgctgcc cccggcggt 2040  
 ggtgcccgcc tgccacaact ccaaggacac agtcaccatc tcgggacctc agggcccgg 2100  
 gtttgagttc gtggagcagc tgaggaagga ggggtgtgtt gccaggagg tgcgaccgg 2160  
 cggtatggcc ttccactcct acttcatgga ggccatcgca cccctactgc tgcaggagct 2220  
 caagaagggt atccgggagc cgaagccacg ttcagcccg cggctcagca cctctatccc 2280  
 cgaggcccag tggcacagca gcctggcacg cacgtcctcc gccagtaga atgtcaacaa 2340  
 cctggtgagc cctgtgctgt tccaggaggc cctgtggcac gtgcctgagc acgcggtggt 2400  
 gctggagatc gcgccccacg ccctgctgca ggctgtcctg aagcggtggc tgaagccgag 2460  
 ctgcaccatc atccccctga tgaagaagga tcacagggac aacctggagt tcttcctggc 2520  
 cggcattccg aggctgcacc tctcaggcat cgacgccaac ccaatgcct tgttcccacc 2580  
 tgtggagttc ccagctcccc gaggaactcc cctcatctcc ccactcatca agtgggacca 2640  
 cagcctggcc tgggacgtgc cgcccgccga ggacttcccc aacggttcag gttccccctc 2700  
 agccgccatc tacaacatcg acaccagctc cgagtctcct gaccactacc tggaggacca 2760  
 caccctcgac ggtcgcgtcc tcttccccgc cactggctac ctgagcatag tgtggaagac 2820  
 gctggcccga cccctgggccc tgggcgtcga gcagctgcct gtggtgtttg aggatgtggt 2880  
 gctgcaccag gccaccatcc tgccaagac tgggacagtg tccctggagg tacggctcct 2940  
 ggaggcctcc cgtgccttcg aggtgtcaga gaacggcaac ctggtagtga gtgggaaggt 3000  
 gtaccagtgg gatgacctg accccaggct cttcgaccac ccggaagcc ccaccccaa 3060  
 cccacggag cccctcttcc tggcccaggc tgaagtttac aaggagctgc gtctgcgtgg 3120  
 ctacgactac ggccctcatt tccagggcatt cctggaggcc agcctggaag gtgactcggg 3180  
 gaggtgctg tggaggata actgggtgag cttcatggac accatgctgc agatgtccat 3240  
 cctgggctcg gccaaagcag gcctgtacct gccacccgt gtcaccgcca tccacatcga 3300  
 ccctgccacc cacaggcaga agctgtacac actgcaggac aaggcccaag tggctgacgt 3360  
 ggtggtgagc aggtggtga gggtcacagt ggccggaggc gtccacatct ccgggctcca 3420  
 cactgagtcg gccccgcggc ggagcagga gcagcagggt cccatcctgg agaagttttg 3480  
 cttactccc cacacggagg aggggtgcct gtctgagcgc gctgccctgc aggaggagct 3540  
 gcaactgtgc aaggggctgg tgaggcact gcagaccaag gtgaccagc aggggctgaa 3600

gatggtggtg cccggactgg atggggccca gatcccccg gacccctcac agcaggaact 3660  
gccccggctg ttgtcggctg cctgcaggct tcagctcaac gggaacctgc agctggagct 3720  
ggcgaggtg ctggcccagg agaggcccaa gctgccagag gacctctgc tcagcggcct 3780  
cctggactcc ccggcactca aggcctgcct ggacactgcc gtggagaaca tgcccagcct 3840  
gaagatgaag gtggtggagg tgctggccgg ccacggtcac ctgtattccc gcatcccagg 3900  
cctgctcagc ccccatcccc tgctgcagct gagctacacg gccaccgacc gccaccccca 3960  
ggccctggag gctgcccagg ccgagctgca gcagcacgac gttgcccagg gccagtggga 4020  
tcccgcagac cctgccccca gcgcctggg cagcgccgac ctcttggtgt gcaactgtgc 4080  
tgtggctgcc ctgggggacc cggcctcagc tctcagcaac atggtggctg ccctgagaga 4140  
agggggcttt ctgctcctgc acacactgct ccgggggcac ccctcgggac atgtggcctt 4200  
cctcacctcc actgagccgc agtatggcca gggcatcctg agccaggacg cgtgggagag 4260  
cctcttctcc aggggtgtccg tgcgcctggg gggcctgaag aagtccttct acggctccac 4320  
gctcttctctg tgccgcgggc ccaccccgca ggacagcccc atcttctctgc cgggtggacga 4380  
taccagcttc cgctgggtgg agtctctgaa gggcatcctg gctgacgaag actcttcccc 4440  
gcctgtgtgg ctgaaggcca tcaactgtgc cacctcgggc gtggtgggct tgggtgaactg 4500  
tctccgccga gagcccggcg gaacgctccg gtgtgtgctg ctctccaacc tcagcagcac 4560  
ctcccacgtc ccggaggtgg acccgggctc cgcagaactg cagaagggtg tgcagggaga 4620  
cctggtgatg aacgtctacc gcgacggggc ctggggggct ttccgccact tcctgctgga 4680  
ggaggacaag cctgaggagc cgacggcaca tgcctttgtg agcaccctca cccgggggga 4740  
cctgtcctcc atccgtggg tctgtcctc gctgcgcat gccagccca cctgccctgg 4800  
cgcccagctc tgcacggtct actacgcctc cctcaacttc cgcgacatca tgctggccac 4860  
tggcaagctg tcccctgatg ccatcccagg gaagtggacc tcccaggaca gcctgctagg 4920  
tatggagttc tcgggccgag acgccagcgg caagcgtgtg atgggactgg tgcctgccaa 4980  
gggcctggcc acctctgtcc tgctgtcacc ggacttcctc tgggatgtgc cttccaactg 5040  
gacgctggag gaggcggcct cgggtcctgt cgtctacagc acggcctact acgcgctggt 5100  
ggtgctggg cgggtgcgcc ccggggagac gctgtcatc cactcgggct cgggcggcgt 5160  
gggccaggcc gccatcgcca tcgccctcag tctgggtgc cgcgtcttca ccaccgtggg 5220  
gtcggctgag aagcgggcgt acctccaggc caggttcccc cagctcgaca gcaccagctt 5280  
cgccaactcc cgggacacat ccttcgagca gcatgtgctg tggcacacgg gcgggaaggg 5340  
cgttgacctg gtcttgaact ccttggcgga agagaagctg caggccagcg tgaggtgctt 5400  
ggctacgcac ggtcgcttcc tggaaattgg caaattcgac ctttctcaga accaccgct 5460  
cggcattggt atcttctga agaacgtgac attccacggg gtcttactgg atgcgttctt 5520  
caacgagagc agtgtgact ggcgggaggt gtgggcgctt gtgcaggccg gcatccggga 5580  
tggggtggta cggccctca agtgcacggt gttccatggg gccaggtgg aggacgcctt 5640

ccgctacatg gcccaggga agcacattgg caaagtcgtc gtgcaggtgc ttgcggagga	5700
gccggaggca gtgctgaagg gggccaaacc caagctgatg tcggccatct ccaagacctt	5760
ctgcccggcc cacaagagct acatcatcgc tgggtggtctg ggtggcttcg gcctggagtt	5820
ggcgcagtgg ctgatacagc gtgggggtgca gaagctcgtg ttgacttctc gctccgggat	5880
ccggacaggc taccaggcca agcagggtccg ccggtggagg cgccagggcg tacagggtgca	5940
ggtgtccacc agcaacatca gctcactgga gggggcccgg ggccctcattg ccgaggcggc	6000
gcagcttggg cccgtgggcg gcgtcttcaa cctggccgtg gtcttgagag atggcttgct	6060
ggagaaccag accccagagt tcttccagga cgtctgcaag cccaagtaca gcggcacct	6120
gaacctggac aggggtgacct gagaggcgtg ccctgagctg gactactttg tggctcttctc	6180
ctctgtgagc tgcgggctg gcaatgcggg acagagcaac tacggctttg ccaattccgc	6240
catggagcgt atctgtgaga aacgccggca cgaaggcctc ccaggcctgg ccgtgcagt	6300
gggcgccatc ggcgacgtgg gcattttggt ggagacgatg agcaccaacg acacgatcgt	6360
cagtggcacg ctgccccagc gcatggcgtc ctgcctggag gtgctggacc tcttctgaa	6420
ccagccccac atggtcctga gcagctttgt gctggctgag aaggctgcgg cctatagga	6480
caggacagc cagcgggacc tgggtggaggc cgtggcacac atcctgggca tccgcgactt	6540
ggctgctgtc aacctggaca gctcactggc ggacctgggc ctggactcgc tcatgagcgt	6600
ggagggtgcg cagacgctgg agcgtgagct caacctgggt ctgtccgtgc gcgagggtgcg	6660
gcaactcacg ctccggaaac tgcaggagct gtcctcaaag gcggatgagg ccagcgagct	6720
ggcatgccc acgcccagg aggatgggtct ggcccagcag cagactcagc tgaacctgcg	6780
ctccctgctg gtgaacccgg agggccccac cctgatgcgg ctcaactccg tgcagagctc	6840
ggagcggccc ctgttctggt tgcacccaat cgagggtctc accaccgtgt tccacagcct	6900
ggcctcccgg ctgagcatcc ccacctatgg cctgcagtgc acccgagctg cggcccttga	6960
cagcatccac agcctggctg cctactacat cgactgcac aggcagggtgc agcccagggg	7020
cccctaccgc gtggccggct actcctacgg ggcctgcgtg gcctttgaaa tgtgctccca	7080
gctgcaggcc cagcagagcc cagccccac ccacaacagc ctcttctgt tcgacggctc	7140
gcccacctac gtactggcct acaccagag ctaccgggca aagctgacct caggctgtga	7200
ggctgaggct gagacggagg ccatatgctt cttcgtgcag cagttcacgg acatggagca	7260
caacaggggtg ctggaggcgc tgctgccgt gaagggccta gaggagcgtg tggcagccgc	7320
cgtggacctg atcatcaaga gccaccaggg cctggaccgc caggagctga gctttgcggc	7380
ccggtccttc tactacaagc tgcgtgccgc tgagcagtac acaccaagg ccaagtacca	7440
tggcaacgtg atgctactgc gcgccaaagc ggggtggcgc tacggcgagg acctgggcgc	7500
ggactacaac ctctcccagg tatgcgacgg gaaagtatcc gtccacgtca tcgagggtga	7560
ccaccgcacg ctgctggagg gcagcggcct ggagtcctac atcagcatca tccacagctc	7620
cctggctgag ccacgcgtga gcgtgcggga gggctaggcc cgtgccccg cctgccaccg	7680

gaggtcactc caccatcccc accccacccc accccacccc cgccatgcaa cgggattgaa 7740  
 gggtcctgcc ggtgggaccc tgtccggccc agtgccactg ccccccagg ctgctagacg 7800  
 taggtgttag gcatgtccca cccaccgcc gcctccacg gcacctcggg gacaccagag 7860  
 ctgccgactt ggagactcct ggtctgtgaa gagccggtgg tgcccgtgcc cgcaggaact 7920  
 gggctgggcc tcgtgcgccc gtggggctctg cgcttggctt ttctgtgctt ggatttgcat 7980  
 atttattgca ttgctggtag agacccccag gcctgtccac cctgccaaga ctctcaggc 8040  
 agcgtgtggg tcccgactc tgccccatt tccccgatgt cccctgcggg cgcgggcagc 8100  
 cacccaagcc tgctggctgc ggccccctct cgccaggca ttggctcagc ccgctgagtg 8160  
 gggggtcgtg ggccagtccc cgaggagctg ggccctgca caggcacaca gggcccggcc 8220  
 acaccagcg gcccccgca cagccacccg tggggtgctg cccttatgcc cggcgccggg 8280  
 caccaactcc atgtttggtg tttgtctgtg tttgttttc aagaaatgat tcaaattgct 8340  
 gcttggtttt tgaaatttac tgtaactgtc agtgtaacg tctggacccc gtttcatttt 8400  
 tacaccaatt tggtaaaaat gctgctctca gcctcccaca attaaaccgc atgtgatctc 8460  
 c 8461

<210> 5

<211> 1444

<212> DNA

<213> Homo sapiens

<400> 5

acggtcaccc gttgccagct ctagccttta aattcccggc tcggggacct ccacgcaccg 60  
 cggctagcgc cgacaaccag ctagcgtgca aggcgcgcg gctcagcgcg taccggcggg 120  
 cttcgaacc gcagtcctcc ggcgaccccg aactccgctc cggagcctca gccccctgga 180  
 aagtgatccc ggcatccgag agccaagatg ccggcccact tgctgcagga cgatatctct 240  
 agctcctata ccaccaccac caccattaca gcgcctccct ccagggtcct gcagaatgga 300  
 ggagataagt tggagacgat gccccctctac ttggaagacg acattcgccc tgatataaaa 360  
 gatgatatat atgacccac ctacaaggat aaggaaggcc caagcccaa ggttgaatat 420  
 gtctggagaa acatcatcct tatgtctctg ctacacttg gagccctgta tgggatcact 480  
 ttgattccta cctgcaagtt ctacacctgg ctttggggg tatttacta ttttgtcagt 540  
 gccctgggca taacagcagg agctcatcgt ctgtggagcc accgctctta caaagctcgg 600  
 ctgcccctac ggctctttct gatcattgcc aacacaatgg cattccagaa tgatgtctat 660  
 gaatgggctc gtgaccaccg tgcccaccac aagttttcag aaacacatgc tgatcctcat 720  
 aattcccgac gtggcttttt cttctctcac gtgggttggc tgcttgtgcg caaacaccca 780  
 gctgtcaaag agaaggggag tacgctagac ttgtctgacc tagaagctga gaaactgggtg 840



atgttccaga ggaggtacta caaacctggc ttgctgatga tgtgcttcat cctgcccacg 900  
 cttgtgccct ggtatttctg gggtgaaact ttcaaaaaca gtgtgttcgt tgccactttc 960  
 ttgcgatatg ctgtggtgct taatgccacc tggctggtga acagtgctgc ccacctcttc 1020  
 ggatatcgtc cttatgacaa gaacattagc ccccgggaga atatcctggg ttcacttgga 1080  
 gctgtgggtg agggcttcca caactaccac cactcctttc cctatgacta ctctgccagt 1140  
 gagtaccgct ggcacatcaa cttcaccaca ttcttcattg attgcatggc cgccctcggg 1200  
 ctggcctatg accggaagaa agtctccaag gccgccatct tggccaggat taaaagaacc 1260  
 ggagatggaa actacaagag tggctgagtt tggggtcctt caggttcctt ttcaaaaac 1320  
 cagccaggca gaggttttaa tgtctgttta ttaactactg aataatgcta ccaggatgct 1380  
 aaagatgatg atgttaaccc attccagtac agtattcttt taaaattcaa aagtattgaa 1440  
 agcc 1444

<210> 6

<211> 4154

<212> DNA

<213> Homo sapiens

<400> 6  
 taacgaggaa cttttcgccg gcgccgggccc gcctctgagg ccagggcagg acacgaacgc 60  
 gcggagcggc ggcggcgact gagagccggg gccgcggcgg cgctccctag gaaggggcgt 120  
 acgaggcggc gggcccggcg ggcctcccgg aggaggcggc tgcgccatgg acgagccacc 180  
 cttcagcgag gcggttttgg agcaggcgct gggcgagccg tgcgatctgg acgcggcgct 240  
 gctgaccgac atcgaagaca tgcttcagct tatcaacaac caagacagtg acttccctgg 300  
 cctatttgac ccaccctatg ctgggagtgg ggcagggggc acagaccctg ccagccccga 360  
 taccagctcc ccaggcagct tgtctccacc tcctgccaca ttgagctcct ctcttgaagc 420  
 cttcctgagc gggccgcagg cagcgccctc acccctgtcc cctccccagc ctgcaccac 480  
 tccattgaag atgtaccctg ccatgcccgc tttctcccct gggcctggta tcaaggaaga 540  
 gtcagtgcc a ctgagcatcc tgcagacccc caccacacag cccctgccag gggccctcct 600  
 gccacagagc tttccagccc cagccccacc gcagttcagc tccaccctg tgtaggcta 660  
 cccagccct ccgggaggct tctctacagg aagccctccc gggaacaccc agcagccgct 720  
 gcctggcctg cactggctt ccccgccagg ggtcccggc gtctccttg acaccaggt 780  
 ccagagtgtg gtccccagc agtactgac agtcacagct gccccacgg cagccctgt 840  
 aacgaccact gtgacctgc agatccagca ggtcccggc ctgctgcagc cccacttcat 900  
 caaggcagac tcgctgttc tgacagccat gaagacagac ggagccactg tgaaggcggc 960  
 aggtctcagt cccctggtct ctggcaccac tgtgcagaca gggcctttgc cgaccctggt 1020

gagtggcggg accatcttgg caacagtccc actggtcgta gatgcggaga agctgcctat 1080  
 caaccggctc gcagctggca gcaaggcccc ggctctgcc cagagccgtg gagagaagcg 1140  
 cacagcccac aacgccattg agaagcgcta ccgctcctcc atcaatgaca aaatcattga 1200  
 gctcaaggat ctggtggtgg gcaactgaggc aaagctgaat aaatctgctg tcttgcgcaa 1260  
 ggccatcgac tacattcgct ttctgcaaca cagcaaccag aaactcaagc aggagaacct 1320  
 aagtctgctc actgctgtcc acaaaagcaa atctctgaag gatctggtgt cggcctgtgg 1380  
 cagtggaggg aacacagacg tgctcatgga gggcgtaag actgaggtgg aggacacact 1440  
 gacccacccc cctcggatg ctggctcacc ttccagagc agcccttgt ccttggcag 1500  
 caggggcagt ggcagcggg gcagtggcag tgactcggag cctgacagcc cagtcttga 1560  
 ggacagcaag gcaaagccag agcagcggcc gtctctgcac agccggggca tgctggaccg 1620  
 ctcccgcctg gccctgtgca cgctcgtctt cctctgcctg tctgcaacc ccttgccctc 1680  
 cttgctgggg gcccgggggc ttcccagccc ctgagatacc accagcgtct accatagccc 1740  
 tgggcgcaac gtgctgggca ccgagagcag agatggccct ggctggggcc agtggctgct 1800  
 gccccagtg gtctggctgc tcaatgggct gttggtgtc gtctccttg tgcttctctt 1860  
 tgtctacggt gagccagtca cacggcccca ctgagccccc gccgtgtact tctggaggca 1920  
 tcgcaagcag gctgacctgg acctggccc gggagacttt gcccaggctg cccagcagct 1980  
 gtggctggcc ctgcgggcac tgggcccggc cctgcccacc tcccacctgg acctggcttg 2040  
 tagcctctc tggaacctca tccgtcacct gctgcagcgt ctctgggtgg gccgctggct 2100  
 ggcaggccgg gcagggggcc tgcagcagga ctgtgctctg cgagtggatg ctagcgccag 2160  
 cgcccagac gcagccctgg tctaccataa gctgcaccag ctgcacacca tggggaagca 2220  
 cacaggcggg cacctcactg ccaccaacct ggcgctgagt gccctgaacc tggcagagtg 2280  
 tgcaggggat gccgtgtctg tggcgacgct ggccgagatc tatgtggcgg ctgcattgag 2340  
 agtgaagacc agtctccac gggccttgca ttttctgaca cgcttcttcc tgagcagtgc 2400  
 ccgccaggcc tgcctggcac agagtggctc agtgccctc gccatgcagt ggctctgcca 2460  
 ccccggtggc caccgtttct tcgtggatgg ggactggtcc gtgctcagta ccccatggga 2520  
 gagcctgtac agcttgggcg ggaaccagc ggacccctg gcccagggtga ctgagctatt 2580  
 ccgggaacat ctcttagagc gagcactgaa ctgtgtgacc cagcccaacc ccagccctgg 2640  
 gtcagctgat ggggacaagg aattctcgga tgccctcggg tacctgcagc tgctgaacag 2700  
 ctgttctgat gctgcggggg ctctgccta cagcttctcc atcagttcca gcatggccac 2760  
 caccaccggc gtagaccggg tggccaagtg gtgggcctct ctgacagctg tggatgacca 2820  
 ctggctgcgg cgggatgagg aggcggctga gcggctgtgc ccgctggtg agcacctgcc 2880  
 ccgggtgctg caggagtctg agagaccct gcccagggca gctctgact cttcaaggc 2940  
 tgcccgggcc ctgctgggct gtgccaaggc agagtctggt ccagccagcc tgaccatctg 3000  
 tgagaaggcc agtgggtacc tgcaggacag cctggctacc acaccagcca gcagctccat 3060

tgacaaggcc gtgcagctgt tcctgtgtga cctgcttctt gtggtgcgca ccagcctgtg 3120  
 gcggcagcag cagcccccg ccccgcccc agcagcccag ggcaccagca gcaggcccca 3180  
 ggcttccgcc cttgagctgc gtggcttcca acgggacctg agcagcctga ggcggctggc 3240  
 acagagcttc cggcccgcga tgcggagggt gttcctacat gaggccacgg cccggctgat 3300  
 ggcggggggcc agccccacac ggacacacca gctcctcgac cgcagtctga ggcggcgggc 3360  
 agggccccgt ggcaaaggag gcgcggtggc ggagctggag ccgcggccca cgcggcggga 3420  
 gcacgcggag gccttgctgc tggcctcctg ctacctgcc cccggcttcc tgtcggcgcc 3480  
 cgggcagcgc gtgggcatgc tggctgaggc ggcgcgaca ctcgagaagc ttggcgatcg 3540  
 ccggctgtg cactgtgtc agcagatgct catgcgctg ggcgggtggga ccactgtcac 3600  
 ttccagctag acccctgtc cccggcctca gcaccctgt ctctagccac tttggtccc 3660  
 tgcagcttct gtcctgcgtc gaagctttga aggccgaagg cagtgaaga gactctggcc 3720  
 tccacagttc gacctgcggc tgctgtgtgc cttcgcggtg gaaggcccga ggggcgcgat 3780  
 cttgacctta agaccggcgg ccatgatggt gctgacctct ggtggccgat cggggcactg 3840  
 caggggcccga gccatttttg ggggcccccc tccttgctct gcaggcacct tagtggcttt 3900  
 tttcctcctg tgtacaggga agagaggggt acatttccct gtgctgacgg aagccaactt 3960  
 ggctttccc gactgcaagc agggctctgc ccagaggcc tctctctccg tcgtgggaga 4020  
 gagacgtgta catagtgtag gtcagcgtgc ttagcctcct gacctgaggc tcctgtgcta 4080  
 ctttgccctt tgcaaaactt atttcatag attgagaagt tttgtacaga gaattaaaaa 4140  
 tgaaattatt tata 4154

<210> 7

<211> 10412

<212> DNA

<213> Homo sapiens

<400> 7

gtaattgcga gcgagagtga gtggggccgg gaccgcaga gccgagccga cccttctctc 60  
 ccgggctgcg gcagggcagg gcggggagct ccgcgcacca acagagccgg ttctcagggc 120  
 gctttgtctc ttgttttttc cccggttctg ttttctccc ttctccgga ggttgtcaa 180  
 ggggtaggag aaagagacgc aaacacaaaa gtggaaaaca gttaatgacc agccacggcg 240  
 tccctgtgt gagctctggc cgctgccttc cagggtccc gagccacacg ctgggggtgc 300  
 tggctgaggg aacatggctt gttggcctca gctgagggtg ctgctgtgga agaacctcac 360  
 tttcagaaga agacaaacat gtcagctgct gctggaagtg gcctggcctc tatttatctt 420  
 cctgatcctg atctctgttc ggctgagcta cccaccctat gaacaacatg aatgccattt 480  
 tccaaataaa gccatgccct ctgcaggaac acttccttgg gttcagggga ttatctgtaa 540

tgccaacaac ccctgtttcc gttacccgac tcctggggag gctcccggag ttgttgghaa	600
ctttaacaaa tccattgtgg ctgcctgtt ctcagatgct cggaggcttc tttatacag	660
ccagaaagac accagcatga aggacatgcg caaagtcttg agaacattac agcagatcaa	720
gaaatccagc tcaaacttga agcttcaaga tttcctgggtg gacaatgaaa ctttctctgg	780
gttcctgtat cacaacctct ctctcccaa gtctactgtg gacaagatgc tgagggtga	840
tgtcattctc cacaaggat ttttgcaagg ctaccagtta catttgacaa gtctgtgcaa	900
tggatcaaaa tcagaagaga tgattcaact tgggtacca gaagtttctg agctttgtgg	960
cctaccaagg gagaaactgg ctgcagcaga gcgagtactt cgttccaaca tggacatcct	1020
gaagccaatc ctgagaacac taaactctac atctcccttc ccgagcaagg agctggctga	1080
agccacaaaa acattgctgc atagtcttgg gactctggcc caggagctgt tcagcatgag	1140
aagctggagt gacatgcgac aggaggtgat gtttctgacc aatgtgaaca gctccagctc	1200
ctccaccaa atctaccagg ctgtgtctcg tattgtctgc gggcatccc agggaggggg	1260
gctgaagatc aagtctctca actggtatga ggacaacaac tacaagccc tctttggagg	1320
caatggcact gaggaagatg ctgaaacctt ctatgacaac tctacaactc cttactgcaa	1380
tgatttgatg aagaatttgg agtctagtc tcttcccg c attatctgga aagctctgaa	1440
gccgtgctc gttgggaaga tcctgtatac acctgacact ccagccacaa ggcaggctcat	1500
ggctgaggtg aacaagacct tccaggaact ggctgtgttc catgatctgg aaggcatgtg	1560
ggaggaactc agcccaaga tctggacctt catggagaac agccaagaaa tggaccttgt	1620
ccggtgctg ttggacagca gggacaatga ccacttttg gaacagcagt tggatggctt	1680
agattggaca gccaagaca tcgtggcggt tttggccaag caccagagg atgtccagtc	1740
cagtaatggt tctgtgtaca cctggagaga agctttcaac gagactaacc aggcaatccg	1800
gaccatatct cgcttcatgg agtgtgtcaa cctgaacaag ctagaacca tagcaacaga	1860
agtctggctc atcaacaagt ccatggagct gctggatgag aggaagttct gggctggtat	1920
tgtgttact ggaattactc caggcagcat tgagctgcc catcatgtca agtacaagat	1980
ccgaatggac attgacaatg tggagaggac aaataaaatc aaggatgggt actgggacct	2040
tggtcctcga gctgacctt ttgaggacat gcggtacgtc tgggggggct tcgctactt	2100
gcaggatgtg gtggagcagg caatcatcag ggtgtgacg ggcaccgaga agaaaactgg	2160
tgtctatatg caacagatgc cctatccctg ttacgttgat gacatcttc tgcgggtgat	2220
gagccggtca atgcccctct tcatgacgtt ggcctggatt tactcagtgg ctgtgatcat	2280
caagggcatc gtgtatgaga aggaggcacg gctgaaagag accatgcgga tcatgggcct	2340
ggacaacagc atcctctggt ttagctgggt cattagtagc ctcatcttc tcttgtgag	2400
cgctggcctg ctagtgtca tcctgaagtt aggaaacctg ctgccctaca gtgatccag	2460
cggtgtgtt gtcttctgt ccgtgtttgc tgtgtgaca atcctgcagt gcttctgtat	2520
tagcacactc ttctccagag ccaacctggc agcagcctgt gggggcatca tctacttcac	2580

gctgtacctg ccctacgtcc tgtgtgtggc atggcaggac tacgtgggct tcacactcaa 2640  
 gatcttcgct agcctgctgt ctctgtggc ttttggggtt ggctgtgagt actttgccct 2700  
 ttttgaggag cagggcattg gagtgcagtg ggacaacctg tttgagagtc ctgtggagga 2760  
 agatggcttc aatctcacca cttcggtctc catgatgctg tttgacacct tcctctatgg 2820  
 ggtgatgacc tggtagattg aggtgtctt tccaggccag tacggaattc ccaggccctg 2880  
 gtattttcct tgcaccaagt cctactggtt tggcgaggaa agtgatgaga agagccaccc 2940  
 tggttccaac cagaagagaa tatcagaaat ctgcatggag gaggaacca cccacttgaa 3000  
 gctgggcgtg tccattcaga acctggtaaa agtctaccga gatgggatga aggtggctgt 3060  
 cgatggcctg gcaactgaatt tttatgaggg ccagatcacc tccttcctgg gccacaatgg 3120  
 agcggggaag acgaccacca tgtcaatcct gaccgggttg ttccccccga cctcgggcac 3180  
 cgctacatc ctgggaaaag acattcgtc tgagatgagc accatccggc agaacctggg 3240  
 ggtctgtccc cagcataacg tgctgtttga catgctgact gtcgaagaac acatctggtt 3300  
 ctatgccgc ttgaaagggc tctctgagaa gcacgtgaag gcggagatgg agcagatggc 3360  
 cctggatgtt ggtttgccat caagcaagct gaaaagcaaa acaagccagc tgtcaggtgg 3420  
 aatgcagaga aagctatctg tggccttggc ctttgtcggg ggatctaagg ttgtcattct 3480  
 ggatgaacct acagctggtg tggaccctta ctcccgagg ggaatatggg agctgctgct 3540  
 gaaataccga caaggccgca ccattattct ctctacacac cacatggatg aagcggacgt 3600  
 cctgggggac aggattgcca tcattctcca tgggaagctg tgctgtgtgg gctcctccct 3660  
 gtttctgaag aaccagctgg gaacaggcta ctacctgacc ttggtcaaga aagatgtgga 3720  
 atcctccctc agttcctgca gaaacagtag tagcactgtg tcataacctga aaaaggagga 3780  
 cagtgtttct cagagcagtt ctgatgctgg cctgggcagc gaccatgaga gtgacacgt 3840  
 gaccatcgat gtctctgcta tctccaacct catcaggaag catgtgtctg aagcccggt 3900  
 ggtggaagac atagggcatg agctgacctt tgtgctgcca tatgaagctg ctaaggaggg 3960  
 agcctttgtg gaactctttc atgagattga tgaccggctc tcagacctgg gcattttctag 4020  
 ttatggcatc tcagagacga ccctggaaga aatattcctc aaggtggccg aagagagtgg 4080  
 ggtggatgct gagacctcag atggtacctt gccagcaaga cgaaacaggc gggccttcgg 4140  
 ggacaagcag agctgtcttc gcccgttcac tgaagatgat gctgctgac caaatgattc 4200  
 tgacatagac ccagaatcca gagagacaga cttgctcagt gggatggatg gcaaagggtc 4260  
 ctaccagggt aaaggctgga aacttacaca gcaacagttt gtggcccttt tgtggaagag 4320  
 actgctaatt gccagacgga gtcggaaagg attttttgc cagattgtct tgccagctgt 4380  
 gtttgtctgc attgcccttg tgttcagcct gatcgtgcca ccctttggca agtaccacag 4440  
 cctggaactt cagccctgga tgtacaacga acagtacaca tttgtcagca atgatgctcc 4500  
 tgaggacacg ggaaccttgg aactcttaaa cgccctcacc aaagacctg gcttcgggac 4560  
 ccgctgtatg gaaggaaacc caatcccaga cacgccctgc caggcagggg aggaagagt 4620

gaccactgcc ccagttcccc agaccatcat ggacctcttc cagaatggga actggacaat 4680  
gcagaaccct tcacctgcat gccagtgtag cagcgacaaa atcaagaaga tgctgcctgt 4740  
gtgtcccccga ggggcagggg ggctgcctcc tccacaaaga aaacaaaaca ctgcagatat 4800  
ccttcaggac ctgacaggaa gaaacatttc ggattatctg gtgaagacgt atgtgcagat 4860  
catagccaaa agcttaaaga acaagatctg ggtgaatgag tttaggtatg gcggccttttc 4920  
cctgggtgtc agtaatactc aagcacttcc tccgagtcaa gaagttaatg atgccatcaa 4980  
acaaatgaag aaacacctaa agctggccaa ggacagttct gcagatcgat ttctcaacag 5040  
cttggaaga tttatgacag gactggacac caaaaataat gtcaagggtgt ggttcaataa 5100  
caagggctgg catgcaatca gctctttcct gaatgtcatc aacaatgcca ttctccgggc 5160  
caacctgcaa aaggagaga accctagcca ttatggaatt actgctttca atcatcccc 5220  
gaatctcacc aagcagcagc tctcagaggt ggctctgatg accacatcag tggatgtcct 5280  
tgtgtccatc tgtgtcatct ttgcaatgtc cttcgtccca gccagctttg tcgtattcct 5340  
gatccaggag cgggtcagca aagcaaaaca cctgcagttc atcagtggag tgaagcctgt 5400  
catctactgg ctctctaatt ttgtctggga tatgtgcaat tacgttgtcc ctgccacact 5460  
ggtcattatc atcttcatct gcttcagca gaagtcctat gtgtcctcca ccaatctgcc 5520  
tgtgctagcc cttctacttt tgctgtatgg gtggtcaatc acacctctca tgtaccagc 5580  
ctcctttgtg ttcaagatcc ccagcacagc ctatgtggtg ctcaccagcg tgaacctctt 5640  
cattggcatt aatggcagcg tggccacctt tgtgctggag ctgttcaccg acaataagct 5700  
gaataatatc aatgatatcc tgaagtccgt gttcttgatc ttcccacatt tttgcctggg 5760  
acgagggctc atcgacatgg tgaaaaacca ggcaatggct gatgccctgg aaagggttgg 5820  
ggagaatcgc tttgtgtcac cattatcttg ggacttggtg ggacgaaacc tcttcgccat 5880  
ggccgtggaa ggggtggtgt tcttcctcat tactgttctg atccagtaca gattcttcat 5940  
caggcccaga cctgtaaatg caaagctatc tcctctgaat gatgaagatg aagatgtgag 6000  
gcgggaaaga cagagaattc ttgatggtgg aggccagaat gacatcttag aaatcaagga 6060  
gttgacgaag atatatagaa ggaagcggaa gcctgctgtt gacaggattt gcgtgggcat 6120  
tcctcctggt gagtgccttg ggctcctggg agttaatggg gctggaaaat catcaacttt 6180  
caagatgtta acaggagata ccactgttac cagaggagat gctttcctta acaaaaatag 6240  
tatcttatca aacatccatg aagtacatca gaacatgggc tactgccctc agtttgatgc 6300  
catcacagag ctgttgactg ggagagaaca cgtggagttc tttgcccttt tgagaggagt 6360  
cccagagaaa gaagttggca aggttggtga gtgggcgatt cggaaactgg gcctcgtgaa 6420  
gtatggagaa aaatatgctg gtaactatag tggaggcaac aaacgcaagc tctctacagc 6480  
catggctttg atcggcgggc ctctgtggt gtttctggat gaaccacca caggcatgga 6540  
tcccaaagcc cggcggttct tgtggaattg tgccctaagt gttgtcaagg aggggagatc 6600  
agtagtgctt acatctcata gtatggaaga atgtgaagct ctttgacta ggatggcaat 6660

catggtcaat ggaaggttca ggtgccttgg cagtgtccag catctaaaaa ataggtttgg	6720
agatggttat acaatagttg tacgaatagc agggccaac ccggacctga agcctgtcca	6780
ggatttcttt ggacttgcatt ttcctggaag tgttctaaaa gagaaacacc ggaacatgct	6840
acaataccag cttccattct cattatcttc tctggccagg atattcagca tcctctccca	6900
gagcaaaaag cgactccaca tagaagacta ctctgtttct cagacaacac ttgaccaagt	6960
atttgtgaac ttgccaagg accaaagtga tgatgaccac ttaaaagacc tctcattaca	7020
caaaaaccag acagtagtgg acgttgcagt tctcacatct tttctacagg atgagaaagt	7080
gaaagaaagc tatgtatgaa gaatcctgtt catacggggg ggctgaaagt aaagaggaaac	7140
tagactttcc ttgcaacct gtgaagtgtt gtggagaaaa gagccagaag ttgatgtggg	7200
aagaagtaaa ctggatactg tactgatact attcaatgca atgcaattca atgcaatgaa	7260
aacaaaattc cattacaggg gcagtgcctt tgtagcctat gtcttgtatg gctctcaagt	7320
gaaagacttg aatttagttt tttaacctata cctatgtgaa actctattat ggaaccaat	7380
ggacatatgg gtttgaactc acactttttt tttttttttt gttcctgtgt attctcattg	7440
gggttgcaac aataattcat caagtaatca tggccagcga ttattgatca aaatcaaaag	7500
gtaatgcaca tcctcattca ctaagccatg ccatgccag gagactgggt tcccggtgac	7560
acatccattg ctggcaatga gtgtgccaga gttattagt ccaagttttt cagaaagttt	7620
gaagcaccat ggtgtgtcat gctcactttt gtgaaagctg ctctgctcag agtctatcaa	7680
cattgaatat cagttgacag aatggtgcc aagcgtggcta acatcctgct ttgattccct	7740
ctgataagct gttctggtgg cagtaacatg caacaaaaat gtgggtgtct ccaggcacgg	7800
gaaacttggt tccattgtta tattgtccta tgcttcgagc catgggtcta cagggtcatc	7860
cttatgagac tcttaaatat acttagatcc tggtaagagg caaagaatca acagccaaac	7920
tgctggggct gcaagctgct gaagccaggg catgggatta aagagattgt gcgttcaaac	7980
ctagggaaagc ctgtgcccatt ttgtcctgac tgtctgctaa catggtacac tgcattcaa	8040
gatgtttatc tgacacaagt gtattatttc tggctttttg aattaatcta gaaaatgaaa	8100
agatggagtt gtattttgac aaaaatgttt gtacttttta atgttatttg gaattttaag	8160
ttctatcagt gacttctgaa tccttagaat ggcctctttg tagaaccctg tggatatagag	8220
gagtatggcc actgccccac tatttttatt ttcttatgta agtttgcata tcagtcatga	8280
ctagtgccta gaaagcaatg tgatggtcag gatctcatga cattatatatt gagtttcttt	8340
cagatcattt aggatactct taatctcact tcatcaatca aatatTTTTT gagtgtatgc	8400
tgtagctgaa agagtatgta cgtacgtata agactagaga gatattaagt ctgagtacac	8460
ttcctgtgcc atgttattca gctcactggg ttacaaatat aggttgtctt gtggttgtag	8520
gagccactg taacaatact gggcagcctt tttttttttt tttttaattg caacaatgca	8580
aaagccaaga aagtataagg gtcacaagtc taaacaatga attcttcaac agggaaaaca	8640
gctagcttga aaacttgctg aaaaacacaa cttgtgttta tggcatttag taccttcaaa	8700

```

taattggctt tgcagatatt ggatacccca ttaaactctga cagtcctcaa tttttcatct 8760
cttcaatcac tagtcaagaa aaatataaaa acaacaaata cttccatatg gagcattttt 8820
cagagttttc taaccagtc ttatttttct agtcagtaaa catttgtaaa aatactgttt 8880
cactaatact tactgttaac tgtcttgaga gaaaagaaaa atatgagaga actattgttt 8940
ggggaagttc aagtgatctt tcaatatcat tactaacttc ttccactttt tccagaattt 9000
gaatattaac gctaaagggtg taagacttca gatttcaaata taatctttct atatttttta 9060
aatttacaga atattatata acccactgct gaaaaagaaa aaaatgattg ttttagaagt 9120
taaagtcaat attgatttta aatataagta atgaaggcat atttccaata actagtata 9180
tggcatcggt gcattttaca gtatcttcaa aaatacagaa tttatagaat aatttctcct 9240
catttaatat ttttcaaaat caaagttatg gtttctcat tttactaaaa tcgtattcta 9300
attcttcatt atagtaaatac tatgagcaac tccttacttc ggttcctctg atttcaaggc 9360
catattttta aaaatcaaaa ggcactgtga actattttga agaaaacaca acattttaat 9420
acagattgaa aggacctctt ctgaagctag aaacaatcta tagttataca tcttcattaa 9480
tactgtgtta ccttttaaaa tagtaatttt ttacattttc ctgtgtaaac ctaattgtgg 9540
tagaaatttt taccaactct atactcaatc aagcaaaatt tctgtatatt ccctgtggaa 9600
tgtacctatg tgagtttcag aaattctcaa aatacgtgtt caaaaatttc tgcttttgca 9660
tctttgggac acctcagaaa acttattaac aactgtgaat atgagaaata cagaagaaaa 9720
taataagccc tctatacata aatgccagc acaattcatt gttaaaaaac aaccaaacct 9780
cacactactg tatttcatta tctgtactga aagcaaatgc tttgtgacta ttaaatgttg 9840
cacatcattc attcactgta tagtaatcat tgactaaagc cattgtctg tgttttcttc 9900
ttgtggttgt atatatcagg taaaatattt tccaaagagc catgtgtcat gtaatactga 9960
accactttga tattgagaca ttaatttgta cccttggtat tatctactag taataatgta 10020
atactgtaga aatattgctc taattctttt caaaattggt gcatccccct tagaatgttt 10080
ctatttccat aaggatttag gtatgctatt atcccttctt ataccctaag atgaagctgt 10140
ttttgtgctc ttgttcatc attggccctc attccaagca ctttacgctg tctgtaatgg 10200
gatctatttt tgcaactggaa tatctgagaa ttgcaaaact agacaaaagt ttcacaacag 10260
atcttcaagt taaatcattt tcattaaaag gaaaaagaaa aaaaaatttt gtatgtcaat 10320
aactttatat gaagtattaa aatgcatatt tctatgttgt aatataatga gtcacaaaat 10380
aaagctgtga cagttctggt ggtctacaga aa 10412

```

&lt;210&gt; 8

&lt;211&gt; 3473

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens



<400> 8  
 ttctttccaa ggggtctctggt gtgaggcccc tgaccttccc aagcctctcc ctgtcttgtg 60  
 aaacctgggc gtgatatacc tcccttttag ggctgctgcg atcatttagg cagattaaac 120  
 ctcataagtg gtttcccata caagaaagat gctagcagtg caacagacag aacacttaac 180  
 tgcctgccct cccgccagga ggtgggtcttc caacttttgc cggaggtcta cagaggggtg 240  
 gccctctctg ctggggctcc gggacatggt caggagaggt tggctctgtct gtaccgccat 300  
 tctcttggcc agactgtggt gtctgggtccc tactcacacc ttctgtcag agtatccaga 360  
 ggccgcagag tatccacacc ctggctgggt gtactggcta cagatggctg tggctccagg 420  
 tcacctgcgt gcctgggtga tgagaaataa tgtcacaaca aatatcccat ctgcattctc 480  
 tgggacactg acccatgaag agaaagcagt tctcacagtt ttacaggca cagccacagc 540  
 cgtgcatgta cagggtggcag ctttagcttc tgctaaactg gagagctcag tgtttgtgac 600  
 agactgcgtg tcctgcaaaa tcgaaaatgt ctgtgattca gctcttcagg gaaaaaggt 660  
 gccgatgtct ggcctacagg gctcaagcat tgtcatcatg ccccatcca accgtccact 720  
 cgccagtgcg gcatcctgca cgtgggtcagt ccaagtcag ggagggcccc atcacctggg 780  
 ggtggctcgt atcagtggca aagtcttgtc agcagctcat ggggcaggaa gggcctatgg 840  
 ttgggggttt cctggcgatc ccatggagga aggatacaag accctcctga aaggaatttc 900  
 cggaagtgc aatagtgtg agttggtggc cattatgggt ccttccgggg ccgggaagtgc 960  
 cacgctgatg aacatcctgg ctggatacag ggagacgggc atgaaggggg ccgtcctcat 1020  
 caacggcctg ccccgggacc tgcgctgctt ccggaaggtg tcctgctaca tcatgcagga 1080  
 tgacatgctg ctgccgcatc tactgtgca ggaggccatg atggtgtcgg cacatctgaa 1140  
 gcttcaggag aaggatgaag gcagaaggga aatgggtcaag gagatactga cagcgtggg 1200  
 cttgctgtct tgcgccaaca cgcggaccgg gagcctgtca ggtggtcagc gcaagcgct 1260  
 ggccatcgcg ctggagctgg tgaacaaccc tccagtcag ttcttcgatg agcccaccag 1320  
 cggcctggac agcgcctcct gcttccagggt ggtctcgtg atgaaagggc tcgctcaagg 1380  
 gggctcgtcc atcatttgca ccatccacca gccagcgcc aaactcttcg agctgttcga 1440  
 ccagctttac gtcctgagtc aaggacaatg tgtgtaccgg ggaaaagtct gcaatcttgt 1500  
 gccatatttg agggatttg gtctgaactg cccaacctac cacaaccag cagattttgt 1560  
 catggagggt gcatccggcg agtacggtga tcagaacagt cggctggtga gagcggttcg 1620  
 ggagggcatg tgtgactcag accacaagag agacctcggg ggtgatgccg aggtgaaccc 1680  
 ttttctttgg caccggccct ctgaagaggt aaagcagaca aaacgattaa aggggttgag 1740  
 aaaggactcc tcgtccatgg aaggctgcca cagcttctct gccagctgcc tcacgcagtt 1800  
 ctgcatcctc ttcaagagga ccttcctcag catcatgagg gactcgggtc tgacacacct 1860  
 gcgcatcacc tcgcacattg ggatcggcct cctcattggc ctgctgtact tggggatcgg 1920  
 gaacgaagcc aagaaggtct tgagcaactc cggcttcctc ttcttctcca tgctgttcct 1980

catgttcgcg gccctcatgc ctactgttct gacatttccc ctggagatgg gagtctttct 2040  
 tcgggaacac ctgaactact ggtacagcct gaaggcctac tacctggcca agaccatggc 2100  
 agacgtgccc tttagatca tgttcccagt ggcctactgc agcatcgtgt actggatgac 2160  
 gtcgcagccg tccgacgccg tgcgctttgt gctgtttgcc gcgctgggca ccatgacctc 2220  
 cctggtggca cagtccctgg gcctgtgat cggagccgcc tccacgtccc tgcaggtggc 2280  
 cactttcgtg ggcccagtga cagccatccc ggtgtcctg ttctcgggt tcttcgtcag 2340  
 cttcgcacc atccccagt acctacagt gatgtctac atctcctatg tcaggatatg 2400  
 gttcgaagg gtcactctt ccatctatg cttagaccgg gaagatctgc actgtgacat 2460  
 cgacgagacg tgccacttcc agaagtcgga ggccatcctg cgggagctgg acgtggaaaa 2520  
 tgccaagctg tacctggact tcactgtact cgggattttc ttcactctcc tccgcctcat 2580  
 tgcctatttt gtcctcaggt acaaaatccg ggcagagagg taaaacacct gaatgccagg 2640  
 aaacaggaag attagacact gtggccgagg gcacgtctag aatcgaggag gcaagcctgt 2700  
 gcccgcagga cgacacagag actcttctga tccaaccct agaaccgcgt tgggtttgtg 2760  
 ggtgtctcgt gctcagccac tctgccagc tgggttgat cttctctcca tcccccttc 2820  
 tagctttaac taggaagatg taggcagatt ggtggtttt ttttttttaa catacagaat 2880  
 tttaaatacc acaactgggg cagaatttaa agctgcaaca cagctggtga tgagaggctt 2940  
 cctcagtcca gtcgctcctt agcaccaggc accgtgggtc ctggatgggg aactgcaagc 3000  
 agcctctcag ctgatggctg cacagtcaga tgtctggtgg cagagagtcc gagcatggag 3060  
 cgattccatt ttatgactgt tgtttttcac attttcatct ttctaagggtg tgtctctttt 3120  
 ccaatgagaa gtcatttttg caagccaaaa gtcgatcaat cgcattcatt ttaagaaatt 3180  
 atacctttt agtacttgct gaagaatgat tcagggtaaa tcacatactt tgtttagaga 3240  
 ggcgaggggt ttaaccgagt caccagctg gtctcataca tagacagcac ttgtgaagga 3300  
 ttgaatgcag gttccagggt gaggaagac gtggacacca tctccactga gccatgcaga 3360  
 cttttttaa agctatacaa aaaattgtga gaagacattg gccaactctt tcaaagtctt 3420  
 tctttttcca cgtgcttctt attttaagcg aaatatattg ttgtttctt cct 3473

<210> 9

<211> 2740

<212> DNA

<213> Homo sapiens

<400> 9

aagtcccagt cctgctgtcc caagggactc cggggtcagg tggagcaggc agggcagtct 60  
 gccacgggct cccaactga agccactctg gggagggtcc ggccaccaga aaatttgccc 120  
 agctttgctg cctgttggtc atgggtgacc tctcatcttt gacccccgga gggccatgg 180

gtctccaagt aaacagaggg tcccagagct ccctggaggg ggctcctgcc accgccccgg	240
agcctcacag cctgggcatc ctccatgcct cctacagcgt cagccaccgc gtgaggccct	300
ggtgggacat cacatcttgc cggcagcagt ggaccaggca gatcctcaaa gatgtctcct	360
tgtacgtgga gagcgggcag atcatgtgca tcctaggaag ctcaggctcc gggaaaacca	420
cgctgctgga cgccatgtcc gggaggctgg ggcgcgcggg gaccttcctg ggggaggtgt	480
atgtgaacgg ccgggcgctg cgccgggagc agttccagga ctgcttctcc tacgtcctgc	540
agagcgacac cctgctgagc agcctcaccg tgcgcgagac gctgcactac accgcgctgc	600
tggccatccg ccgcggcaat cccggctcct tccagaagaa ggtggaggcc gtcattggcag	660
agctgagtct gagccatgtg gcagaccgac tgattggcaa ctacagcttg gggggcattt	720
ccacgggtga gcggcgccgg gtctccatcg cagccagct gctccaggat cctaaggatca	780
tgctgtttga tgagccaacc acaggcctgg actgcatgac tgctaatacag attgtcgtcc	840
tcctgggtgga actggctcgc aggaaccgaa ttgtggttct caccattcac cagccccgtt	900
ctgagctttt tcagctcttt gacaaaattg ccatacctgag cttcggagag ctgattttct	960
gtggcacgcc agcggaaatg cttgatttct tcaatgactg cggttaccct tgtcctgaac	1020
attcaaaccc ttttgacttc tatatggacc tgacgtcagt ggatacccaa agcaaggaa	1080
gggaaataga aacctccaag agagtccaga tgatagaatc tgcctacaag aaatcagcaa	1140
tttgtcataa aactttgaag aatattgaaa gaatgaaaca cctgaaaacg ttaccaatgg	1200
ttcctttcaa aaccaaagat tctcctggag ttttctctaa actgggtgtt ctcttgagga	1260
gagtgacaag aaacttggtg agaaaataagc tggcagtgat tacgcgtctc cttcagaatc	1320
tgatcatggg tttgttcctc cttttcttcg ttctgcgggt ccgaagcaat gtgctaaagg	1380
gtgctatcca ggaccgcgta ggtctccttt accagtttgt gggcgccacc ccgtacacag	1440
gcatgctgaa cgctgtgaat ctgtttcccg tgctgcgagc tgtcagcgac caggagagtc	1500
aggacggcct ctaccagaag tggcagatga tgctggccta tgcactgcac gtcctccct	1560
tcagcgttgt tgccaccatg attttcagca gtgtgtgcta ctggacgctg ggcttacatc	1620
ctgaggttgc ccgatttgga tatttttctg ctgctctctt ggccccccac ttaattggtg	1680
aatttctaac tcttgtgcta cttggtatcg tccaaaatcc aaatatagtc aacagtgtag	1740
tggctctgct gtccattgca ggggtgcttg ttggatctgg attcctcaga aacatacaag	1800
aaatgcccac tccttttaaa atcatcagtt attttacatt ccaaaaatat tgcagtgaga	1860
ttctttagt caatgagttc tacggactga atttcacttg tggcagctca aatgtttctg	1920
tgacaactaa tccaatgtgt gccttcactc aaggaattca attcattgag aaaacctgcc	1980
cagggtgaac atctagattc acaatgaact ttctgatttt gtattcattt attccagctc	2040
ttgtcatcct aggaatagtt gttttcaaaa taagggatca tctcattagc aggtagtga	2100
agccatggct gggaaaatgg aagtgaagct gccgactgtg catgactgct ctgaacgtct	2160
gaaatgagag tgccatgtat ttctttcttg acaggacatc tcaagtcttt taaccattaa	2220

gactccattt gtgcctcttg gatccaagca ggccttgaat gcaatggaag tggtttatag 2280  
 tcccttgctc ttacaacttg caggacatg tggttatttg gaaattgtga ctgagcggac 2340  
 ccaagaatgt aaataatatt cataaaccta tgggagactc gtgtgactat tttttttcct 2400  
 tgttctaggc acagaaaaaa ataggtcagc ttaaaaatat gtttacattg gataaaggat 2460  
 taggcaaaaa taaaatgttt caaggattcc tgaccataag tgacagagaa agagagttgt 2520  
 gggtttagat gaagcaaggc tatcatgcag aattgggtaa gaatgcttct gttcctggaa 2580  
 gaccagagt taaatgcaga tgtccacacg aggggtcggg gttacctgat cacatcgaga 2640  
 gagtgtggg cagatggatg gtgagacca ctgctacaga gcaccagtg attttactga 2700  
 ggattaaaat aaaaaaccgt aggaatgggc tcaacagtga 2740

<210> 10

<211> 2679

<212> DNA

<213> Homo sapiens

<400> 10

ctccaggaaa cagagtgaag aactggccc tggcaggcag cagctgggtc taagagagct 60  
 gcagcccagg gtcacagacc tgtgggcccc atggccggga aggcggcaga ggagagaggg 120  
 ctgccgaaag gggccactcc ccaggatacc tcgggcctcc aggatagatt gttctcctct 180  
 gaaagtgaca acagcctgta cttcacctac agtggccagc ccaacaccct ggaggtcaga 240  
 gacctcaact gccagggtga cctggcctct caggctccctt ggtttgagca gctggctcag 300  
 ttcaagatgc cctggacatc tcccagctgc cagaattctt gtgagctggg catccagaac 360  
 ctaagcttca aagtgagaag tgggcagatg ctggccatca tagggagctc aggttggtgg 420  
 agagcctcct tgctagatgt gatcactggc cgaggtcacg gcggcaagat caagtcaggc 480  
 - cagatctgga tcaatgggca gccagctcg cctcagctgg tgaggaagtg tgtggccac 540  
 gtgcgccagc acaaccagct gctccccaac ttgactgtgc gagagacctt ggccttcatt 600  
 gccagatgc ggctgcccag aaccttctcc caggcccagc gtgacaaaag ggtggaggac 660  
 gtgatcgagg agctgcggct taggcagtgc gctgacaccc gcgtgggcaa catgtacgtg 720  
 cgggggttgt cgggggtga gcgcaggaga gtcagcattg ggtgagct cctgtggaac 780  
 ccaggaatcc ttattctcga cgaaccacc tctgggctcg acagcttcac agcccacaac 840  
 ctggtgaaga cctgtccag gctggccaaa ggcaaccggc tgggtgctcat ctccctccac 900  
 cagcctcgct ctgacatctt caggctgttt gatctggtcc tcctgatgac gtctggcacc 960  
 cccatctact taggggcggc ccagcacatg gtccagtatt tcacagccat cggctacccc 1020  
 tgtctcgtct acagcaatcc tgcgtacttc tatgtggacc tgaccagcat tgacaggcgc 1080  
 agcagagagc aggaattggc caccagggag aaggctcagt cactcgagc cctgtttcta 1140

gaaaaagtgc gtgacttaga tgacttttcta tggaaagcag agacgaagga tcttgacgag 1200  
 gacacctgtg tggaaagcag cgtgaccca ctagacacca actgcctccc gagtcctacg 1260  
 aagatgcctg gggcggtgca gcagtttacg acgctgatcc gtcgtcagat ttccaacgac 1320  
 ttccgagacc tgcccaccct cctcatccat ggggcggagg cctgtctgat gtcaatgacc 1380  
 atcggttcc tctattttgg ccatgggagc atccagctct ccttcatgga tacagccgcc 1440  
 ctcttggttca tgatcggtgc tctcatccct ttcaacgtca ttctggatgt catctccaaa 1500  
 tgttactcag agagggcaat gctttactat gaactggaag acgggctgta caccactggg 1560  
 ccatatttct ttgccaagat cctcggggag cttccggagc actgtgccta catcatcatc 1620  
 tacgggatgc ccacctactg gctggccaac ctgaggccag gcctccagcc cttcctgctg 1680  
 cacttcctgc tgggtgtggct ggtggtcttc tgttgaggga ttatggccct ggccgcccgcg 1740  
 gccctgctcc ccaccttcca catggcctcc ttcttcagca atgccctcta caactccttc 1800  
 tacctcgccg ggggcttcat gataaacttg agcagcctgt ggacagtgcc cgcgtggatt 1860  
 tcaaagtgt ccttcctgcg gtggtgtttt gaagggtga tgaagattca gttcagcaga 1920  
 agaacttata aaatgcctct cggaacctc accatcgcg tctcaggaga taaaatcctc 1980  
 agtgccatgg agctggactc gtaccctctc tacgccatct acctcatcgt cattggcctc 2040  
 agcgggtggct tcatggtcct gtactacgtg tccttaagggt tcatcaaaca gaaaccaagt 2100  
 caagactggt gattcacgcc agacgtctgc ccgctgggtg gggacctgag cagacccttc 2160  
 aactgcactc cctcctcagg agccccctcc tggggacagt gaggacaatg accctacaga 2220  
 tgctcagcta catccggccc aggggtgctgc ggtggcacag accagccaca ggatggcagt 2280  
 agaataaaga cagtcgaaag ggatttctgc tctactggcag gagactgcga tgactgggag 2340  
 aaaacctgca ctcggtggca cctacaacgt tgctaattta tttccttttg atatgcattt 2400  
 atataggcaa ctcgatatag gatgggagca aactaggaat gaattgggta gctagactgt 2460  
 gcaggaattg ttggaacctg gagggaaaca taacagtacc tagcagattt ggcttcatct 2520  
 tccaggggcc ccacactccg tggtagacca ccatcaatac agaaagtgac ctaagatgta 2580  
 ccagcaagat gccatccctt ctttttgtgt ggggtcatgg gctccaaaag ccaacgtgaa 2640  
 caattaaaaa tgtattgagc atctaaaaaa aaaaaaaaaa 2679

<210> 11

<211> 1156

<212> DNA

<213> Homo sapiens

<400> 11

cgcagcggag gtgaaggacg tccttcccca ggagccgact ggccaatcac aggcaggaag 60  
 atgaagggtc tgtgggctgc gttgctggtc acattcctgg caggatgcca ggccaagggtg 120

gagcaagcgg tggagacaga gccggagccc gagctgcgcc agcagaccga gtggcagagc 180  
 ggccagcgct gggaaactggc actgggtcgc ttttgaggatt acctgcgctg ggtgcagaca 240  
 ctgtctgagc aggtgcagga ggagctgctc agctcccagg tcacccagga actgagggcg 300  
 ctgatggacg agaccatgaa ggagttgaag gcctacaaat cggaactgga ggaacaactg 360  
 accccggtgg cggaggagac gcgggcacgg ctgtccaagg agctgcaggc ggcgcaggcc 420  
 cggctgggcg cggacatgga ggacgtgtgc ggccgcctgg tgcagtaccg cggcgagggtg 480  
 caggccatgc tcggccagag caccgaggag ctgcggtgct gcctcgcctc ccacctgcgc 540  
 aagctgcgta agcggctcct ccgcgatgcc gatgacctgc agaagcgcct ggcagtgtac 600  
 caggccgggg cccgcgaggg cgccgagcgc ggcctcagcg ccattccgca gcgcctgggg 660  
 cccctggtgg aacagggccg cgtgcgggccc gccactgtgg gctccctggc cggccagccg 720  
 ctacaggagc gggcccaggc ctggggcgag cggctgcgcg cgcggatgga ggagatgggc 780  
 agccggaccc gcgaccgcct ggacgagggt aaggagcagg tggcgagggt gcgcgccaag 840  
 ctggaggagc agggccagca gatacgcctg caggccgagg ccttcaggc ccgcctcaag 900  
 agctggttcg agcccctggt ggaagacatg cagcgccagt gggccgggct ggtggagaag 960  
 gtgcaggctg ccgtgggcac cagcgccgcc cctgtgccca gcgacaatca ctgaacgccg 1020  
 aagcctgcag ccatgcgacc ccacgccacc ccgtgcctcc tgcctccgcg cagcctgcag 1080  
 cgggagaccc tgtccccgcc ccagccgtcc tcctggggtg gaccctagtt taataaagat 1140  
 tcaccaagtt tcacgc 1156

<210> 12

<211> 417

<212> DNA

<213> Homo sapiens

<400> 12

acctccaac caagccctcc agcaaggatt caggagtgcc cctcgggcct cgccatgagg 60  
 ctcttcctgt cgctcccggc cctgggtggtg gttctgtcga tcgtcttgga agggccagcc 120  
 ccagcccagg ggaccccaga cgtctccagt gccttgata agctgaagga gtttgaaac 180  
 aactggagg acaaggctcg ggaactcatc agccgcatca aacagagtga actttctgcc 240  
 aagatgcggg agtggttttc agagacattt cagaaagtga aggagaaact caagattgac 300  
 tcatgaggac ctgaagggtg acatccagga ggggcctctg aaatttccca caccacgcg 360  
 cctgtgctga ggactccgc catgtggccc caggtgccac caataaaaat cctaccg 417

<210> 13

<211> 753

<212> DNA

&lt;213&gt; Homo sapiens

<400> 13  
gttggtggctg tggagcggaa gtgggtctca accactataa atcctctctg tgcccgtccg 60  
gagctgggtga ggacagcctg ccagagtctg gtctctggac actatgggca cagactcct 120  
cccagctctg tttcttgtcc tcctgggtatt gggatttgag gtccagggga cccaacagcc 180  
ccagcaagat gagatgccta gcccgacctt cctcaccag gtgaaggaat ctctctccag 240  
ttactgggag tcagcaaaga cagccgcca gaacctgtac gagaagacat acctgcccgc 300  
tgtagatgag aaactcaggg acttgtagag caaaagcaca gcagccatga gcacttacac 360  
aggcattttt actgaccaag ttctttctgt gctgaaggga gaggagtaac agccagaccc 420  
cccatcagtg gacaagggga gaggcccta ctcccctgat ccccaggtt cagactgagc 480  
tcccccttcc cagtagctct tgcctcctcc tcccactct agcctgaatt cttttcaata 540  
aaaaatacaa ttcaagttgc ttctcatgga tggcactgct tttctgagga ctcaagggcc 600  
aagatggagg ggctgactca gtccagccaa catttaatga gcacctactt tatgtatgga 660  
gctctaacc atgggtccat ggggaataaag cagtgaatag taacaataaa taatcgtaac 720  
aaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaa 753

&lt;210&gt; 14

&lt;211&gt; 5950

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

<400> 14  
gaattccagg ggacatctgt tgcgcaccta ctgtgctcac gctggggcct ctgggatgga 60  
caggattctg ccaaggcaga catctgggtc aagacagtcc tgcacagttg ttcaggttgt 120  
ggccaagggt gcgtttgcag atttgccatg taaaaataca ggatgctcag ttacatttga 180  
atttcagatt aatagcaaaa aaaacttttt ggtataattc tgaaatattt catgggacat 240  
atttatacta aaacgtcatg cactgttgat ttgaaattca aatgtaattg ggcctcctct 300  
atttcgtctg gcaagcgtag acaaaagaat ccagtccagg ccaggcgtag tggctcaagc 360  
ctgtaatccc agcacttttg gaggccgagg cgggcggatc acgaggctcag gagatcgaga 420  
ccatcctggc taacacggtg aaaccccgct tctactaaaa atacaaaaaa ttagctgggc 480  
gtggtggcg9 gtgcctgtag tcccagctac tgggagggt gaggcaggag aatggcgtga 540  
acctgggagg cggagcttgc agtgagccga gatcgccca cagcactcca gcctgggcga 600  
cagagccaga ctctgtctca aaaaaaaaaa aaagaatcca gtccatagtc ccctgagcca 660  
tgtgccctgg ggtgcagctg ggtccttcag gagaaaaatg ctctatttct ggcactggga 720

ccgagcctga tgtgggtttt ttgttggttt ttgttggtgt tattgttttt gagacaaggt	780
ctcgctccac cacacccggc taatttttgt attttttagta gagacggggt ttactacgt	840
tggccaggct ggtcttgaac tcctgacctc aagttagccg cctgcctcgg cctcccaaag	900
tgctgggatt acaggtggga gccaccgccc tggccctggg cctgatgttg atgacctcct	960
actatgtgca cctgcagctc tcctgcatag gcctcagccg tcctgcatga ggacactggg	1020
aggcagggtgc tccctatcaa ccccggtgta cagttgaaca aactgagccc cagaaaagaa	1080
aacgtattttg ccaggtcac acggtgaaga agtgagggat tcgaagccca ggtccatctg	1140
aagccagagt caccagagg agaaagagtt ggaattgaga actcaaggaa tgcttggaag	1200
tgatcgggct cgagcccacc taggaagaaa cagaggctgg agacatgaga ctgtgttgc	1260
atttcctctc atcaaccctt gggccctatt gaggcctac cacaagcctg gccctgcagc	1320
ccagtgacta ggagaaatta gacacaagat aataataaca gcaatgatct ttttttttt	1380
tctgagacgg agtcttgctc tttcgcccag gctggactgc agtggcgca tctcggtca	1440
atgcaagctc cacctcccag gttcacgcca ttctcctgcc tcagcctccc gagtagctag	1500
gactacaggc gcctgccacc acgcctggct aatttttcat attttttagta gagatggggt	1560
ttcaccgtgt tagccaagat ggtctcaatc tcctgacctc gtgatccgcc tgcctcggcc	1620
tcccaaagtg ttggggttac aggcattgagc caccgcgcct ggccaacagc aatgatcttt	1680
gagcacctat attgccagtc tccacggtaa gagctttctt cattttttgt tttgtttgt	1740
ttcaagacag agtcttgctc tgtcaccag gctggagtgc agtgggtgta tcgcggctca	1800
ctgcagcctt cacttcccgg gttcaagcca ttctcctgcc tcagcctccc aagtagctgg	1860
gattacaggc acgcatcact acttctggct aatttttgta ttttttagtag ggacagggtt	1920
tttcaccatg ttggccagggt tgggtctcaa ctctggcct catatgatct gccacctcg	1980
gcctcccaaa gtgctgggat tacaggcgtg agccactgcg cctttctttg tatttgttca	2040
agtaatatata tgaaatatgt actgtgcctc ccactttatg gaggaggaaa ctgaggccag	2100
caaatgaggc tgtcatggga ggtggagaca ggatttgaac ctgcctcagt gcaggaggct	2160
caagagcctc tgtcttctct cagggcactg tgtgggaggg tgagaaggag ggaggccac	2220
agaggcatga cctctgattg ccactgtcac ctgggccctg ctctctgaag tctctgcaa	2280
gcggggagggt ggccggggga gggccctgct ctgtgcagcc tccccctccc cggcccgcag	2340
agttgagcac agagggacag aggcacggaa cccccagaaa tgtccctcct cagaaacagg	2400
ctccaggccc tgcctgccct gtgcctctgc gtgctggtcc tggcctgcat tgggggtgag	2460
aagaagtggg tggagggatg tggggccac acctggtggg tgtgagtgtg gctgtgtgtc	2520
ctgtggctct gtagccacgt gagacatgag tacggagtgt gtgcgtttca tggcgtgcgt	2580
atgcatgtgc gtgtcgggga gtgtgtgtgt cgggtggctga gagtgaagtg tgaatgtcac	2640
attggtacaa actgggatca tctgtgtgtg tgcacgtgcg tgcgtggaag tgggagtatg	2700
cagtcgtggt aaaaaagtgc atgtctgtgt gcatatgtgt atttgtgtgc acctgtctct	2760



ctgtg999gta tgtgtgtgca aaatatttga gtgtgtggac atgtgtgagg gggtagagtgt 2820  
gtgtg99gtgt gtacgtctgt gttttgcata tgcatttttt tttttttttt ttagacggag 2880  
tctcactctg tcacccaggc tggagtgcag tggtagcagt ggtgcgatct tggctcactg 2940  
catcatccgc ctacccgttt caagggattc tcctgcctca gtcttcagag tatttgggac 3000  
tacagacaca cgccaccatg cctggctaata tttttttttt tgagacggag tctcgtctgt 3060  
ttacccaggc tggagtgcag tggcgtgatc ttggctcact gcaagctccg cctcccgggt 3120  
tcacgccatt ctctgcctc agcctcccga gtagctggga ctacaggagc ccaccaccac 3180  
gcctggctaa ttttttgtat ttttactaga gacgggggtt cgccgtgtta gccaggatgg 3240  
tctccatata ctgacctcgt gatccgcctg cctcggcctt ccaaagtgtc aggattatag 3300  
gcgtgagcca ctgcccctgg ccaatgcctg gctaattttt ttatatattt ggtagagaca 3360  
gggttttggc atgttgccca ggctggctct gaaatcctga cctcagggtga tccgcccggc 3420  
ttggcctccc aaagtgtcgg gattacaggc atgagccacc acgcccggcc atgtacttta 3480  
tgttaaaatg ggatcatatt ctagatcagc attatccagt agaaatttaa atttttaata 3540  
cagggccagg cacgggtggc catgcctgta atcccagcac tttcggaggc cgaggcgggt 3600  
ggatcgcaag gtcaggagat ttgagatcat cctggctaac agatgggtaa aaacccatct 3660  
ctactaaaaa tacaaaaaat tagccatgca tgggtggcatg cgctgtagt cccagctact 3720  
cgggaggctg agggccggaga atcacttgaa cccgggaggc agaggttgca gtgagccgag 3780  
atcgcgccac tgcattccaa cctgggtgac agagcgagac tccgtctgaa aaaaaaaaaa 3840  
aatttaacac gtatgtagac aatgtgcaag gcaccattcc atgtgcatcg tatgtagtaa 3900  
ctcttaattc tcacgataac cctgaggtag atattattac cccgttctac aaaaggagaa 3960  
acagtcttg ggagacagga taagtcaccg gccaaaggac acagctagct acatgtggcc 4020  
cccgcgtgac ggctggctct tgtaggcgag gctttgtcca gatgcgtggg tagaaggctc 4080  
ggcccggaaa gaggaactga cagcaaggct aagccaatgt ctgcccctgg gggcagaaag 4140  
tcacctcctg ctctccctcc actgtccaca gaggtagctc agacagggtg ggggtcacag 4200  
gagaacgaag ggagaagggg gtagttcctg ggcagcaaaa tcagggtggg aagggaggca 4260  
tcagaggatg gcaattagag aggccattag aggggaacca caggcagaca gggtagacagg 4320  
agggactact gacacaagggt gaagagatgg cccagccgga cgggggtggc cacatctgta 4380  
atcccagcat tttgggagcc cgagggtgggt ggatcacttg aggtcaggag ttcgaggccc 4440  
caacatggca aaaccccatc tcttctaaaa atacaaaaat tagccgggca tgatggcaga 4500  
tgcctgtaat ccctgctact cgggaggctg aggcaggaaa attgcctgaa tccaggagggt 4560  
ggagggtgca atgagacgag atcatgacac tgcactccac cctgggcaac agagcaagag 4620  
actgactctg tctcataaaa aaaaagaaaa aagaaaaaaa aaaagagatg gctgatgggt 4680  
aaagaggggt tagcggctcag gggacacata agggtaaagg caggaggcaa gaggactggc 4740  
agggggctgc ccctgggcca ccgggagcga cacaggatga gcatggaggg aaagggagaa 4800

ggggattcta ggggtcccagc ctacccaagt tgccctctgg ttccacctag catgccagcc 4860  
 agaggcccag gaaggaaccc tgagccccc accaaagcta aagatgagtc gctggagcct 4920  
 ggtgaggggc aggatgaagg agctgctgga gacagtgggtg aacaggacca gagacgggtg 4980  
 gcaatggttc tgggtaggggt gtgctggcct ggggtggtggg aggggactcc tgggtctgag 5040  
 ggaggagggg ctggggcctg gacccctgag tctcaggag gaggaagggtg tgggagtggg 5100  
 gctgtgaccc ctaggctctg gaggagtgga gggttagagc tgagagcagg aactcctagg 5160  
 tcacagagag gagcggataa atggggcaga gaacacctgg ggagagctgg ggcctccact 5220  
 gtgatgtcct ctctcctgta ggagcccag caccctccgg ggcttcatgc agacctacta 5280  
 tgacgaccac ctgagggacc tgggtccgct caccaaggcc tggttcctcg aatccaaaga 5340  
 cagcctcttg aagaagaccc acagcctgtg cccagggctt gtctgtgggg acaaggacca 5400  
 ggggttaaaat gttcataaaa gccagggtgtg gttgtggcgg gtgcctgtag tcccagctac 5460  
 tcaggaggct gaggtaggat gatggcttga gcccaggagt tcgagaccag cctgggcaac 5520  
 acagcgagat ctcttggggg taaaacaaaa agaaaaaaa aagttcatac ttctccaata 5580  
 aataaagtct cacctgtgtc cctgtctgga tccttcccca gtgtggccag aaaaaaacc 5640  
 accccactgc ctcccaggaa tcaatgagta gaagagggtga cacctgatgg ggaaggaaga 5700  
 gtagggagggt cgggaagggt atcaaggaat aacaccctat tgtgggcttg cggagaatgg 5760  
 gggacttcaa ggcgtgtcag tttcaggagg gtgagggcag gagcgtgggt ggagtcagca 5820  
 ggtcccatg atggccctca ctgagagctt cgccctgtgc tcctacaagc tctgactcca 5880  
 ttcccagtg gacccagca cctccaaccc ctccacagcc cccaaccag cctctgtcgg 5940  
 aggcgaattc 5950

<210> 15

<211> 3549

<212> DNA

<213> Homo sapiens

<400> 15

cccctcttcc tcctcctcaa gggaaagctg ccactttcta gctgccctgc catccccctt 60  
 aaagggcgac ttgctcagcg ccaaaccgcg gctccagccc tctccagcct ccggctcagc 120  
 cggctcatca gtcggtccgc gccttgacgc tcctccagag ggacgcgccc cgagatggag 180  
 agcaaagccc tgctcgtgct gactctggcc gtgtggctcc agagtctgac cgcctcccg 240  
 ggaggggtgg ccgccgccga ccaaagaaga gatatttatcg acatcgaaag taaatttgcc 300  
 ctaaggaccc ctgaagacac agctgaggac acttgccacc tcattcccgg agtagcagag 360  
 tccgtggcta cctgtcattt caatcacagc agcaaacct tcatggtgat ccatggctgg 420  
 acggtaacag gaatgtatga gagttgggtg caaaacttg tggccgccct gtacaagaga 480

gaaccagact ccaatgtcat tgtggtggac tggctgtcac gggctcagga gcattaccca 540  
 gtgtccgcgg gctacaccaa actggtggga caggatgtgg cccggtttat caactggatg 600  
 gaggaggagt ttaactaccc tctggacaat gtccatctct tgggatacag ccttgagacc 660  
 catgctgctg gcattgcagg aagtctgacc aataagaaag tcaacagaat tactggcctc 720  
 gatccagctg gacctaacct tgagtatgca gaagccccga gtcgtctttc tcctgatgat 780  
 gcagattttg tagacgtctt acacacattc accagagggg cccctggctg aagcattgga 840  
 atccagaaac cagttgggca tgttgacatt taccgaatg gaggtacttt tcagccagga 900  
 tgtaacattg gagaagctat ccgctgatt gcagagagag gacttgaga tgtggaccag 960  
 ctagtgaagt gctcccacga gcgctccatt catctcttca tcgactctct gttgaatgaa 1020  
 gaaaatccaa gtaaggccta cagggtgcagt tccaaggaag cctttgagaa agggctctgc 1080  
 ttgagttgta gaaagaaccg ctgcaacaat ctgggctatg agatcaataa agtcagagcc 1140  
 aaaagaagca gcaaatgta cctgaagact cgctctcaga tgccctacaa agtcttccat 1200  
 taccaagtaa agattcattt ttctgggact gagagtgaag cccataccaa tcaggccttt 1260  
 gagatttctc tgtatggcac cgtggccgag agtgagaaca tcccattcac tctgcctgaa 1320  
 gtttccacaa ataagacct ctccttcccta atttacacag aggtagatat tggagaacta 1380  
 ctcatgttga agctcaaatg gaagagtgat tcatacttta gctggtcaga ctggtggagc 1440  
 agtcccggct tcgccattca gaagatcaga gtaaaagcag gagagactca gaaaaagggtg 1500  
 atcttctgtt ctagggagaa agtgtctcat ttgcagaaag gaaaggcacc tgcggtattt 1560  
 gtgaaatgcc atgacaagtc tctgaataag aagtcaggct gaaactgggc gaatctacag 1620  
 aacaaagaac ggcatgtgaa ttctgtgaag aatgaagtgg aggaagtaac ttttacaaaa 1680  
 cataccaggt gtttgggggtg tttcaaaagt ggattttcct gaatattaat cccagcccta 1740  
 cccttgtagg ttattttagg agacagtctc aagcactaaa aagtggctaa ttcaatttat 1800  
 ggggtatagt ggccaaatag cacatcctcc aacgttaaaa gacagtggat catgaaaagt 1860  
 gctgttttgt cctttgagaa agaaataatt gtttgagcgc agagtaaaat aaggctcctt 1920  
 catgtggcgt attgggccat agcctataat tgggttagaac ctctattttt aattggaatt 1980  
 ctggatcttt cggactgagg ccttctcaaa ctttactcta agtctccaag aatacagaaa 2040  
 atgcttttcc gcggcacgaa tcagactcat ctacacagca gtatgaatga tgttttagaa 2100  
 tgattccctc ttgctattgg aatgtgtgcc agacgtcaac caggaacatg taacttgag 2160  
 agggacgaag aaagggtctg ataaacacag aggttttaaa cagtccctac cattggcctg 2220  
 catcatgaca aagttacaaa ttcaaggaga tataaaatct agatcaatta attcttaata 2280  
 ggctttatcg tttattgctt aatccctctc tcccccttct tttttgtctc aagattatat 2340  
 tataataatg ttctctgggt aggtgttgaa aatgagcctg taatcctcag ctgacacata 2400  
 atttgaatgg tgcagaaaaa aaaaagatac cgtaatttta ttattagatt ctccaaatga 2460  
 ttttcatcaa tttaaaatca ttcaatatct gacagttact cttcagtttt aggcttacct 2520

tggtcatgct tcagttgtac ttccagtgcg tctcttttgt tcctggcttt gacatgaaaa	2580
gataggtttg agttcaaatt ttgcattgtg tgagcttcta cagatttttag acaaggaccg	2640
tttttactaa gtaaaagggg ggagagggtc ctgggggtga ttcctaagca gtgcttgtaa	2700
accatcgcgt gcaatgagcc agatggagta ccatgagggt tgttatttgt tgtttttaac	2760
aactaatcaa gagtgagtga acaactatth ataaactaga tctcctatth ttcagaatgc	2820
tcttctacgt ataaatatga aatgataaag atgtcaaata tctcagaggc tatagctggg	2880
aacccgactg tgaaagtatg tgatatctga acacatacta gaaagctctg catgtgtggt	2940
gtccttcagc ataattcggg agggaaaaca gtcgatcaag ggatgtattg gaacatgtcg	3000
gagtagaaat tgttcctgat gtgccagaac ttcgaccctt tctctgagag agatgatcgt	3060
gcctataaat agtaggacca atgttgtgat taacatcatc aggcttgga tgaattctct	3120
ctaaaaataa aatgatgtat gatttgttgt tggcatcccc ttatttaatt cattaaatth	3180
ctggatttgg gttgtgacct aggggtgcatt aacttaaaag attcactaaa gcagcacata	3240
gcactgggaa ctctggctcc gaaaaactth gttatatata tcaaggatgt tctggctth	3300
cattttatth attagctgta aatacatgtg tggatgtgta aatggagctt gtacatatg	3360
gaaaggctat tgtggctatc tgcatttata aatgtgtggt gctaactgta tgtgtctth	3420
tcagtgatgg tctcacagag ccaactcact cttatgaaat gggctthaac aaaacaagaa	3480
agaaacgtac ttaactgtgt gaagaaatgg aatcagctth taataaaatt gacaacatth	3540
tattaccac	3549

&lt;210&gt; 16

&lt;211&gt; 1790

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 16

gtgaatctct ggggccagga agaccctgct gcccgaaga gcctcatgtt ccgtgggggc	60
tgggcggaca tacatatacg ggctccaggc tgaacggctc gggccactta cacaccactg	120
cctgataacc atgctggctg ccacagtcct gaccctggcc ctgctgggca atgcccattg	180
ctgctccaaa ggcacctcgc acgaggcagg catcgtgtgc cgcatcacca agcctgcctt	240
cctggtgttg aaccacgaga ctgccaaggt gatccagacc gccttccagc gagccagcta	300
cccagatatc acgggcgaga aggccatgat gctccttggc caagtcaagt atgggttgca	360
caacatccag atcagccact tgtccatcgc cagcagccag gtggagctgg tggagccaa	420
gtccattgat gtctccattc agaacgtgtc tgtggtcttc aaggggacct tgaagtatgg	480
ctacaccact gcctgggtggc tgggtattga tcagtccatt gacttcgaga tcgactctgc	540
cattgacctc cagatcaaca cacagctgac ctgtgactct gtagagtgc ggaccgatgc	600

ccctgactgc tacctgtctt tccataagct gctcctgcat ctccaagggg agcgagagcc 660  
 tgggtggatc aagcagctgt tcacaaattt catctccttc accctgaagc tggctcctgaa 720  
 gggacagatc tgcaaagaga tcaacgtcat ctctaacatc atggccgatt ttgtccagac 780  
 aagggtgccc agcatccttt cagatggaga cattgggggtg gacatttccc tgacaggtga 840  
 tcccgctatc acagcctcct acctggagtc ccatcacaag ggtcatttca tctacaagaa 900  
 tgtctcagag gacctcccc tccccacctt ctgcccaca ctgctggggg actcccgcat 960  
 gctgtacttc tggttctctg agcgagtctt cactcgtctg gccaaggtag ctttccagga 1020  
 tggccgcctc atgctcagcc tgatgggaga cgagttcaag gcagtgtctg agacctgggg 1080  
 cttaacacc aaccaggaaa tcttccaaga ggttgtcggc ggcttcccc gccaggcca 1140  
 agtcaccgtc cactgcctca agatgccccaa gatctcctgc caaaacaagg gagtcgtggt 1200  
 caattcttca gtgatggtga aattcctctt tccacgcca gaccagcaac attctgtagc 1260  
 ttacacattt gaagaggata tcgtgactac cgtccaggcc tcctattcta agaaaaagct 1320  
 cttcttaagc ctcttggtt tccagattac accaaagact gtttccaact tgactgagag 1380  
 cagctccgag tccatccaga gcttcctgca gtcaatgatc accgctgtgg gcatccctga 1440  
 ggtcatgtct cggtcagagg tagtgtttac agccctcatg aacagcaaag gcgtgagcct 1500  
 cttcgacatc atcaaccctg agattatcac tcgagatggc ttcctgctgc tgcagatgga 1560  
 ctttggtctt cctgagcacc tgctgggtgga tttcctccag agcttgagct agaagtctcc 1620  
 aaggaggctg ggatggggct tgtagcagaa ggcaagcacc aggtcacag ctggaaccct 1680  
 ggtgtctcct ccagcgtggt ggaagtggg ttaggagtag ggagatggag attggctccc 1740  
 aactcctccc tctcctaaag gccactggc attaaagtgc tgtatccaag 1790

<210> 17

<211> 2688

<212> DNA

<213> Homo sapiens

<400> 17

tttaaagctg ggaggttctg ccaccaagca cggccttccc actgggaaca caaacttgct 60  
 ggcgggaaga gcccggaaag aaacctgtgg atctcccttc gagatcatcc aaagagaaga 120  
 aagggtgacct cacattcgtg ccccttagca gcaactctgca gaaatgcctc ctcagctgca 180  
 aaacggcctg aacctctcgg ccaaagtgtt ccagggaagc ctggacagcc tgccccaggc 240  
 agtgagggag tttctcgaga ataacgctga gctgtgtcag cctgatcaca tccacatctg 300  
 tgacggctct gaggaggaga atgggaggct tctgggccag atggaggaa agggcatcct 360  
 caggcggctg aagaagtatg acaactgctg gttggctctc actgaccca gggatgtggc 420  
 caggatcgaa agcaagacgg ttatcgtcac ccaagagcaa agagacacag tgcccatccc 480

caaaacaggc ctcagccagc tcggtcgctg gatgtcagag gaggattttg agaaagcgtt 540  
 caatgccagg ttcccagggt gcatgaaagg tcgcaccatg tacgtcatcc cattcagcat 600  
 ggggccgctg ggctcgccctc tgtcaaagat cggcatcgag ctgacggatt caccctacgt 660  
 ggtggccagc atgcggatca tgacgcggat gggcacgccc gtcctggaag cactgggcga 720  
 tggggagttt gtcaaagtcc tccattctgt ggggtgccct ctgcctttac aaaagccttt 780  
 ggtcaacaac tggccctgca acccgagct gacgctcatc gcccacctgc ctgaccgcag 840  
 agagatcatc tcctttggca gtgggtacgg cgggaactcg ctgctcggga agaagtgttt 900  
 tgctctcagg atggccagcc ggctggccaa ggaggaaggg tggctggcag agcacatgct 960  
 ggttctgggt ataaccaacc ctgagggtga gaagaagtac ctggcgccg catttccag 1020  
 cgctgcggg aagaccaacc tggccatgat gaacccagc ctcccgggt ggaaggttga 1080  
 gtgctcggg gatgacattg cctggatgaa gtttgacgca caaggtcatt taagggccat 1140  
 caaccagaa aatggctttt tcggtgtcgc tcctgggact tcagtgaaga ccaaccccaa 1200  
 tgccatcaag accatccaga agaacacaat ctttaccat gtggccgaga ccagcgacgg 1260  
 gggcgtttac tgggaaggca ttgatgagcc gctagcttca ggtgtcacca tcacgtcctg 1320  
 gaagaataag gagtggagct cagaggatgg ggaaccttgt gccacccca actcgaggtt 1380  
 ctgcacccct gccagccagt gcccacatcat tgatgctgcc tgggagtctc cggaagggtg 1440  
 tcccattgaa ggcattatct ttggaggccg tagacctgct ggtgtccctc tagtctatga 1500  
 agctctcagc tggcaacatg gagtctttgt gggggcggcc atgagatcag aggccacagc 1560  
 ggctgcagaa cataaaggca aaatcatcat gcatgacccc ttgccatgc ggcccttctt 1620  
 tggctacaac ttcggcaaata acctggccca ctggcttagc atggcccagc acccagcagc 1680  
 caaactgccc aagatcttcc atgtcaactg gttccggaag gacaagggaag gcaaattcct 1740  
 ctggccaggc tttggagaga actccagggt gctggagtggt atgttcaacc ggatcgatgg 1800  
 aaaagccagc accaagctca cgcccatagg ctacatcccc aaggaggatg ccctgaacct 1860  
 gaaaggcctg gggcacatca acatgatgga gcttttcagc atctccaagg aattctggga 1920  
 gaaggagggt gaagacatcg agaagtatct ggaggatcaa gtcaatgccg acctcccctg 1980  
 tgaaatcgag agagagatcc ttgccttgaa gcaaagaata agccagatgt aatcagggcc 2040  
 tgagtgtttt acctttaaaa tcattccctt tcccatccat aagggtgcagt aggagcaaga 2100  
 gagggcaagt gttcccaaata tgacgccacc ataataatca tcaccacacc gtgagcagat 2160  
 ctgaaaggca cactttgatt tttttaagga taagaaccac agaacactgg gtagtagcta 2220  
 atgaaattga gaagggaaat cttagcatgc ctccaaaaat tcacatccaa tgcatagttt 2280  
 gttcaaatat aaggttactc aggcattgat cttttcagtg ttttttact ttagctatgt 2340  
 ggattagcta gaatgcacac caaaaaata cttgagctgt atatatatat gtgtgtgtgt 2400  
 gtgtgtgtgt gtgtgtgtgt gtgtgcatgt atgtgcacat gtgtctgtgt ggtatatattg 2460  
 tgtatgtgta tttgtatgta ctgttattga aaatatattt aatacctttg gaaaaatctt 2520

gggcaagatg acctactagt tttccttgaa aaaaagttgc tttgttatta atattgtgct 2580  
 taaattatTT ttatacacca ttgttcctta cctttacata attgcaatat ttccccctta 2640  
 ctacttcttg gaaaaaaatt acaaaatgaa gttttataga aaagatgg 2688

<210> 18

<211> 3095

<212> DNA

<213> Homo sapiens

<400> 18  
 tagcagagca atcaccacca agcctggaat aactgcaagg gctctgctga catcttcctg 60  
 aggtgccaag gaaatgagga tggaggaagg aatgaatgtt ctccatgact ttgggatcca 120  
 gtcaacacat tacctccagg tgaattacca agactcccag gactggttca tcttggtgtc 180  
 cgtgatcgca gacctcagga atgccttcta cgtcctcttc cccatctggt tccatcttca 240  
 ggaagctgtg ggcattaaac tcctttgggt agctgtgatt ggagactggc tcaacctcgt 300  
 ctttaagtgg attctctttg gacagcgtcc atactgggtg gttttggata ctgactacta 360  
 cagcaacact tccgtgcccc tgataaagca gttccctgta acctgtgaga ctggaccagg 420  
 gagccccctt ggccatgcca tgggcacagc aggtgtatac tacgtgatgg tcacatctac 480  
 tctttccatc tttcagggaa agataaagcc gacctacaga tttcgggtgt tgaatgtcat 540  
 tttgtggttg ggattctggg ctgtgcagct gaatgtctgt ctgtcacgaa tctaccttgc 600  
 tgctcatTTT cctcatcaag ttgttgctgg agtcctgtca ggcattgctg ttacagaaac 660  
 tttcagccac atccacagca tctataatgc cagcctcaag aaatattttc tcattacctt 720  
 cttcctgttc agcttcgcca tcggatttta tctgtgtctc aagggactgg gtgtagacct 780  
 cctgtggact ctggagaaaag cccagagggt gtgcgagcag ccagaatggg tccacattga 840  
 caccacaccc tttgccagcc tcctcaagaa cctgggcacg ctctttggcc tggggctggc 900  
 tctcaactcc agcatgtaca gggagagctg caaggggaaa ctgagcaagt ggctcccatt 960  
 ccgcctcagc tctattgtag cctccctcgt cctcctgcac gtctttgact ccttgaaacc 1020  
 cccatcccaa gtcgagctgg tcttctacgt cttgtccttc tgcaagagtg cggtagtgcc 1080  
 cctggcatcc gtcagtgtca tcccctactg cctcgcccag gtcctgggccc agccgcacaa 1140  
 gaagtcgttg taagagatgt ggagtcttcg gtgtttaaag tcaacaacca tgccagggat 1200  
 tgaggaggac tactatttga agcaatgggc actggtatTT ggagcaagtg acatgccatc 1260  
 cattctgccg tcgtggaatt aaatcacgga tggcagattg gagggctgcc tggcttatTC 1320  
 ccatgtgtga ctccagcctg ccctcagcac agactctttc agatggagggt gccatatcac 1380  
 gtacaccata tgcaagtttc ccgccaggag gtcctcctct ctctacttga atactctcac 1440  
 aagtagggag ctactccca ctggaacagc ccattttatc tttgaatggt cttctgccag 1500

```

cccattttga ggccagaggt gctgtcagct cagggtggccc tcttttaca tcctaatcat 1560
attgggtaat gtttttgaaa agctaataa gctattgaga aagacctgtt gctagaagtt 1620
gggtgtttct ggattttccc ctgaagactt acttattctt ccgtcacata tacaaaagca 1680
agacttccag gtagggccag ctcaaacg ccaggctggag atcctaactg agaattttct 1740
acctgtgttc attcttaccg agaaaaggag aaaggagctc tgaatctgat agggaaagaa 1800
ggctgcctaa ggaggagttt ttagtatgtg gcgtatcatg caagtgtat gccaaagccat 1860
gtctaaatgg ctttaattat atagtaatgc actctcagta atgggggacc agcttaagta 1920
taattaatag atggttagtg gggtaattct gcttctagta ttttttttac tgtgcataca 1980
tgttcatcgt atttcttgg atttctgaat ggctgcagtg acccagatat tgcactaggt 2040
caaaacattc aggtatagct gacatctcct ctatcacatt acatcatcct cttataagc 2100
ccagctctgc tttttccaga ttcttccact ggctccacat ccacccact ggatcttcag 2160
aaggctagag ggcgactctg gtggtgcttt tgtatgtttc aattaggctc tgaaatcttg 2220
ggcaaaatga caaggggagg gccaggattc ctctctcagg tcaactccagt gttactttta 2280
attcctagag ggtaaataatg actcctttct ctatcccaag ccaaccaaga gcacattctt 2340
aaaggaaaag tcaacatctt ctctcttttt tttttttttt gagacagggc ctactatgt 2400
tgcccaggct gctcttgaat tcctgggctc aagcagtcct cccaccctac cacagcgtcc 2460
cgcgtagctg gcatacaggt gcaagccact atgtccagct agccaactcc tccttgctg 2520
cttttctttt tttttctttt tttgagacgg cgcacctatc acccaggctg gagtggagt 2580
gcacgatctt ggctcactgc aacctcttcc tcctgggtca agcgattctc atgtctcagc 2640
ctctcagta gctaggacta ccggcgtgca ccacatgcc aggctaattt ttatattttt 2700
agaattttag aagagatggg atttcatcat gttggccagg ctggtctcga actcctgacc 2760
tcaagtgatc cacctgcctt ggctcccaa ggtgctagga ttacaggcat gagccaccgc 2820
accgggccct ccttgctgt tttcaatct catctgatat gcagagtatt tctgccccac 2880
ccacctacc ccacaaaaaa gctgaagcct atttatttga aagtccttgt ttttgctact 2940
aattatatag tataccatac attatcattc aaaacaacca tctgctcat aacatctttg 3000
aaaagaaaaa tatatatgtg cagtatttta ttaaagcaac attttattta agaataaagt 3060
cttgtaatt actatatttt agatgcaatg tgatc 3095

```

<210> 19

<211> 2128

<212> DNA

<213> Homo sapiens

<400> 19

```

gggggtccca tcgggcccgc cctcgcacgt cactccggga ccccgcggc ctccgcaggt 60

```



tctgcgctcc aggccggagt cagagactcc aggatcggtt ctttcatctt cgccgcccct 120  
gcgcgtccag ctcttctaag acgagatgcc gtcgggcttc caacagatag gctccgaaga 180  
tggggaaccc cctcagcagc gagtgactgg gaccctggtc cttgctgtgt tctctgcggt 240  
gcttggtccc ctgcagtttg ggtacaacat tggggtcatac aatgcccctc agaagggtgat 300  
tgaacagagc tacaatgaga cgtggctggg gaggcagggg cctgagggac ccagctccat 360  
ccctccaggc accctcacca ccctctgggc cctctccgtg gccatctttt ccgtgggcgg 420  
catgatttcc tccttctca ttggtatcat ctctcagtggt cttggaagga aaagggccat 480  
gctggtcaac aatgtcctgg cgggtgctggg gggcagcctc atgggcctgg ccaacgctgc 540  
tgcctcctat gaaatgtca tccttgagc atttctcatt ggcgcctact cagggctgac 600  
atcagggctg gtgcccattg acgtggggga gattgctccc actcacctgc ggggcgccc 660  
ggggacgctc aaccaactgg ccattgttat cggcattctg atcgcccagg tgctgggctt 720  
ggagtccctc ctgggcactg ccagcctgtg gccactgctc ctgggcctca cagtgtacc 780  
tgccctctg cagctggtcc tgctgccctt ctgtcccag agccccgct acctctacat 840  
catccagaat ctcgaggggc ctgccagaaa gagtctgaag cgcctgacag gctgggccga 900  
tgtttctgga gtgctggctg agctgaagga tgagaagcgg aagctggagc gtgagcggcc 960  
actgtccctg ctccagctcc tgggcagccg taccaccgg cagcccctga tcattgcggt 1020  
cgtgctgacg ctgagccagc agctctctgg catcaatgct gtttctatt attcgaccag 1080  
catcttcgag acagcagggg taggccagcc tgcctatgcc accataggag ctggtgtggt 1140  
caacacagtc ttcaccttg tctcgtgtgt gttggtggag cgggcggggc gccggacgct 1200  
ccatctcctg ggcctggcgg gcatgtgtgg ctgtgccatc ctgatgactg tggctctgct 1260  
cctgctggag cgagttccag ccattgagcta cgtctccatt gtggccatct ttggcttcgt 1320  
ggcatttttt gagattggcc ctggcccat tccttggttc atcgtggccg agctcttcag 1380  
ccagggaccc cgccggcag ccattggtgt ggctggtttc tccaactgga cgagcaactt 1440  
catcattggc atgggtttcc agtatgttg ggaggctatg gggccctacg tcttcttct 1500  
atttgcggtc ctctgctgg gcttcttcat cttcaccttc ttaagagtac ctgaaactcg 1560  
agggcgacg tttgaccaga tctcagctgc cttccaccgg acaccctctc ttttagagca 1620  
ggaggtgaaa ccagcacag aacttgagta tttagggcca gatgagaacg actgaggggc 1680  
caggcagggg tgggagagcc agctctctct acccgccca gagaccctt ctttctctt 1740  
gcagcacttt aacctctct tccctattat ttccgggtgg aaaagaatcc ctgcagcctg 1800  
gtagaattgg gaagctgggg gaagggtggt ctgagcacc cctcattccc ctggtgtgac 1860  
tctcttggat tatttatgtg ttgtggttg gccgtggcca tcaggggtgg ccactctccc 1920  
ctccctcttc cttccccat ccccttctc cccaccttc ccagactca gctccagaat 1980  
accttcttcg ctgctagaga agggggattg gagggagac aggtctagac tttctcagtg 2040  
ggacaaacca gagcagagag caggacagga gacaagaaat ccagtttccc accaccttgg 2100

actcctccca caatctggga ctttcact

2128

&lt;210&gt; 20

&lt;211&gt; 1496

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 20

```

ggcacgagga aaatcaagat aaaaatgttc acaattaagc tccttctttt tattgttcct      60
ctagttatatt cctccagaat tgatcaagac aattcatcat ttgattctct atctccagag      120
ccaaatcaa gatttgctat gttagacgat gtaaaaattt tagccaatgg cctccttcag      180
ttgggacatg gtcttaaaga ctttgtccat aagacgaagg gccaaattaa tgacatatatt      240
caaaaactca acatatttga tcagtctttt tatgatctat cgctgcaaac cagtgaaatc      300
aaagaagaag aaaaggaact gagaagaact acatataaac tacaagtcaa aaatgaagag      360
gtaaagaata tgtcacttga actcaactca aaacttgaaa gcctcctaga agaaaaaatt      420
ctacttcaac aaaaagtga atatttagaa gagcaactaa ctaacttaat tcaaaatcaa      480
cctgaaactc cagaacaccc agaagtaact tcacttaaaa cttttgtaga aaaacaagat      540
aatagcatca aagaccttct ccagaccgtg gaagaccaat ataaacaatt aaaccaacag      600
catagtcaaa taaaagaaat agaaaatcag ctcagaagga ctagtattca agaaccaca      660
gaaatttctc tatcttccaa gccaagagca ccaagaacta ctccctttct tcagttgaat      720
gaaataagaa atgtaaaaca tgatggcatt cctgctgaat gtaccaccat ttataacaga      780
ggtgaacata caagtggcat gtatgccatc agaccagca actctcaagt ttttcatgtc      840
tactgtgatg ttatatcagg tagtccatgg acattaattc aacatcgaat agatggatca      900
caaaacttca atgaaacgtg ggagaactac aaatatgggt ttgggaggct tgatggagaa      960
ttttggttgg gcctagagaa gatatactcc atagtgaagc aatctaatta tgttttacga     1020
attgagttgg aagactggaa agacaacaaa cattatatgg aatattcttt ttacttggga     1080
aatcacgaaa ccaactatac gctacatcta gttgcgatta ctggcaatgt cccaatgca     1140
atcccggaac acaaagattt ggtgttttct acttgggatc acaaagcaaa aggacacttc     1200
aactgtccag agggttattc aggaggctgg tgggtggcatg atgagtgtgg agaaaacaac     1260
ctaaatggta aatataacaa accaagagca aaatctaagc cagagaggag aagaggatta     1320
tcttgaagat ctcaaaatgg aaggttatac tctataaaat caaccaaaat gttgatccat     1380
ccaacagatt cagaaagctt tgaatgaact gaggcgaatt taaaaggcaa taatttaaac     1440
attaacctca ttccaagtta atgtggtcta ataactctgg attaaatcct taagag         1496

```

&lt;210&gt; 21

&lt;211&gt; 1415

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

```

<400> 21
ggaggaggga gagagagaga agagaagaaa aagaaaaaag aacatcaata aaaagaagtc      60
agatttggttc gaaatcttga ggagtcttca ggccagctcc ctgtcggatg gcttttatga      120
aaaaatatct cctccccatt ctggggctct tcatggccta ctactactat tctgcaaacg      180
aggaattcag accagagatg ctccaaggaa agaaagtgat tgtcacaggg gccagcaaag      240
ggatcggaag agagatggct tatcatctgg cgaagatggg agcccatgtg gtggtgacag      300
cgagggtcaaa agaaactcta cagaagggtg tatccactg cctggagctt ggagcagcct      360
cagcacacta cattgctggc accatggaag acatgacctt cgcagagcaa tttgttgccc      420
aagcaggaaa gctcatggga ggactagaca tgctcattct caaccacatc accaactt      480
ctttgaatct ttttcatgat gatattcacc atgtgcgcaa aagcatggaa gtcaacttcc      540
tcagttacgt ggtcctgact gtagctgcct tgcccatgct gaagcagagc aatggaagca      600
ttgttgtcgt ctctctctg gctgggaaag tggcttatcc aatggttgct gcctattctg      660
caagcaagtt tgctttggat gggttcttct cctccatcag aaaggaatat tcagtgtcca      720
gggtcaatgt atcaatcact ctctgtgttc ttggcctcat agacacagaa acagccatga      780
aggcagtttc tgggatagtc catatgcaag cagctccaaa ggaggaatgt gccctggaga      840
tcatcaaagg gggagctctg cgccaagaag aagtgtatta tgacagctca ctctggacca      900
ctcttctgat cagaaatcca tgcaggaaga tcctggaatt tctctactca acgagctata      960
atatggacag attcataaac aagtaggaac tccctgaggg ctgggcatgc tgagggattt     1020
tgggactgtt ctgtctcatg tttatctgag ctcttatcta tgaagacatc ttcccagagt     1080
gtccccagag acatgcaagt catgggtcac acctgacaaa tggaaggagt tcctctaaca     1140
tttgcaaaat ggaaatgtaa taataatgaa tgtcatgcac cgctgcagcc agcagttgta     1200
aaattgttag taaacatagg tataattacc agatagttat attaaattta tatcttatat     1260
ataataatat gtgatgatta atacaatatt aattataata aaggtcacat aaactttata     1320
aattcataac tggtagctat aacttgagct tattcaggat ggtttcttta aaaccataaa     1380
ctgtacaaat gaaatttttc aatatttggt tctta                                1415

```

&lt;210&gt; 22

&lt;211&gt; 1405

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 22

```

acaattcaga ggctgctgcc tgcttaggag gttgtagaaa gctctgtagg ttctctctgt      60
gtgtcctaca ggagtcttca ggccagctcc ctgtcggatg gcttttatga aaaaatatct      120
cctccccatt ctggggctct tcatggccta ctactactat tctgcaaacg aggaattcag      180
accagagatg ctccaaggaa agaaagtgat tgtcacaggg gccagcaaag ggatcggaag      240
agagatggct tatcatctgg cgaagatggg agcccatgtg gtggtgacag cgagggtcaaa      300
agaaactcta cagaagggtg tatcccactg cctggagctt ggagcagcct cagcacacta      360
cattgctggc accatggaag acatgacctt cgcagagcaa tttgttgccc aagcaggaaa      420
gctcatggga ggactagaca tgctcattct caaccacatc accaactctt ctttgaatct      480
ttttcatgat gatattcacc atgtgcgcaa aagcatggaa gtcaacttcc tcagttacgt      540
ggtcctgact gtagctgcct tgcccatgct gaagcagagc aatggaagca ttgttgctgt      600
ctcctctctg gctgggaaaag tggcttatcc aatggttgct gcctattctg caagcaagtt      660
tgctttggat gggttcttct cctccatcag aaaggaatat tcagtgacca ggggtcaatgt      720
atcaatcact ctctgtgttc ttggcctcat agacacagaa acagccatga aggcagtttc      780
tgggatagtc catatgcaag cagctccaaa ggaggaatgt gccctggaga tcatcaaagg      840
gggagctctg cgccaagaag aagtgtatta tgacagctca ctctggacca ctcttctgat      900
cagaaatcca tgcaggaaga tcctggaatt tctctactca acgagctata atatggacag      960
attcataaac aagtaggaac tccctgaggg ctgggcatgc tgagggatgt tgggactgtt     1020
ctgtctcatg tttatctgag ctcttatcta tgaagacatc ttcccagagt gtcccagag      1080
acatgcaagt catgggtcac acctgacaaa tggaggaggt tcctctaaca ttgcaaaaat     1140
ggaaatgtaa taataatgaa tgtcatgcac cgctgcagcc agcagttgta aaattgttag      1200
taaakatagg tataattacc agatagttat attaaattta tatcttatat ataataatat     1260
gtgatgatta atacaatatt aattataata aaggtcacat aaactttata aattcataac     1320
tggtagctat aacttgagct tattcaggat ggtttcttta aaaccataaa ctgtacaaat     1380
gaaatttttc aatatttgtt tctta                                           1405

```

&lt;210&gt; 23

&lt;211&gt; 1944

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 23

```

ccctctcgcg cccagggccg gtgtaccccc gactccgcg ccccgcccta gaagctctct      60
ctccccgctc cccggcccg ccccgcccc gcccgcccc agcccgctgg gccgcatgg      120
agcgtggcc ttggccgctg ggcggcgctt ggctgctcgt ggctgcccgc gcgctgctgc      180
agctgctgcg ctcacacctg cgtctgggcc gcccgctgct ggcggcgctg gcgctgctgg      240

```

ccgcgctcga ctggctgtgc cagcgccctgc tgcccccgcc ggccgcactc gccgtgctgg	300
ccgccgccgg ctggatcgcg ttgtcccgcc tggcgcgccc gcagcgccctg ccggtggcca	360
ctcgcgcggt gctcatcacc ggctgtgact ctggttttgg caaggagacg gccaagaaac	420
tggactccat gggcttcacg gtgctggcca ccgtattgga gttgaacagc cccggtgcca	480
tcgagctgcg tacctgtgctg tcccctcgcc taaggctgct gcagatggac ctgaccaaac	540
caggagacat tagccgcgtg ctagagttca ccaaggccca catcaccagc accggcctgt	600
ggggcctcgt caacaacgca ggccacaatg aagtagttgc tgatgcggag ctgtctccag	660
tggccacttt ccgtagctgc atggaggtga atttctttgg cgcgctcgag ctgaccaagg	720
gcctcctgcc cctgctgctg agctcaaggg gccgcacgt gactgtgggg agcccagcgg	780
gggacatgcc atatccgtgc ttgggggcct atggaacctc caaagcggcc gtggcgctac	840
tcatggacac attcagctgt gaactccttc cctgggggggt caaggtcagc atcatccagc	900
ctggctgctt caagacagag tcagtgagaa acgtgggtca gtgggaaaag cgcaagcaat	960
tgctgctggc caacctgcct caagagctgc tgcaggccta cggcaaggac tacatcgagc	1020
acttgcattg gcagttcctg cactcgctac gcctggccat gtccgacctc accccagttg	1080
tagatgccat cacagatgctg ctgctggcag ctcggccccg ccgcccgtat taccgccggc	1140
agggcctggg gctcatgtac ttcattccact actacctgcc tgaaggcctg cggcgccgct	1200
tcctgcaggc cttcttcctc agtcactgtc tgcctcgagc actgcagcct ggccagcctg	1260
gcactacccc accacaggac gcagcccagg gcccacacct gagccccggc ctttccccag	1320
cagtggctcg gtgagccatg tgcacctatg gccagccac tgcagcacag gaggctccgt	1380
gagcccttgg ttcctccccg aaaacccccca gcattacgat cccccaagtg tcctggaccc	1440
tggcctaaag aatcccaccc ccacttcatg cccactgccc atgcccacac caggcccggg	1500
gaggccaagg tttcccagtg agcctctgct cctctccact gtttcatgag cccaaacacc	1560
ctcctggcac aacgctctac cctgcagctt ggagaactcc gctggatggg gagtctcatg	1620
caagacttca ctgcagcctt tcacaggact ctgcagatag tgcctctgca aactaaggag	1680
tgactagggtg ggttggggac cccctcagga ttgtttctcg gcaccagtgc ctcagtgtg	1740
caattgaggg ctaaatccca agtgtctctt gactggctca agaattaggg cccaactac	1800
acacccccaa gccacagga agcatgtact gtacttccca attgccacat tttaaataaa	1860
gacaaatfff tttttcttct aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa	1920
aaaaaaaaaa aaaaaaaaaa aaaa	1944

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP 03/10036

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/517 C07D403/04 A61P3/06

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, WPI Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE CHEMCATS CHEMICAL ABSTRACTS SERVICES, COLUMBUS, OHIO, US; XP0002225148 ORDER NUMBER: TRG10400#07364-D; TRG10400#01815-D; TRG10400#01814-D; TRG10400#01812-D; TRG10400#01811-D; TRG10400#01809-D; TRG10400#01736-D; TRG10400#01735-D; TRG10400#01732-D; TRG10400#01729-D &amp; "Chem.Follo" 15 May 2001 (2001-05-15), LION BIOSCIENCE , HEIDELBERG, GERMANY</p> <p style="text-align: center;">----- -/--</p>	1-3

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

\*A\* document defining the general state of the art which is not considered to be of particular relevance

\*E\* earlier document but published on or after the International filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the International filing date but later than the priority date claimed

\*T\* later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*G\* document member of the same patent family

Date of the actual completion of the International search

12 January 2004

Date of mailing of the international search report

30/01/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.  
Fax: (+31-70) 340-3016

Authorized officer

Kollmannsberger, M

## INTERNATIONAL SEARCH REPORT

International Publication No

PCT/EP 03/10036

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	COLLINS J L ET AL: "Identification of a Nonsteroidal Liver X Receptor Agonist through Parallel Array Synthesis of Tertiary Amines" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 45, 2002, pages 1963-1966, XP002225147 ISSN: 0022-2623 the whole document	1-34
A	GUPTA C M ET AL: "Drugs acting on the central nervous system. Syntheses of substituted quinazolones and quinazolines and triazepino- and triazocinoquinazolones" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 11, no. 2, 26 February 1968 (1968-02-26), pages 392-395, XP002156695 ISSN: 0022-2623 example 15; table 1	1-34
A	WO 97/20823 A (CRISCIONE LEOLUCA ; YAMAGUCHI YASUCHIKA (CH); CIBA GEIGY AG (CH); MAH) 12 June 1997 (1997-06-12) page 74; example 28 claims 1,12	1-34

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/EP 03/10036

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Although claims 13-24, 33,34 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compounds/compositions.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.



# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 03/10036

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9720823	A	12-06-1997	AU 7692996 A	27-06-1997
			WO 9720823 A2	12-06-1997
			ZA 9610020 A	01-06-1997
<hr/>				